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ABSTRACT 
 The genome-wide association study (GWAS) approach has identified novel loci 
for a variety of complex diseases. However, for most of these disorder much of the 
heritability is not explained by this approach, which focuses on identifying common 
variants that are associated with disease risk. The unexplained heritability may be due to 
genetic or phenotypic heterogeneity or the influence of rare variants. The motivation 
behind this thesis was to uncover the unexplained heritability by applying joint analyses 
of sets of variants (gene-based association test) and multiple disease-related phenotypes 
(called multivariate gene-based association test). First, we evaluated multivariate gene-
based methods for detecting association of common genetic variants with correlated 
phenotypes. An extensive simulation study showed that the method combining the 
MultiPhen and GATES software performed best for most tested scenarios especially 
when correlations among phenotypes are relatively low. We developed a new 
multivariate gene-based test using rare variants called VEMPHAS. A simulation study 
using VEMPHAS showed that this method correctly controls for type I error in all tested 
scenarios. We applied VEMPHAS to analysis of various phenotypes related to Alzheimer 
 vii 
disease (AD) and found suggestive association (P < 4.15x10-6) with the gene TRIM22, 
which has been identified in a previous sequencing study of AD onset in PSEN1/2 
mutation carriers. We also developed software with a graphical user interface which is 
designed for integrating information from different types of data sources including 
genetic data (from GWAS or sequencing), expression data (from RNA-Seq), and protein 
structures (from protein data banks). This software has several features including 1) 
testing associations between genetic variants and gene expressions; 2) locating amino 
acids, encoded by the variants, in a protein structure; and 3) retrieving genetic locations 
(chromosome and base pair positions) of amino acids of interest in the protein structure. 
The last feature can be applied for prioritizing coding variants for gene-based association 
testing. The methods and strategies developed for this dissertation project can effectively 
uncover a portion of the remaining heritability of complex diseases that is unexplained by 
traditional GWAS approaches. 
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CHAPTER 1 Introduction 
1.1 Genome-wide Association Study 
 The goal of a genetic association study is to identify loci which are associated 
with a disease or other observable traits1,2. The basic design of a genetic association study 
entails comparison of the frequency of alleles or genotypes for a genetic marker between 
persons with and without disease3,4. Family-based linkage analysis (designed for tracking 
co-segregation of disease and marker alleles within families) and candidate gene 
association study approaches have successfully identified genetic variants associated with 
(and even causing) many Mendelian disorders3. However, these approaches have often 
failed to yield definitive results for complex diseases3. Linkage analysis is useful for 
identifying rare highly penetrant variants with a strong effect on disease risk3. By 
contrast, linkage analysis is generally not optimal for detecting variants influencing risk 
of complex diseases for which many common low-penetrance variants often contribute to 
the underlying genetic architecture2. The candidate gene association approach has been 
modestly successful when applied to complex diseases because it depends on prior 
knowledge about the biology of the disease which can be very limited2,3. The advent of 
affordable microarray genotyping technology and extensive knowledge about common 
genetic variation in large human populations allowed identification of linkage 
disequilibrium (LD) patterns on a genome-wide scale through HapMap and 1000 
Genomes projects3,5,6. These crucial advances facilitated large-scale analyses of variants 
across the entire human genome known as the genome-wide association study (GWAS)1,2 
The main goal of GWAS is to provide biological underpinnings of genetic susceptibility 
  
2 
for diseases which can be used for making predictions of disease risk for persons or 
preventing disease onset/progression1.  
 
1.2. Limitation of Conventional GWAS 
 Since the first GWAS in 2005 7, GWAS has been successfully applied to a variety 
of complex diseases and reported more than 10,000 genetic factors underlying complex 
diseases8,9. However, genetic variants found in GWAS often explain a relatively small 
proportion of the disease heritability10. For example, 697 genetic loci have been detected 
as being associated with human height, of which estimated heritability is about 80%, but 
they explain only about 20% of the phenotypic variance11,12. Another example for the 
unexplained heritability is Alzheimer’s disease (AD). AD is a complex disease that is 
highly heritable, with an estimated heritability as high as 79% in twin studies13. The AD 
loci identified in a large scale of GWAS account for about 30% of the variation14. 
 One plausible reason for unexplained heritability is due to the genetic architecture 
of complex diseases, which are affected by many common variants with low penetrance 
(i.e. small effect)2,15. Odds ratios for observed genetic variants for complex diseases are 
generally modest (i.e. a median OR of 1.33)15,16. GWAS requires very conservative 
significance threshold (i.e. P < 5.0x10-8) to control false positive associations that result 
from performing more than 500,000 independent tests, which reduces the chance to 
detect disease-associated variants with modest effect size, unless sample sizes are large 
enough. Also, causal variants are often not genotyped, but may be “tagged” by genotyped 
variants in LD with the genotyped ones. However, genetic variants may have different 
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allele frequencies and LD pattern across different genetic backgrounds, which may lead 
to non-replication of the same variants in populations with different genetic backgrounds. 
Moreover, rare variants with minor allele frequency (MAF) less than 5% or 1% can fill 
some portion of the unexplained heritability17-19. Recent advance in next-generation 
sequencing technologies allows to analyze rare variants in complex diseases. However, 
analysis of individual rare variants suffers from lack of power due to their low 
frequencies20.  
 Gene-based analysis, which considers the aggregate effect of multiple genic 
variants in a single test, can overcome some of the aforementioned and other issues 
including the very low significance threshold, genetic heterogeneity, and lack of power 
for analysis of rare variants. The number of test in gene-based analyses is much smaller 
than testing individual variants, which alleviates somewhat the multiple testing burden. 
Many methods for testing association between a set of rare variants in a gene region and a 
single phenotype have been developed, including variance component score test 21 and 
burden test22,23. 
 Another type of reason for unexplained heritability is phenotypic heterogeneity. 
Most complex diseases, such as AD, schizophrenia, diabetes mellitus, or cardiovascular 
diseases, are the end result from multiple physiological or pathophysiological processes 
that may be measured as intermediate phenotypes or endophenotypes24. For example, the 
susceptibility to AD is influenced by a variety of neuropathologies including abnormal 
accumulations of beta-amyloid (Aβ) and phosphorylated tau (p-Tau), which can be 
assessed by measuring their levels in cerebrospinal fluid (CSF) 25 or by positron emission 
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tomography (PET) scan26. Conventional genome-wide association (GWA) studies 
consider a univariate clinical outcome of complex diseases (e.g. disease diagnosis or a 
composite score of several disease-related traits). GWAS based on disease diagnosis will 
unlikely provide a full explanation of the genetic architecture of complex diseases 
because the multiple mechanisms underlying such diseases is often not captured entirely 
by simple presence or absence of clinical symptoms or related phenotypes27,28. Also, 
GWAS of a disease outcome (case-control) is designed to identify genetic associations 
for disease risk, which differs from other aspects of a complex disease including disease 
progression, age at onset (AAO), or changes under specific pathologies/disease stages. In 
general, intermediate phenotypes are highly heritable, are strongly associated with 
disease pathologies as well as disease status, and represent various aspects of disease. In 
addition, intermediate phenotypes are usually quantitative traits, which can improve 
statistical power compared to binary outcomes for identifying genetic associations. 
Therefore, GWAS of various intermediate phenotypes related with complex diseases is 
an alternative and powerful approach to uncover a portion of unexplained heritability, as 
well as identify novel loci associated with complex traits. 
 Some genetic variants may be relevant to multiple intermediate phenotypes which 
are in turn causally linked to a complex disease (called pleiotropy effect)29. Analogous to 
a gene-based analysis, joint analysis of multiple disease-related (intermediate) 
phenotypes (i.e. multivariate analysis) rather than analysis of a single phenotype (i.e. 
univariate analysis) can increase the statistical power to detect genetic variants by 
aggregating weak association with each phenotype29.  
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 It is also possible that a gene contains several disease-associated variants with 
modest individual effects for multiple intermediate phenotypes which are related to a 
complex disease. In this case, multivariate gene-based analysis, which combines gene-
based analysis (aggregates of genetic variants) and multivariate analysis (aggregates of 
multiple phenotypes), can boost detection of genetic associations for complex diseases30-
32. Several gene-based association methods have been developed and successfully applied 
to GWA studies of complex diseases33,34, and the same is true for multivariate association 
methods35,36. Recently, van der Sluis et al. developed a multivariate gene-based test 
(MGAS) which combines the TATES method37  for multivariate SNP association testing 
and the GATES method38 for gene-based univariate association testing39. MGAS has 
been applied to genetic association tests with diverse endophenotypes related to two 
complex traits (metabolism and myopia), and novel genetic associations were 
reported31,40. This indicates that multivariate gene-based association analysis can also 
uncover a part of the unexplained heritability of complex diseases.  
 One of the aims in this thesis is an evaluation of the statistical performance of 
multivariate gene-based association methods by combining multivariate association 
methods and gene-based association methods in various simulation models. Based on the 
comparisons of many combined methods, we provide guidance on how to optimally 
select multivariate gene-based association method for analyzing common variants given 
the correlation of phenotypes and genetic background (e.g. LD). Also, we propose a new 
multivariate gene-based method, called VErsatile Multi-PHenotype gene-based 
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ASsociation test (VEMPHAS) which is designed for combining rare variant associations 
from multiple phenotypes. 
 
1.3. Alzheimer’s Disease 
1.3.1 Background 
 AD is a neurodegenerative disease and can be classified into early-onset AD 
(EOAD) or late-onset (LOAD). LOAD accounts for most AD cases (>99%) and is the 
most common form of age-related dementia among people older than 65 years41,42. The 
major clinical symptom of AD is progressive and irreversible cognitive decline43. The 
average duration of AD after onset is 8-10 years, but the life time including preclinical 
and prodromal stages of AD can be over two decades44.  
 AD pathology is present many years prior to observation of clinical symptoms of 
AD45-47. Abnormal protein aggregations such as amyloid plaques and neurofibrillary 
tangles (NFT) are usually observed first in the frontal and temporal lobes, and they 
slowly spread through other areas including the cerebral cortex and hippocampus46. 
Amyloid plaque is an oligomeric form of Amyloid-β (Aβ), a protein which contains 
peptides with 40 or 42 amino acids and is produced by cleavage of amyloid precursor 
protein (APP) by BACE1 and presenilin proteins 1 and 2 (PSEN1 and PSEN2)48. Rare 
mutations in APP, PSEN1, and PSEN2 cause most cases of EOAD45-47. Amyloid plaques, 
which associated with axonal and dendritic injury, are often observed within neurites48. 
NFTs are composed of phosphorylated tau protein encoded by the gene, microtubule-
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associated protein tau (MAPT)45. Tau itself is soluble, but many kinases are responsible 
for hyperphosphorylation of tau. Phosphorylated tau is dissociated from microtubules and 
leads to microtubule destabilization and deleterious effects on axonal transport 
mechanism45.  
 
1.3.2 Review of AD genetic findings 
 AD is a complex disease and has a strong genetic component (60-80% population 
attributable risk)49, a small portion14 (30.62%) of which is explained by about 30 genes 
identified by GWAS of several large cohorts49,50.  
 Apolipoprotein-E (APOE) is the major genetic factor for AD and is involved in 
neuronal growth, repair response to tissue injury, Aβ clearance, and 
immunoregulation51,52. APOE has different isoforms (ε2, ε3, and ε4) by three allelic 
variants at two sites (rs429358 and rs7412). APOE ε4 increase risk for LOAD51,53, and 
the estimated risk effect of APOE ε4 is up to 15-fold for ε4 homozygous carriers (APOE 
ε44) compared to the most common wild-type form, APOE ε3352. APOE ε2 is known to 
have protective effect51,54. APOE genotype accounts for about 25% of the estimated 
heritability for AD14.  
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 Large scale AD GWA studies containing thousands of cases and controls have 
been successfully conducted by the four large consortia including European AD Initiative 
(EADI)55, Genetic and Environmental Risk in AD (GERAD)56, Cohorts for Heart and 
Aging Research in Genomic Epidemiology(CHARGE)57, , and AD Genetics Consortium 
(ADGC)58. In 2009, EADI and GERAD identified genome-wide significant associations 
at Complement component receptor (CR1), Clusterin (CLU), and Phosphatidylinositol 
binding clathrin assembly protein (PICALM)55,56. CHARGE discovered Bridging 
integrator 1 (BIN1) from a meta-analysis of their datasets with EADI and GERAD in 
201057. ADGC identified Membrane spanning 4-domains A4A/6E (MS4A4/MS4A6E), 
CD2 associated protein (CD2AP), CD33, and Erythropoietin-producing hepatoma 
receptor A1 (EPHA1) from a meta-analysis of several studies with more than 10,000 AD 
patients and age-matched controls in 201158.  
 The datasets from these four consortia were meta-analyzed by a world-wide 
collaborative effort known as the International Genomics of Alzheimer’s Project 
(IGAP)49. Eleven additional genetic loci have been identified through the IGAP GWAS, 
(Table 1.1). After the first wave of the IGAP GWAS, other genes including Microtubule 
associated protein tau (MAPT), Heparin binding EGF like growth factor (HBEGF), and 
Translocator protein associated protein 1 (TSPOAP1) have been detected in ADGC or 
IGAP50,59. Although each of these loci has a much weaker effect on AD risk compared to 
APOE genotype, these new findings advanced our knowledge about pathophysiological 
pathways involved in AD mechanisms related to APP and Tau (Table 1.1). For example, 
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bridging integrator 1 (BIN1) is involved in clathrin-mediated endocytosis which plays an 
important role for recycling of synaptic vesicles after synaptic releases60. Sortilin-related 
receptor-1 (SORL1), which was initially detected in candidate gene study prior to the 
GWAS era, is involved in lipid transport and APP processing61,62. Complement 
component receptor (CR1) has roles in complement activation/regulation and innate 
immunity63.  
 
1.4 Dissertation Outline 
 The primary aims of this dissertation are the followings: 
1) Identification of novel AD loci through two GWA studies of a variety of phenotypes 
related with AD (in chapter 2) 
2) Comparison of the statistical performance (type I error and power) of multivariate 
gene-based association methods for common variants (in chapter 3).  
3) Development and testing of a new multivariate gene-based association method for rare 
variants (in chapter 4).  
4) Development of a software with graphic user interface which integrates genetic 
variants from GWAS or sequencing data, transcript expression levels from RNA-Seq 
data, and protein structures from protein data bank (in chapter 5). 
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 In chapter 2, I present the results of two GWA studies of phenotypes related with 
AD. These two GWA studies show that analysis of AD-related phenotypes other than 
disease diagnosis can identify novel genetic loci which can be relevant with diseases 
progression or disease-related pathologies. In chapter 2-1, we conduct a GWAS for the 
AD-related endophenotypes including brain hippocampal volume (HPV) by Magnetic 
resonance imaging (MRI), logical memory test scores (LMT), and CSF levels of Aβ42 
and total/phosphorylated tau (t-/p-Tau)  in 305 clinically normal (CN), 581 mild 
cognitive impairment (MCI), and 190 AD subjects from the Alzheimer’s Disease 
Neuroimaging Initiative study (ADNI). In chapter 2-2, we introduce bivariate analyses 
using association summary statistics from the Beecham et al. study64 of AD-related 
neuropathological traits including neuritic plaque (NP), NFT, and cerebral amyloid 
angiopathy (CAA). 
 In chapter 3, we evaluate methods for multivariate gene-based association test 
using common variants. We combine three methods for multivariate association test with 
two gene-based association tools, and then compare statistical performance (type I error 
and power) of those combined methods using extensive simulation studies. We also apply 
these methods that control correct type I errors for AD-related neuropathological traits 
(NP, NFT, and CAA).  
In chapter 4, we develop a new method for testing a set of rare variants with multiple 
disease-related phenotypes, called VEMPHAS. We perform extensive simulation studies 
to evaluate statistical performance of VEMPHAS in various scenarios. We apply 
VEMPHAS for analyzing to real genetic data which is ADNI data with AD-related 
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endophenotypes including CSF biomarkers, MRI brain scans, and cognitive test 
measures. 
 In chapter 5, a software with graphical user interface (GUI) is introduced, which 
is designed for combining information from genetic data (GWAS or sequencing), 
expression data (RNA-Seq), and protein structures.  
 In chapter 6, we summarize the research findings and discuss future work. 
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Table 1.1. Alzheimer’s disease susceptibility loci identified by previous GWA studies. 
Gene SNP RAF OR (95% CI) Function 
Relevant to  
APP pathway 
Relevant to  
Tau pathway 
APOE ε4 0.16 3.78 (2.60-5.48)  Lipid transport Aβ clearance -  
MAPT rs2732703-A 0.87 1.37 (1.23-1.53) Microtubule stabilization - 
Hyper- 
phosphorylation  
of Tau 
SORL1 rs11218343-T 0.96 1.30 (1.22-1.39) Vesicle trafficking 
Aβ generation  
and clearance 
- 
BIN1 rs6733839-T 0.41 1.22 (1.18-1.25) Clathrin-mediated endocytosis - tau toxicity 
CR1 rs6656401-A 0.20 1.18 (1.14-1.22) 
Regulation of complement  
activation 
Aβ clearance - 
CLU rs9331896-T 0.62 1.16 (1.12-1.19) 
Chaperone function 
regulation of cell proliferation 
Aβ 
aggregation 
and clearance 
- 
PICALM rs10792832-G 0.64 1.15 (1.12–1.18) 
Trafficking of  
synaptic vesicle proteins 
APP 
trafficking 
and Aβ 
clearance 
Colocalization 
in NFTs 
ABCA7 rs4147929-A 0.19 1.15 (1.11–1.19) 
Efflux of phospholipids and  
phagocytosis 
Aβ clearance - 
FERMT2 rs17125944-C 0.09 1.14 (1.09–1.19) 
Actin assembly and cell shape  
modulation 
- Tau toxicity 
CASS4 rs7274581-T 0.92 1.14 (1.09–1.19) Scaffolding protein - - 
MS4A6A rs983392-A 0.60 1.11 (1.09–1.15) Signal transduction - - 
EPHA1 rs11771145-G 0.66 1.11 (1.08–1.14) 
Brain development, modulating  
cell migration, axon guidance,  
and synapse development  
and plasticity 
- - 
HLA-DRB5, 
DRB1 
rs9271192-C 0.28 1.11 (1.08–1.18) 
Immunocompetence and  
histocompatibility 
- - 
PTK2B rs28834970-C 0.37 1.10 (1.08–1.13) 
Ion signaling and induction of  
long-term potentiation  
in the hippocampal CA1 neurons 
- - 
CD2AP rs10948363-G 0.27 1.10 (1.07–1.13) 
Cytoskeletal reorganization  
and vesicle movement 
Aβ clearance 
Protection 
 against 
tau toxicity 
ZCWPW1 rs1476679-T 0.71 1.10 (1.06–1.12) Epistatic regulation - - 
SLC24A4 rs10498633-G 0.78 1.10 (1.06–1.14) 
Neural development and  
regulation of blood pressure  
and hypertension 
- - 
TSPOAP1 rs2632516-G 0.60 1.08 (1.06-1.09) Benzodiazepine receptor binding 
Reverse Aβ 
accumulation 
- 
HBEGF rs11168036-T 0.50 1.08 (1.06-1.10) 
EGF-like growth factor  
in cardiac hypertrophy 
- - 
USP6NL rs7920721-G 0.40 1.08 (1.04-1.13) 
GTPase-activating protein  
in EGFR pathway 
- - 
INPP5D rs35349669-T 0.49 1.08 (1.05–1.11) 
Regulation of gene expression  
and posttranslational  
modification of proteins,  
microglial and myeloid function 
- - 
MEF2C rs190982-A 0.59 1.08 (1.05–1.11) Synaptic plasticity - - 
NME8 rs2718058-A 0.63 1.08 (1.05–1.11) Ciliary functions - - 
CELF1 rs10838725-C 0.32 1.08 (1.05–1.11) 
RNA splicing, editing,  
and translation 
- tau toxicity 
CD33 rs3865444-C 0.69 1.06 (1.04–1.1) 
Cell-cell interactions and cell 
functions  
in the innate and adaptive immune 
systems 
Aβ clearance -  
This table is modified from Van Cauwenberghe C. et al. study52. Genes and SNPs (the most significant 
association) are identified by meta-analyses49,58,59. RAF is the risk allele frequency. APP means amyloid 
precursor protein, Aβ is beta amyloid protein, and NFT is neurofibrillary tangles.  
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CHAPTER 2 Genetic Association Studies of Endophenotypes Related with 
Alzheimer’s Disease 
2.1 Genome-wide Association Study of Alzheimer’s Disease Endophenotypes at 
Preclinical Stages 
 Genetic associations for endophenotypes of AD in cognitive stages preceding AD 
have not been thoroughly evaluated.  
 We conducted genome-wide association studies using brain HPV, LMT, and CSF 
levels of Aβ42 and t-/p-Tau separately in 305 CN, 581 MCI, and 190 AD subjects from 
the ADNI database. Study-wide significant associations (SWS; P<8.3x10-9) were further 
examined by analysis of expression SNPs and differential gene expression patterns. 
 In CN subjects, SWS loci were identified for t-Tau with SNPs near SRRM4 (best 
SNP: rs10775009, P=1.59x10-9) and C14orf79 (rs2819438, P=4.58x10-9) and for HPV 
with SNPs near MTUS1 (rs4921790, P=1.38x10-9). In MCI subjects, SWS association 
was found with SNPs near ZNF804B for LMT-delayed recall (best SNP: rs73705514, 
P=2.27x10-9). Expression of MTUS1 was significantly elevated in AD compared in 
control brain (P=0.02) and associated with increased severity of tangle formation 
(P=3.9x10-4) from the hippocampal area of human brains. The expression patterns of 
C14orf79 and MTUS1 in AD brains compared in controls were consistent with the 
direction of effects with risk alleles of rs2819438 and rs4921790 for AD endophenotypes 
among AD cases. Genes associated with AD endophenotypes at preclinical stages were 
highly enriched (P<4x10-4) in neuronal synapse plasticity, axon quantity, microtubule 
dynamics, abnormal morphology of dentate gyrus, and development of neurons.  
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 Our findings for AD-related brain changes before onset of AD provide further 
insight about biological processes prior to AD development and potential targets for early 
stage intervention of AD. 
 
2.1.1 Introduction 
 The AD is the most common type of dementia and typically occurs after age 65 
years46,47. It is highly heritable, but the known genetic risk factors (currently numbering 
more than 25 loci including APOE) account for no more than 50% of the heritability of 
the disorder13,14,58. However, genetic association findings based on AD risk do not 
explain the whole genetic architecture of AD because the mechanistic complexity 
underlying AD is not captured entirely by disease status27,28. To overcome this limitation 
and understand preclinical stages of AD, researchers have examined the genetic 
underpinnings of AD-related endophenotypes including CSF levels of Aβ42 and tau 
proteins, structural brain changes quantified by MRI, and neuropsychological test 
measures of cognitive functioning, including memory loss65,66. GWA studies for AD-
related endophenotypes have identified novel loci in the ADNI study which enrolled 
appreciable numbers of subjects with AD, MCI, and CN67. Previous ADNI studies 
indicated the importance of delineating different stages of subjects68,69. We hypothesized 
that some genes may contribute to AD-related processes specifically during stages prior 
to AD onset. Genes and pathways that are strongly associated with AD-related 
endophenotypes in early disease stages may be promising targets for developing AD 
biomarkers and preventive medicines. To test this hypothesis, we conducted GWA 
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analyses for AD-related endophenotypes in cognitive subgroups of the ADNI sample. 
Here, we focused on the association tests in the CN and MCI subgroups because we are 
interested in identifying genes that may contribute to AD-related processes prior to AD 
onset. 
 
2.1.2 Subjects and Methods 
2.1.2.1 Subjects 
 GWA and phenotype data for ADNI participants were downloaded from a public-
access database (http://www.loni.usc.edu). A total of 1,076 subjects before QC were 
available with GWA data from two different chips (ADNI-1, n=757 and ADNI-GO/2, 
n=432).  Demographic information and mean endophenotype values for each of the 
clinical subgroups as well as the entire sample are presented in Appendix Table A.1. Age 
is similarly distributed in each subgroup. Sample sizes for analyses of CSF biomarkers 
were considerably smaller than for those of other traits. We stratified subjects based on 
baseline cognitive-impairment stages as defined by the standard ADNI protocol. 
 
2.1.2.2 Phenotypic Evaluation 
 Previously suggested AD-related endophenotypes including CSF biomarkers70, 
MRI brain imaging measures71 and episodic memory tests72 were selected for GWA 
analyses in this study. CSF biomarkers of Aβ42, t-Tau, and p-Tau, brain MRI measure for 
HPV, and scores for logical memory immediate (LMiT) and delayed (LMdT) recall tests 
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which were all measured at baseline were analyzed in this study. Details about collection 
of CSF biomarkers, brain MRI scan data, and neuropsychological tests are reported 
elsewhere73,74.  
  
2.1.2.3 Genotyping, QC, Imputation, and Population Substructure Analysis 
 Details of quality control (QC), genotype imputation, and population substructure 
analyses are described in Appendix A. After QC, the ADNI-1 sample with GWA data 
consisted of 187 CN, 329 MCI, and 163 AD subjects, and the ADNI-GO/2 contained 118 
CN, 252 MCI, and 27 AD subjects with GWA data. 
 
2.1.2.4 Genome-wide association tests 
 Prior to the association tests, each of the six endophenotypes was adjusted for 
covariates using linear regression. Age and sex were used as covariates for the six 
endophenotypes. A term for education level was additionally included in the regression 
models for LMiT and LMdT, while HPV was further adjusted for total intracranial 
volume. The residuals derived from the regression models were rank-transformed for 
normalization as previously described75. Analyses were conducted for all autosomal 
SNPs using the expected genotype dose, a quantitative measure between 0 and 2 of the 
number of effect alleles computed from the imputed genotype probabilities as the 
predictor. Association of the rank-normalized endophenotypes with each SNP was 
evaluated using a linear regression model including covariate terms for the first three 
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principal components (PC) of population substructure using the R software package. The 
two ADNI datasets were analyzed independently for the CN and MCI subjects and the 
results from the two ADNI datasets were combined by meta-analysis using inverse 
variance weights as implemented in the METAL program76. AD cases from the two 
ADNI datasets were analyzed as one group because the ADNI-GO/2 sample included 
only 27 AD subjects, and regression models for this group included an extra covariate for 
ADNI dataset. The genome-wide significant (GWS) threshold was set at 5.0x10-8. We 
determined a conservative SWS level of 8.3x10-9 which was calculated as the GWS level 
divided by the effective number of two endophenotypes and three clinical subgroups. The 
effective number of endophenotypes was computed by counting the number of 
eigenvalues greater than one from the PC analysis of all six endophenotypes. A threshold 
of P<10−6 was considered as suggestive evidence of association in the functional/pathway 
analysis.  
 
2.1.2.5 Expression SNP Analysis 
 We evaluated predicted function of SNPs showing suggestive association (P<10-6) 
from the GWA tests using HaploReg 
(http://www.broadinstitute.org/mammals/haploreg/)77. ENCODE78 data were used to 
evaluate potential regulatory function. We examined association of the SWS SNPs (allele 
counts) with transcript-level expression, i.e., expression SNP (eSNP), using the GTEx 
Portal (http://www.gtexportal.org)79.  
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2.1.2.6 Differential Gene Expression Analysis 
 Differential gene expression (DGE) was evaluated for genes containing or near 
significantly associated SNPs in two independent human brain expression datasets from 
Eisai Brain Bank (EBB) and Mt. Sinai Hospital (MSH; Gene Expression Omnibus [GEO] 
accession code: GSE44772)80.  
 The Eisai Brain Bank has gene expression measures obtained from RNA 
sequencing from the hippocampal area (HIPP) of samples collected from autopsied brains 
from 35 AD cases and 16 normal subjects ascertained at the University of Miami and 
McLean Hospital (Belmont, Massachusetts). A measure of neurofibrillary tangle 
involvement in the same samples was assessed following the previous protocol. Details 
about sample collection, preparation, and demographic characteristics are provided in 
Appendix B. The association of log2-transformed transcript expression levels (outcome) 
with AD status (predictor) was evaluated using linear regression adjusting for site, age, 
sex, and RNA integrity (RIN). A model testing the effect of Braak stage (0-6 stages) on 
transcript expression levels was also evaluated including the same covariates. The MSH 
microarray expression data were generated from autopsied brain tissue collected from 
dorsolateral prefontal cortex (DLPFC), visual cortex (VCX), and cerebellum (CER) 
regions in 129 AD patients and 101 controls. Samples were profiled on a custom-made 
Agilent 44K array containing 40,638 human genes. Gene expression data were 
normalized using Rosetta Resolver gene-expression analysis software as previously 
described80. The association of log2-transformed gene expression level (outcome) and AD 
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status (predictor) was tested using a linear regression model adjusting for RIN, 
postmortem interval (PMI), batch, preservation method, tissue pH, age, and sex.  
 
2.1.2.7 Co-expression Network Analysis of Human Brain RNA-Sequence Data 
 The top-ranked genes at or near (< 50kb) loci that achieved suggestive 
significance (P<10-6) in GWA tests of any trait in CN or MCI subjects or in the total 
sample were further evaluated for gene co-expression networks. We built gene co-
expression networks in the EBB HIPP RNA-Seq data (41,249 transcripts) by weighted 
gene co-expression network analysis (WGCNA), an approach which defines modules (or 
subsets) of genes that are highly co-expressed (or co-regulated)81. Details of this 
approach are described in Appendix C. In the HIPP co-expression network, we selected 
modules which carry both the top-ranked genes from this study and previously known 
AD genes27,28,33. The selected modules were functionally annotated by two enrichment 
analyses of ‘gene ontology (GO)’ and ‘disease-associated genes’ with a hypergeometric 
test. The ‘disease-associated genes’, genes involved in risk of diseases, were downloaded 
from GWASdb282. A P-value of significance for each enrichment test was calculated 
along with a false discovery rate (FDR), estimated using the Benjamini-Hochberg 
procedure. We used an FDR threshold of 0.05 to define associated GOs or diseases. The 
selected modules were further examined for correlations with traits (AD status and Braak 
stages) using the EBB sample by calculating the Pearson’s correlations between the 
module eigengene and the traits. 
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2.1.2.8 Functional Analysis and Brain Cell Type-Specific Expression Profiling 
 To identify shared functions among the top-ranked genes, we performed 
functional analysis using Ingenuity Pathway Analysis software (IPA, QIAGEN, 
Redwood, CA). IPA determines which molecular/cellular function terms (e.g., top-ranked 
genes in association tests) are statistically over represented, suggesting the GWA findings 
capture functional mechanisms underlying disease-related biological processes. We used 
a nominal P-value threshold of 0.05 to flag associated functions. We also examined 
neuronal cell type-specific expression for the top-ranked genes using single cell RNA 
sequencing data (GEO accession code: GSE67835). Further details of this analysis are 
described in Appendix D. 
 
2.1.3 Results 
2.1.3.1 Genome-wide Association Results 
 There was slight genomic inflation in GWA results for Aβ42 and LMdT in CN 
subjects (λ=1.02 for both traits; Appendix Figures A.1-12). Associations of the APOE ɛ4 
allele were SWS with the CSF biomarkers and suggestive with the other traits in MCI 
subjects, whereas ɛ4 was significantly associated only with Aβ42 level in CN subjects 
(Appendix Table A.2). Eleven of 25 other previously known AD loci – CR1, INPP5D, 
MEF2C, HBEGF, HLA region, ZCWPW1, USP6NL, MS4A region, PICALM, 
SLC2A4A, and CASS4 – were nominally significant (P<0.05) with at least one trait in 
CN and/or MCI groups (Appendix Tables A.3-8). 
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 Novel SWS associations were observed for endophenotypes in the CN and/or 
MCI subgroups (Table 2.1.1). In the CN group, there was SWS association for t-Tau with 
SNPs located 28 kb upstream of SRRM4 (best SNP: rs10775009, P=1.6x10-9; Figure. 
2.1.1A) and 66.8 kb upstream of C14orf79 (rs2819438; P=6.9x10-9; Figure. 2.1.1B). 
Rs10775009 and rs2819438 were also associated with p-Tau in this group (P<2.0x10-4). 
Another SWS association in CN subjects was detected for HPV with rs4921790 in 
PDGFRL and near MTUS1 (P=4.6x10-9; Figure. 2.1.1C). This finding was supported by 
suggestive association with many SNPs in high LD (r2>0.8 and D`>0.9) with rs4921790 
which are spread out across MTUS1. In the MCI subgroup, SWS association of LMdT 
was identified with three SNPs in ZNF804B (best SNP: rs73705514; P=2.9x10-9; Figure 
2.1.1D). In the AD subgroup, SWS association was observed with a SNP near 
LINC00271 and PDE7B for HPV (Appendix Figure. A.13.A).  
 
2.1.3.2 Expression-SNP Association Results 
 Several eSNPs under the SWS association peaks for the endophenotypes in the 
CN or MCI groups were significantly associated with expression of genes in those 
regions (Table 2). The minor allele of intergenic SNP rs2819438 was significantly 
associated with increased expression of C14orf79 in hippocampus (P=3.8x10-4, Figure. 
2.1.2A) and other brain regions, but not with expression of PLD4 and AHNAK2 which 
are located between rs2819438 and C14orf79. Rs4921790 was not associated with 
expression of MTUS1, however the minor alleles of rs4921790 proxy SNPs, rs55653268 
and rs10089607, were significantly associated with lower expression of MTUS1 in 
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several brain regions (Table 2.1.2 and Figure. 2.1.2B). In particular, the minor allele of 
rs10089607 was significantly associated with lower expression of MTUS1 in 
hippocampus (β=-0.23, P=5.3x10-3). Rs10089607 was not tested for PDGFRL 
expression, since its expression in brain areas was minimal according to the GTEx 
database. SRRM4 and ZNF804B SNPs, rs119390525 and rs73705514, were not 
significantly associated with expression in any brain regions.  
 
2.1.3.3 Association of Gene Expression with AD and Braak Stage 
 Further examination of C14orf79 and MTUS1 in the Eisai Brain Bank and Mt. 
Sinai gene expression datasets revealed several significant associations with AD status 
and Braak stage in several brain regions (Table 2.1.3). C14orf79 was not differentially 
expressed in hippocampus (P=0.76), but its expression was significantly lower in AD 
cases than controls in cerebellum (P=7.5x10-8), DLPFC (P=3.3x10-7), and VCX 
(P=2.1x10-8, Figure 2.1.2A). The association of C14orf79 expression with decreasing 
Braak stage was nearly significant (β [SE]=-0.07 [0.03], P=0.06) (Figure 2.1.2A). 
MTUS1 expression was significantly higher in AD cases than controls in hippocampus 
(P=0.02), DLPFC (P=0.01) and VCX (P=0.01, Figure 2.1.2B), MTUS1 expression was 
also positively correlated with Braak stage (β [SE]=0.16 [0.04], P=3.9x10-4; Figure 
2.1.2B). 
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2.1.3.4 Gene Co-expression Network Analysis in Hippocampus 
 Sixteen of 61 top-ranked genes (Appendix Table A.9) were clustered together 
with 17 known AD genes as co-expressed networks in eight modules (M1-M8; Appendix 
Table A.10) from WGCNA based the human HIPP transcriptome. These eight modules 
were significantly associated with AD status or Braak stages (Figure 2.1.3A). C14orf79 
was co-expressed with MAPT-AS1 in M1. MTUS1 was co-expressed with ZCWPW1 in 
M4. SRRM4 and ZNF804B were co-expressed with previously known AD genes – APP, 
BZRAP1, MAPT, MEF2C, PLXNA4, PTK2B, and PSEN2 – in M7. The M7 module is 
enriched for genes involved in neuronal processes including ‘chemical synaptic 
transmission’ (FDR=1.8x10-84), ‘dendrite’ (FDR=1.7x10-33), and ‘axon guidance’ 
(FDR=1.6x10-24). Modules M2, 4, 5, 6, and 8 are enriched for genes involved in ‘protein 
binding’, ‘signal transduction’, and ‘microtubule binding’ (Appendix Table A.10). 
Modules 1, 2, 5, 7, and 8 include genes that are associated with neurodegenerative and 
neuropsychiatric disorders including AD, Parkinson disease, and schizophrenia, and with 
cognitive performance (Appendix Table A.10).  
 
2.1.3.7 Functional Analysis 
 The top-ranked genes from the GWA analyses in the CN and MCI groups 
(Appendix Tables A.9) are enriched in neuronal processes including synapse plasticity 
(P=3.4x10-5), axon quantity (P=2.6x10-4), microtubule dynamics (P=2.8x10-4), abnormal 
morphology of dentate gyrus (P=3.4x10-4), and neuronal development (P=3.5x10-4). 
These findings indicate that genes associated with AD-related endophenotypes among 
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participants in clinical stages preceding AD dementia have particular roles in functioning 
of neuronal synapses (Figure 2.1.3C). Single-cell transcriptome analysis of the human 
brain confirmed that the genes in Figure 2.1.3C were highly expressed in neurons. Some 
genes were also expressed in other cell types: APOE, MTUS1, ERBIN, and AKAP9 in 
astrocytes; MTUS1, ERBIN, and AKAP9 in oligodendrocytes; and AKAP9 and RCAN1 
in endothelial cells. 
 
2.1.4 Discussion 
 A goal of this study was to identify genes that were both associated with AD-
related endophenotypes in older, non-demented individuals and co-regulated with known 
AD genes. Using a GWA approach, we identified SWS associations in cognitively 
normal elders including CSF t-Tau level with SRRM4 and C14orf79, HPV with MTUS1, 
and CSF Aβ42 level with APOE. In MCI subjects we detected SWS associations for 
LMdT with ZNF804B, and for CSF levels of Aβ42, t-Tau, and p-Tau with APOE.  
 Angiotensin II (AT2) interacting protein (ATIP) isoforms encoded by MTUS1 are 
highly expressed in most brain regions83. ATIP1 binds to AT2 proteins, mediating 
neuronal differentiation survival and regeneration in brain83-85. ATIP3 colocalizes with 
microtubules and regulates their polymerization, thereby regulating neuronal 
differentiation and neurite outgrowth85. Gene expression analysis revealed that the risk 
allele of eSNP near MTUS1 was associated with increased expression of MTUS1 in 
caudate. DGE analyses demonstrated that expression of MTUS1 was higher in AD cases 
than controls in HIPP, DLPFC, and VCX. Also, expression of MTUS1 was significantly 
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greater in brains showing severe neurofibrillary tangle involvement. The ADNI GWAS 
findings together with these expression findings suggest that MTUS1 expression may be 
related to changes in hippocampal volume prior to onset of cognitive impairment.  
 SRRM4 encodes the neural-specific Ser/Arg repeat-related protein of 100kDa 
(nSR100) that promotes neurite outgrowth and alternative splicing and controls most 
neural microexons86-88. Down-regulated SRRM4 alters splicing of microexons in autism 
brains86. Association of SRRM4 SNP rs1997111 with t-Tau level in a subset of ADNI 
controls (i.e., from “ADNI 1” only) was previously identified at a significance level one 
order of magnitude less (P=1.1x10-8) than the result we obtained among CN subjects in 
our study (P=1.76x10-9)89. The functional relevance of C14orf79 and ZNF804B, the two 
other SWS but poorly characterized genes, to AD is unclear.  
 We also detected two notable GWS associations including GRIN2B with Aβ42 
level in the CN group (Appendix Figure.A.13.B) and SNPs upstream of NRG1 with 
LMiT score in the MCI group (Appendix Figure.A.13.C). GRIN2B encodes the GluN2B 
subunit of the N-methyl-D-aspartate (NMDA) receptor (GluN2B-NMDA) which is 
involved in synaptic plasticity and memory function90. GluN2B-NMDA is the target of 
memantine, a drug that provides symptomatic relief in patients with AD by antagonizing 
the GluN2B-NMDA receptor. A suggestive association of GRIN2B with temporal lobe 
volume (P=1.3x10-7) was reported in a previous GWA study in the ADNI-1 sample91. 
NRG1 functions as an epidermal growth factor in the nervous system92 and is involved in 
the neuregulin signal transduction pathway for synapse maturation and dendritic 
morphology93. 
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 Among the known AD genes, we found suggestive evidence for association with 
several SNPs located 381 kb upstream of AKAP9 with p-Tau level in MCI subjects 
(Appendix Figure A.13.D). We also found a suggestive association between 
rs149454736, located between exons 45 and 46 of AKAP9, and HPV in AD dementia 
subjects (P=2.2x10-7). Previously, we identified significant association of AD with two 
rare coding AKAP9 missense mutations in exons 31 (rs144662445) and 46 
(rs149979685) in African Americans94, and our study is the first to report association 
with this gene for AD risk in European ancestry individuals. Rs149454736 is located 1.5 
kb away from rs149979685. AKAP9 has functional similarity with the tau protein in 
terms of microtubule stability and assembly95.  
 Our findings may provide important insights about the sequence of processes 
leading to AD. The SWS associations in CN subjects (SRRM4 with t-Tau and MTUS1 
with HPV) implicate neuronal signaling, development and loss, but with the exception of 
APOE, they do not involve Aβ processing in the asymptomatic stage of AD. It is 
noteworthy that the APOE Ɛ4 allele was not associated with the CSF Tau biomarkers and 
other endophenotypes in cognitively normal subjects. The variants associated with CSF 
biomarkers and HPV could also be interpreted to be markers of cognitive 
reserve/resilience because they predict the extent of AD pathology in cognitively normal 
persons, but not in MCI or AD subjects. There is extensive evidence supporting the 
cognitive reserve hypothesis in AD96. Also, the variants identified for memory 
performance and HPV in cognitively normal individuals could be markers of inherent 
memory function and hippocampal volume, completely independent of AD.  
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 Our study has several limitations. The sample sizes for analyses of all traits in 
each clinical group, especially AD cases, were relatively small. Thus, we had low power 
to identify variants having small effects. In addition, it is possible that our top findings 
are false positives.  However, the significant SNPs were supported by evidence in both 
constituent datasets (ADNI-1 and -GO/2) and from expression data analysis. Nonetheless, 
it is necessary to repeat these analyses in independent samples to confirm our findings 
and increase power to elevate the significance of true associations which did not attain 
study-wide significance. 
 In summary, we identified novel genes associated with AD-related 
endophenotypes in cognitively normal and MCI subjects. These genes had not been 
previously identified with AD risk and most of them are involved in neuronal 
development and signaling. Our findings suggest that genes influencing AD-related 
processes in individuals with normal cognition or with mild cognitive impairment may 
differ from those influencing these processes in individuals with AD dementia. In 
addition, our study provides new insights about early mechanisms leading to AD 
pathophysiology and development of novel early biomarkers and therapeutic and 
preventive strategies before symptoms of AD appear. 
  
Table 2.1.1. Genome-wide significant association (P<5.0x10-8) of novel genes from the ADNI GWAS using the sample prior to AD. 
Group Traits CHR BP SNP MA MAF BETA SE P Closest Genes 
ALL Aβ42 8 20647323 rs55644114 A 0.16 0.41 0.07 2.54x10-8 GFRA2, LZTS1 
 
Aβ42 
12 13870464 rs74442473 G 0.07 -1.02 0.18 2.53x10-8 GRIN2B 
 17 59687842 rs2378873 T 0.44 -0.53 0.10 2.03x10-8 BRIP1, NACA2 
 
t-Tau 
12 119390525 rs10775009 T 0.34 0.51 0.09 1.59x10-9 SRRM4 
CN 14 105385352 rs2819438 A 0.13 -0.80 0.14 6.94x10-9 PLD4, C14orf79 
 HPV 8 17496561 rs4921790 C 0.12 0.61 0.10 4.58x10-9 PDGFRL, MTUS1 
 
LMdT 
1 57739164 rs74834332 A 0.03 0.79 0.14 4.30x10-8 DAB1 
 10 53818149 rs12268753 C 0.21 0.30 0.05 2.01x10-8 PRKG1 
 
LMdT 
4 86416554 rs111882035 G 0.02 -0.93 0.17 2.74x10-8 ARHGAP24 
MCI 7 88406552 rs73705514 C 0.02 -0.84 0.14 2.86x10-9 ZNF804B 
 LMiT 8 31228770 rs118130881 G 0.04 -0.61 0.11 1.72x10-8 NRG1 
AD HPV 6 136077929 rs79846291 T 0.02 1.85 0.31 1.76x10-8 LINC00271, PDE7B 
MA is minor allele, and MAF is the minor allele frequency. Bold SNPs denote the study-wide significant association (P<8.33x10-9) with a trait.  
  
  
Table 2.1.2. Genotype specific effect of the expression level among study-wide significant (8.33x10-9) SNPs using the GTEx Portal database. 
            
Gene 
  eSNP Association Summary 
   Association  LD   Hippocampus   Other brain region 
eSNP EA RA Traits Group β (SE) P   with SNP r2 D`     P-value (β)   P-value (β) Region 
rs10775009  T C t-Tau CN 0.5 (0.1) 1.6x10-9   . . .   SRRM4   0.09 (0.09)   0.16 (0.10) Frontal Cortex 
rs2819438 A C t-Tau CN -0.8 (0.1) 6.9x10-9 
  
. . . 
  PLD4   0.47 (0.12)   0.10 (0.42) 
Anterior  
cingulate  
cortex 
  AHNAK2  0.15 (0.23)  0.06 (-0.28) 
Cerebellar  
hemisphere 
  C14orf79  3.8x10-4 (0.44)  
3.9x10-3 (0.31) 
6.0x10-3 (0.44) 
Cortex 
Cerebellum 
rs4921790  C A HPV CN 0.6 (0.1) 4.6x10-9   . . .   
MTUS1 
  1.0 (0.0)   0.09 (-0.16) Caudate 
rs55653268 T G HPV CN 0.6 (0.1) 4.2x10-7  rs4921790 0.7 1.0   0.8 (0.04)  
9.7x10-3 (-0.33) 
0.02 (-0.41) 
Caudate 
Nucleus  
accumbens 
rs10089607 G C HPV CN 0.1 (0.7) 0.03   rs4921790 0.2 0.9     5.3x10-3 (-0.23)   
4.2x10-6 (-0.34) 
1.8x10-4 (-0.33) 
2.4x10-4 (-0.31) 
Caudate 
Cortex 
Putamen 
EA and RA indicate effect allele and reference allele, respectively. Positive effect (β) in eSNP association summary means that carriers with effect alleles of a SNP tend 
to have higher expression level of a gene. 
 
  
  
Table 2.1.3. Summary statistics of association between expression levels of the genes (MTUS1 and C14orf79) and AD status as well as Braak Stage.  
    MTUS1  C14orf79 
Source Brain region Predictor  β SE P  β SE P 
Eisai 
Brain 
Bank 
HIPP AD Status  0.38 0.16 0.02  0.04 0.14 0.76 
HIPP Braak Stages  0.16 0.04 3.9x10-4  -0.07 0.03 0.06 
Mount. 
Sinai 
Hospital 
CER AD Status  0.00 0.02 0.78  -0.13 0.02 7.5x10-8 
DLPFC AD Status  0.09 0.04 0.01  -0.13 0.02 3.3x10-7 
VCX AD Status  0.09 0.03 0.01  -0.15 0.03 2.1x10-8 
Brain regions tested were hippocampus (HIPP), cerebellum (CER), dorsolateral prefontal cortex (DLPFC), visual cortex (VCX). Positive effect (β) for AD status means 
that a gene is up-regulated in AD cases vs. in controls. Positive effect for Braak stages means that the expression of a gene is positively correlated with the Braak stages. 
Linear regression was applied for the association tests after adjusting for covariates (details in the chapter 2.1.2.3). 
  
  
Figure 2.1.1. Regional association plots.  
A. B. 
  
C. D. 
  
(A) SRRM4 and (B) C14orf79 for CSF total tau in the CN subjects, (C) MTUS1 for hippocampal volume in the CN subjects, and (D) ZNF804B for logical memory 
delayed recall test in the MCI subjects 
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Figure 2.1.2. Expression studies of (A) C14orf79 and (B) MTUS1. 
 
Boxplots for expression SNP associations of rs2819438 for C14orf79 and rs10089607 for MTUS1 and (left column); 
boxplots for differentially expressed genes in the brain hippocampus (HIPP) of the Eisai Brain Bank data and in the 
brain dorsolateral prefontal cortex (DLPFC) of the Mount. Sinai Hospital data (middle column); and plots of gene 
expressions by Braak stages of the Eisai Brain Bank data (right column). P-values in plots were computed from linear 
regression models after adjusting for covariates (details in the Methods). 
  
Figure. 2.1.3. Co-expression network analysis and functional analysis.  
 
(A) A heat-map of correlations between AD traits and the first principal component values of genes in modules. Deeper colors indicate higher correlation with the traits 
(red: positive and blue: negative). Values in the heat-map are correlation P-values. (B) Connectivity plot of genes in modules M4 and M7, which were identified in this 
study or in previously reported in AD genome-wide association studies (GWAS). Light colored circles indicate the genes identified in this study, and deep colored circles 
indicate previously identified AD genes. (C) The role of genes identified in GWAS of AD-related endophenotypes among cognitively normal and mild cognitively 
impaired subjects in the top-ranked canonical pathways; colors indicate the level of association significance of the genes identified in this study (red = study-wide 
significance; blue = genome-wide significance; orange = P<1.0x10-6 (except for BDNF in Appendix Figure A.13.E). 
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2.2 Bivariate Genome-wide Association Study of Neuropathological Traits Related 
to Alzheimer’s Disease 
 Simultaneous consideration of two neuropathological traits related to AD has not 
been attempted in a genome-wide association study.  
 We conducted bivariate analysis using association summary statistics from the 
Beecham et al. study of AD-related neuropathological traits including NP, NFT, and 
CAA. Significant findings were further examined by expression quantitative trait locus 
and differentially expressed gene analyses in AD vs control brains using gene expression 
data.  
 Genome-wide significant associations were observed for the bivariate NP and 
NFT outcome with SNP rs34487851 upstream of ECRG4 (Pbivariate=2.4x10-8) and for the 
bivariate NFT and CAA outcome with HDAC9 SNP rs79524815 (Pbivariate=1.1x10-8). 
Gene-based testing revealed study-wide significant associations (P<2.0x10-6) with for the 
NFT+CAA outcome with adjacent genes TRAPPC12, TRAPPC12-AS1, and ADI1). Risk 
alleles of proxy SNPs for rs79524815 were associated with significantly lower expression 
of HDAC9 in brain (P=3.0x10-3), and HDAC9 was significantly down-regulated in AD 
subjects compared to controls in the prefrontal (P=7.9x10-3) and visual (P=5.6x10-4) 
cortices.  
 Our findings suggest that bivariate analysis is a useful approach to identify novel 
genetic associations with complex diseases and their endophenotypes. Functional studies 
are needed to determine whether ECRG4 or HDAC9 are plausible therapeutic targets. 
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2.2.1 Introduction 
 The AD is the most common type of dementia in persons age 65 years and 
older42,97. Pathologically, it is primarily characterized by the appearance of both NP 
containing oligomers of Aβ and NFT, accompanied by a progressive loss of neurons in 
the brain97,98. Also, CAA, which is caused by aggregates of β-amyloid in walls of blood 
vessels in brain, is found in as many as 90% of autopsy-confirmed AD cases99. 
Previously, Beecham et al. identified multiple significant gene associations by GWAS for 
several AD-related neuropathological traits including NP, NFT, and CAA measured in 
brains from subjects with pathologically-confirmed AD cases and controls with no 
evidence of neurological disease64. We hypothesized that additional novel associations 
could be identified in models allowing a genetic variant to influences more than one trait 
(i.e., pleiotropy). In this study, we performed genome-wide analyses of bivariate 
outcomes of NP, NFT and CAA using data from the previous study3. 
 
2.2.2 Methods 
2.2.2.1 Study Population, Neuropathological Trait Selection, and Data Processing 
 We obtained summary statistics from univariate GWAS of NP, NFT, and CAA64. 
These results were derived from meta-analyses of 12 studies including 3,598 subjects 
(3,135 AD cases, 463 controls) of European ancestry64. Neuropathologic data for the 
entire sample were reviewed and harmonized by one neuropathologist for consistency 
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across studies. Although Beecham et al. also evaluated Lewy body disease, hippocampal 
sclerosis and vascular brain disease, we limited our analyses to neuropathological 
outcomes most directly linked to AD and moderately correlated with each other (i.e. NP, 
NFT and CAA). Uncorrelated traits are unlikely to show significant bivariate associations 
and results from bivariate analysis will be similar to those from univariate models if the 
traits are highly correlated. Details of subject recruitment, genotyping, genotype 
imputation, quality control procedures, population substructure analysis, and statistical 
methods for association analyses of individual traits were reported previously58,64. 
Sample demography of the 3,598 subjects with autopsied brains and genotypes (3,135 
cases and 463 controls) is described in Appendix Table B.1. 
 
2.2.2.2 Univariate genome-wide association analyses 
 Results from the association tests by Beecham et al.64 in each dataset for each 
neuropathologic trait with genotypes imputed using the 1000 Genomes reference panel 
(GRCh37 at Dec. 2010). for a genome-wide set of SNPs were obtained using ordinal 
logistic regression models including the first three principal components of ancestry as 
covariates to account for population substructure64. NP and NFT measures were analyzed 
in well-established ordinal rankings (NPs: none, sparse, moderate, and frequent by 
consortium to establish a registry for AD [CERAD] scoring100; NFT: none, 
transentorhinal, limbic, and isocortical by Braak and Braak staging41), and CAA was 
analyzed as binary trait (present or absent). Full details of these analyses are reported 
elsewhere64. We used meta-analyzed GWAS summary statistics (β and standard error 
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[SE]) of the three neuropathologic traits for 6.5 million imputed SNPs after filtering 
SNPs with minor allele frequency > 1%, imputation quality (R2) > 0.4, and dosage 
variance 0.02. 
 
2.2.2.3 Bivariate genome-wide association analyses 
 We conducted a bivariate GWAS for each pairing of the three neuropathologic 
traits using two approaches. First, we constructed conditional quantile-quantile (QQ) 
plots from the univariate summary statistics to evaluate the relative enrichment of SNPs 
showing evidence for association with both traits in each pairing. Following the 
technique described previously101,102, for two traits A and B, we plot the observed versus 
expected –log10 (p-values) of trait B for each stratum of p-values for trait A. The 
conditional QQ plots reveal the enrichment of GWAS signals between the two traits101. 
We also applied the O’Brien method for pleiotropy analysis103,104 which is implemented 
in an R library, CUMP105. This method combines univariate test statistics (Z scores from 
βs and standard error [SE]s) of all SNPs from separate GWAS for multiple phenotypes to 
compute a multivariate normal distribution with mean, combined test statistics for all 
SNPs, and covariance matrix of the multiple phenotypes (correlation). The covariance 
matrix was approximated by the sample covariance matrix of the test statistics of all 
SNPs. Under the null hypothesis for a bivariate analysis, a SNP is not associated with any 
of the phenotypes. Alternatively, a SNP is associated with at least one of the phenotypes. 
We defined a SNP having a pleiotropic effect on two phenotypes when the bivariate P-
value (Pbivariate) of the SNP is at least one order of magnitude lower than the univariate P-
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values (Punivariate) for both phenotypes and the univariate P-values are at least nominally 
significant (Punivariate < 0.05).  
 
2.2.2.4 Gene-based association 
 We performed genome-wide gene-based tests for each bivariate outcome using 
results from individual SNP tests. SNPs within 30 kb of transcription start and end sites 
were included in each gene-based test. These analyses were carried out using the VEGAS 
method106 which computes an empirical P-value through Monte Carlo simulations (or 
permutations) based on linkage disequilibrium patterns of the European ancestry 
population in the 1000 genome project (GRCh 37 released at March 2012). Gene-wide 
significant level for gene-based test was set as 2.7x10-6 which was calculated as the 
nominal significance level divided by the total number of genes tested (n = 18,500).  
 
2.2.2.5 Expression Quantitative Trait Locus (eQTL) Analysis 
 The association of SNP genotypes with gene-level expression, eQTLs, was 
evaluated using the GTEx Portal database (http://www.gtexportal.org)79 and data from 
the Mayo Clinic brain expression GWAS (eGWAS) (https://www.synapse.org)107. The 
GTEx Portal provides eQTL association summary statistics (β and P-value) across 43 
different tissues from 175 subjects. The Mayo Clinic brain eGWAS data were generated 
from CRE (197 AD and 177 non-AD controls) and temporal cortex (TCX; 202 AD and 
197 non-AD controls) regions. Gene expression measures for 24,526 probes were 
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generated with the Illumina Whole Genome DASL array. SNP genotype data for the 
Mayo Clinic eGWAS was obtained from the Mayo Clinic LOAD GWAS108. AD cases 
were diagnosed as definite AD according to NINCDS-ADRDA criteria, whereas non-AD 
controls had other neuropathologies. For each brain region, association of gene 
expression and imputed SNP genotype (GRCh36) was evaluated using linear regression 
including covariates for AD status, APOE ε4 dosage (0, 1, or 2), age at death, gender, 
plate, RIN, and (RIN-RINmean2). Analyses were also conducted for AD cases and non-
AD controls, separately.  
 
2.2.2.6 Differential Gene Expression Analysis 
 DGE analysis was performed using publically available brain whole 
transcriptome RNA-Seq109 data and microarray data (GEO accession code: GSE44772)80. 
The RNA-Seq data include DGE summary statistics for the CER and TCX derived from 
86 AD patients and 80 controls (https://www.synapse.org). Following QC, 80 AD and 76 
control brains were analyzed. All subjects underwent RNAseq using Illumina HiSeq 
2000, 101 base-pair, paired end sequencing at the Mayo Clinic Genomic Core Facility. 
All AD and some of the control brains were from the Mayo Clinic Brain Bank; whereas 
other control brains were from the Banner Sun Health Institute. Following quality 
control, raw read counts normalized according to conditional quantile normalization 
(CQN) using the Bioconductor package were used in the analyses. For DGE comparing 
AD vs. controls, multi-variable linear regression analyses were conducted in R, using 
CQN normalized gene expression measures and including age at death, gender, RIN, 
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brain tissue source, and flowcell as biological and technical covariates. We also included 
cell specific gene levels as covariates, using the expression levels for the 5 central nerve 
system (CNS)-specific genes as follows: ENO2 for neurons (ENCODE ID: 
ENSG00000111674), GFAP for astrocytes (ENSG00000131095), CD68 for microglia 
(ENSG00000129226), OLIG2 for oligodendrocytes (ENSG00000205927) and CD34 for 
endothelial cells (ENSG00000174059), to account for any CNS cell-population changes 
that occur as a consequence of disease pathology.  
 The microarray gene expression data were generated from autopsied brains 
collected from DLPFC, VCX, and CER regions of 129 AD patients and 101 controls. 
Samples were profiled on a custom-made Agilent 44K array containing 40,638 human 
genes. Gene expression data were normalized using Rosetta Resolver gene-expression 
analysis software as previously described107. The association between expression of each 
gene (outcome) and AD status (predictor) was tested using linear regression adjusting for 
RIN, postmortem interval (PMI), batch, preservation method, pH in tissues, age, gender, 
and the five cell-type markers. 
 
2.2.3 Results 
2.2.3.1 Correlation among the Analyzed Neuropathological Traits 
 NP, NFT, and CAA, were moderately correlated (NP-NFT, r=0.68; NP-CAA, 
r=0.56; NFT-CAA, r=0.40; P-value for each pair of traits < 2.2x10-16) indicating a 
potential for discovery of novel associations in bivariate analysis. 
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2.2.3.2 Conditional Q-Q plots 
 There was significant SNP enrichment with all pairwise combinations of the three 
neuropathologic traits (Figure 2.2.1). For progressively stringent P-values thresholds (i.e., 
increasing values of the nominal –log10 (p-value)) for each trait, we found strong 
enrichment (ie, leftward shift or decreasing values of the empirical –log10 (p-value)) for 
each of the other two traits.  Excluding SNPs from the APOE region did not result in 
attenuation of genetic enrichment for the pairs NP+NFT (Figure 2.2.1A) and NFT+CAA 
(Figure 2.2.1C), indicating that the observed pleiotropy between the traits was not 
confined to the APOE region. However, there was no evidence for pleiotropy between 
NP and CAA outside of the APOE region (Figure 2.2.1B).  
 
2.2.3.3 Bivariate GWAS Results 
 There was no inflation in P-values for the GWAS of the three neuropathologic 
traits analyzed individually (genomic control parameter, λ, = 1.00, 1.01, and 0.96 for NP, 
NFT, and CAA, respectively) or as bivariate outcomes (Appendix Figure B.1). Results of 
the bivariate GWAS are shown in Appendix Figure B.2. As reported previously, with the 
exception of APOE, only 15 of 25 previously known AD loci attained at least nominal 
association with NP, NFT, or CAA64. Three of the previously established AD loci – 
BIN1, HLA region, and PICALM – were moderately associated (P < 10-4) in the bivariate 
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analysis for NP and NFT at a significance level of at least one order of magnitude smaller 
compared to the results from univariate analyses (Appendix Table B.2).  
Two novel GWS (P < 5.0x10-8) associations were detected in the bivariate analyses 
(Table 2.2.1, Figure 2.2.2). Rs34487851, a SNP located approximately 40 kb upstream of 
ECRG4, was associated with the bivariate model of NP and NFT (Pbivariate = 2.0x10-8). An 
intronic SNP in HDAC9, rs79524815, was associated with the bivariate model of NFT 
and CAA (Pbivariate = 1.1x10-8). The major allele A of rs34487851 and the minor allele G 
of rs79524815 are associated with increased NP and NFT and with increased NFT and 
the presence of CAA, respectively. Both of these findings were at least one order of 
magnitude more significant than for the univariate traits (Table 2.2.1) and were supported 
by evidence from multiple SNPs at those locations (Figure 2.2.2, Appendix Table B.3).  
 
2.2.3.4 Gene-based Bivariate Analysis Results 
 Three contiguous novel genes on chromosome 2p25.3 (TRAPPC12, TRAPPC12-
AS1, and ADI1) were associated with the bivariate pair of NFT and CAA at a gene-wide 
significant level (P < 2.0x10-6; Table 2.2.2; Appendix Figure B.3). Of note, one SNP in 
this region (rs35067331 in TRAPPC12) was associated with the NFT-CAA outcome at 
near the GWS level (Pbivariate = 5.8x10-8; Appendix Table B.4).  
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2.2.3.5 eQTL Analysis 
 We performed eQTL association analysis to examine whether the expression 
levels of the five GWS significant genes identified in the bivariate association tests 
differed between carriers and non-carriers of the risk alleles from those loci. Because 
information about the two GWS SNPs was not available in the GTEx Portal database or 
the Mayo Clinic brain eGWAS, we analyzed proxy SNPs that are in high LD (D` ≥ 80) 
with the GWS SNPs. According to GTEx, rs34487851 proxy SNP rs1232803 is a cis-
acting eQTL and the major allele A, which is associated with higher NP and NFT, is also 
significantly associated with decreased expression of ECRG4 in several tissues including 
esophagus (P = 3.5x10-5), transverse colon (P = 4.7x10-4), and tibeal artery (P = 1.7x10-3), 
but not in any brain regions. In the Mayo Clinic brain eGWAS, proxy SNPs for 
rs34487851 were not cis-acting eQTLs for ECRG4. In GTEx, proxy SNPs for 
rs79524815 were not associated with the expression of HDAC9. However, in the brain 
eGWAS, the minor alleles of proxy SNPs for rs79524815, which are associated with 
higher NFT and CAA, were significantly associated with lower HDAC9 levels in the 
CER (probe ID: ILMN_1803563; best eQTL: rs4721721, P = 0.003) but not in the TCX 
(Appendix Table B.3). According to GTEx, rs35067331 is a cis-acting eQTL, and its 
major allele C, which is associated with higher NFT and CAA, is significantly associated 
with increased expression of TRAPPC12-AS1 in several brain regions (best P = 2.1x10-7 
in cortex) and ADI1 (P = 0.03) in caudate, but not with differential expression of 
TRAPPC12 in any brain regions (Appendix Table B.4). In the Mayo Clinic brain 
eGWAS data, rs35067331 and its proxy SNPs were not cis-acting eQTLs for ADI1 or 
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TRAPPC12. Unfortunately, information about TRAPPC12-AS1 was unavailable in the 
brain eGWAS.  
 
2.2.3.6 Differential Gene Expression Analysis 
 We investigated whether the expression levels of ECRG4, HDAC9, and 
TRAPPC12/TRAPPC12-AS1/ADI1 differed in AD brains compared to non-AD control 
brains in the publicly available RNS-Seq and microarray datasets (Table 2.2.3). There 
were no significant differences in ECRG4 expression between AD subjects and controls 
in TCX or CER in the Mayo Clinic RNA-Seq DGE profiling. However, ECRG4 was 
significantly down-regulated in AD subjects compared to controls in CER (P = 1.6x10-3), 
DLPFC (P = 0.04), and VCX (P = 2.7x10-3) in the microarray brain expression data. 
HDAC9 was significantly down-regulated in AD subjects compared to controls in several 
brain regions including TCX (P = 1.5x10-4) and CER (P = 0.04) in the RNA-Seq profiling 
data and in DLPFC (P = 7.9x10-3) and VCX (P = 5.6x10-4) in the microarray expression 
data. ADI1 expression was down-regulated in AD subjects in CER in the microarray data 
(P = 4.9x10-4). The RNA-Seq DGE profiling indicated that TRAPPC12-AS1 expression 
was significantly increased in AD subjects in TCX (P = 1.3x10-3). In contrast, expression 
of TRAPPC12 was significantly lower in AD subjects than controls in TCX (P = 0.01) in 
the RNA-Seq and in CER (P = 1.1x10-3) and VCX (P = 3.2x10-4) in the microarray data. 
Information about expression of TRAPPC12-AS1 was not available in the microarray 
data. 
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2.2.4 Discussion 
 A previous GWAS of neuropathologic traits including NP, NFT, and CAA 
identified GWS associations with APOE only1. Our bivariate analysis of all pairwise 
combinations of these traits identified GWS associations with APOE and three regions 
not previously reported with any neuropathologic traits or AD risk, including ECRG4 for 
the bivariate trait comprising NP and NFT, and HDAC9 and TRAPPC12/TRAPPC12-
AS1/ADI1 for the bivariate trait comprising NFT and CAA. Our differential gene 
expression study found that HDAC9 is significantly down-regulated in several brain 
regions in AD subjects compared with controls. Moreover, we observed that the G allele 
of HDAC9 SNP rs79524815 is associated with a higher level of the joint outcome of 
NFT and CAA, and proxy SNPs for rs79524815 (which are suggestively associated with 
the joint outcome of NFT and CAA) are associated with decreased HDAC9 expression in 
AD subjects (Appendix Table B.3). The bivariate analysis also revealed that four (BIN1, 
HLA, PICALM, and APOE) of the 25 previously reported GWS AD risk loci, were at 
least one order of magnitude more significantly associated with the bivariate trait 
NP+NFT compared with each of these traits analyzed separately, suggesting that these 
genes are involved in pathways leading to both plaques and tangles110,111.  
 Esophageal cancer-related gene-4 (ECRG4) is a known tumor suppressor gene112 
that encodes a peptide hormone which is involved in the NFT formation in transgenic 
mice113, senescence of precursor cells in central nervous system during aging114, and 
activation of microglia and peripheral mononuclear leukocytes115. We observed that 
rs34487851 allele A is associated with higher NP and NFT and lower expression of 
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ECRG4 albeit not in brain. We also found that ECRG4 expression was significantly 
lower in AD cases compared to controls in several brain regions. Abnormally down-
regulation of ECRG4 was previously reported in brain injury, as well as in several cancer 
cell types116.  
 HDAC9 encodes a member of class IIa histone genes that deacetylate histones, 
thereby remodeling chromatin structure and controlling gene expressions117,118. GWS 
association of ischemic stroke with a HDAC9 variant was identified by GWAS119,120. 
Structural variants including deletions and copy-number variants in HDAC9 have been 
identified in schizophrenia and autism patients121. MEF2C, one of the well-established 
AD risk loci49, stimulates HDAC9 expression, but HDAC9 suppresses MEF2C 
transcription resulting in a negative feedback loop122. In a previously reported co-
expression network study in AD and control brains, HDAC9 and MEF2C were clustered 
together in the top fourth module ranked by relevance to AD pathology, and HDAC9 and 
MEF2C expression were inversely correlated with Braak stage (HDAC9: r = -0.71, 
MEF2C: r = -0.65) and frontal atrophy (HDAC9: r = -0.57, MEF2C: r = -0.51)80. These 
findings are consistent with our observation that HDAC9 expression is reduced in AD 
subjects and in the subjects with HDAC9 SNP alleles associated with higher NFT and 
CAA. Decreased HDAC9 expression has also been linked to increased neuronal 
apoptosis123,124. Collectively, findings from our and other studies indicate that MEF2C 
and HDAC9 may participate in a pathway leading to NFT formation and brain atrophy.  
 Gene-based analyses identified significant associations with three adjacent loci – 
TRAPPC12, TRAPPC12-AS1, and ADI1 – in a gene-rich region near the end of the short 
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arm of chromosome 2p. ADI1, encoding acireductone dioxygenase, is involved in 
methionine salvage and prostate cancer125, and has no known relationship to AD. 
TRAPPC12 is a subunit of trafficking protein particle complex which has a role in vesicle 
trafficking in endoplasmic reticulum to Golgi126. TRAPPC12-AS1 is an anti-sense (non-
coding) RNA that contains a 1,168 transcript from TRAPPC12. We previously 
established that regulation of vesicular trafficking in the ER-to-Golgi by several VPS10 
receptor domain receptor genes including SORL1 and by other genes encoding members 
of the retromer complex is an important pathway leading to AD62. Of the genes in this 
region, only TRAPPC12-AS1 showed a pattern of expression in AD and control subjects 
that is consistent with the effect direction of the TRAPPC12 rs35067331 allele’s 
influence on NFT and CAA. It should be noted that TRAPPC12 expression was 
significantly lower in AD cases than in controls in TCX (P = 0.01) in the RNA-Seq data 
and CER (P = 1.1x10-3) and VCX (P = 3.2x10-4) in the microarray data, which could be 
due to negative feedback by the anti-sense TRAPPC12-AS1 transcript127.  
 Our study has several potential caveats. The GWS associations identified in the 
bivariate analysis have moderate supportive evidence for association from other SNPs 
under the association peaks, probably because of low LD with the top SNPs. The two 
GWS SNPs near ECRG4 and HDAC9 were not associated with AD risk in one of the 
largest GWAS for AD (rs34487851, P = 0.07; rs79524815, P = 0.73). However, 
approximately 87% of the autopsy samples used in this bivariate analyses (as well as in 
the Beecham et al. study) were from AD patients. This may indicate that our findings are 
more relevant with neuropathological progression after onset of AD clinical symptoms. 
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Alternatively, because our study focused on endophenotypes which might be more 
proximal than disease diagnosis to effects of the genetic variants128,129, our analyses 
might have more power to detect those novel associations. Finally, to our knowledge, 
additional large late onset AD cohorts with neuropathological and genotype data are not 
currently available for replication of our association findings. Therefore, validation of the 
role of these loci in AD will likely require experimental evidence.  
 Our findings suggest that bivariate analysis is a useful approach to identify novel 
genetic associations with complex diseases and their endophenotypes. Functional studies 
are needed to determine whether ECRG4 or HDAC9 are plausible therapeutic targets. 
 
 
 
 
Table 2.2.1. Genome-wide significant association (P<5.0x10-8) of novel genes in the genome-wide bivariate analyses of the three neuropathological traits. 
      Univariate  Bivariate 
    
  AD status NP NFT CAA  NP+NFT NP+CAA NFT+CAA 
CH SNP Gene EA RA EAF β (SE) P β (SE) P β (SE) P β (SE) P  Dir P Dir P Dir P 
2 rs34487851 ECRG4 G A 0.27 
-0.42 
(0.09) 
5.8x10-6 
-0.3 
(0.06) 
7.7 x10-7 
-0.25 
(0.06) 
4.5 x10-6 
-0.14 
(0.08) 
0.06  - 2.0x10-8 - 2.5x10-6 - 2.1x10-5 
7 rs79524815 HDAC9 G T 0.03 
0.69 
(0.31) 
0.03 
0.43 
(0.19) 
0.03 
0.79 
(0.19) 
2.3 x10-5 
1.16 
(0.26) 
9.1x10-6  + 1.3x10-4 + 3.3x10-6 + 1.1x10-8 
Neuritic plaque (NP), neurofibrillary tangles (NFT), and cerebral amyloid angiopathy (CAA) 
  
 
 
 
Table 2.2.2. Gene-wide significant results (P<2.7x10-6) from gene-based tests of bivariate SNP association results.  
    Univariate Gene-based Tests  Bivariate Gene-based Tests 
CH Start End Gene NP NFT CAA  NP+NFT NP+CAA NFT+CAA 
2 3,383,446 3,483,342 TRAPPC12 0.09 4.0x10-5 0.5   0.01 0.07 2.0x10-6 
2  3,485,013 3,486,180 TRAPPC12-AS1 0.002 3.9x10-5 5.0x10-3  1.6x10-5 2.1x10-5 < 1.0x10-6 
2 3,501,690 3,523,350 ADI1 0.003 1.6x10-5 7.0x10-4   3.2x10-5 4.0x10-6 < 1.0x10-6 
Gene-based P-values were computed through one million permutations, so the smallest P-value is 1.0x10-6. 
  
 
 
 
Table 2.2.3. Results of differential gene expression analysis in brain.  
 RNA-Seq  Microarray 
 CER  TCX  CER  DLPFC  VCX 
Gene β (SE) P-value  β (SE) P-value  β (SE) P-value  β (SE) P-value  β (SE) P-value 
ECRG4 0.06 (0.20) 0.77   0.19 (0.24) 0.43   -0.18 (0.05) 1.6x10-3   -0.12 (0.06) 0.04   -0.12 (0.04) 2.7x10-3 
HDAC9 -0.24 (0.12) 0.04  -0.31 (0.08) 1.5x10-4  -0.01 (0.02) 0.77  -0.09 (0.03) 7.9x10-3  -0.06 (0.02) 5.6x10-4 
TRAPPC12 -0.05 (0.06) 0.35  -0.13 (0.05) 0.01  -0.09 (0.03) 1.1x10-3  -0.03 (0.02) 0.09  -0.08 (0.02) 3.2x10-4 
TRAPPC12-AS1 0.22 (0.12) 0.06  0.59 (0.18) 1.3x10-3  . .  . .  . . 
ADI1 -0.10 (0.08) 0.19   -0.07 (0.08) 0.36   -0.10 (0.03) 4.9x10-4   -0.03 (0.03) 0.31   -0.01 (0.03) 0.64 
Results were obtained from analyses of RNA-Seq data in the Synapse database (https://www.synapse.org) and microarray data in the gene expression omnibus 
(GSE44771). Negative β indicates lower level of gene expression in AD cases compared with controls, and vice versa. CER = cerebellum; TCX = temporal cortex; 
DLPFC = dorsolateral prefrontal cortex; VCX = visual cortex. 
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Figure 2.2.1. Conditional QQ plots 
 
(A) NFT conditional on NP p-values, (B) CAA conditional on NP p-values, and (C) CAA conditional on NFT p-values 
(black: all SNPs; magenta: SNPs with conditioned-on trait P-value < 0.05; blue: SNPs with conditioned-on trait P-value 
< 5.0x10-3; red: SNPs with conditioned-on trait P-value < 5.0x10-4). Plots on the left side include SNPs in the APOE 
region, and the plots on the right does not. 
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Figure 2.2.2. Regional association plots of ECRG4 and HDAC9 
(A) 
 
(B) 
 
(A) ECRG4 from the bivariate model of NP and NFT and (B) HDAC9 from the bivariate model of NFT and CAA. 
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CHAPTER 3 Comparison of Methods for Multivariate Gene-based Association 
Tests Using Common Variants for Complex disease 
 Complex diseases are usually associated with multiple correlated phenotypes, and 
the analysis of composite scores or disease status may not fully capture the complexity 
(or multidimensionality) of a disease. Joint analysis of multiple disease-related 
phenotypes in genetic tests could potentially increase power to detect SNPs (or genes) 
associated with a disease. Gene-based tests are designed to detect genes with multiple 
risk variants with weak association with a univariate trait.  
 In this study, we combined three multivariate association tests including O’Brien 
method, Trait-based Association Test that uses the Extended Simes procedure (TATES), 
and MultiPhen with two gene-based association tests (GATES and VEGAS), and 
compared performance (type I error and power) of six multivariate gene-based methods 
using simulated data. We simulated data (N=2,000) for genetic sequence and correlated 
phenotypes by varying causal variant proportions and phenotype correlations for various 
scenarios. We applied these gene-based association methods to a GWAS dataset from the 
Alzheimer’s Disease Genetics Consortium containing three neuropathological traits 
related to Alzheimer disease (AD) including neuritic plaque, neurofibrillary tangles, and 
cerebral amyloid angiopathy measured in 3,500 autopsied brains. 
 Our simulation study showed that the two multivariate association tests (TATES 
and MultiPhen, but not O’Brien) paired with VEGAS have inflated type I error in all 
scenarios, while the three multivariate association tests paired with GATES have correct 
type I error. MultiPhen paired with GATES has higher power than competing methods if 
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the correlations among phenotypes are low (r < 0.57). We identified gene-level 
significant evidence (P < 2.7x10-6) in a region on chromosome 2 containing three 
contiguous genes (TRAPPC12, TRAPPC12-AS1, and ADI1) using O’Brien and VEGAS. 
The results for these three genes using other approaches (O’Brien with GATES and 
TATES with GATES) were less significant (P < 7.0x10-5). Gene-wide significant 
associations with these genes were not observed in a univariate gene-based test of each 
neuropathological trait.  
 Our comparison of multivariate gene-based association methods showed 
noticeable differences among the methods, dependent on the various scenarios. Overall, 
MultiPhen with GATES performed best for most tested scenarios, but we also suggest 
O’Brien with VEGAS or TATES with GATES as alternative method because MultiPhen 
requires individual-level data (genotypes and phenotypes). 
 
3.1 Introduction 
 GWAS is a primary tool to identify association of genetic variants with 
phenotypes2,15. GWAS has been successfully applied to a variety of complex diseases and 
identified genetic factors underlying complex diseases8,130. However, there is still a 
considerable heritability of complex diseases which could not be explained by 
conventional GWAS10,131. One plausible reason for the limit of GWAS is due to 
heterogeneity of genetic variants (i.e. different mutations in a same gene which may be 
related to different genetic backgrounds)10. Gene-based analysis, which considers the 
aggregate effect of multiple genic variants in a single test, is an alternative approach to 
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overcome the genetic heterogeneity problem38,132. Conventional GWAS may also be 
limited by phenotypic heterogeneity10,37,131. Most GWA studies consider a univariate 
clinical outcome (e.g. disease diagnosis or a composite score of several disease-related 
traits). It is well understood that some variants may influence multiple traits associated 
with a single complex disease, but association of those variants may not be detected in a 
model with a broadly defined outcome66. Thus, multiphenotype analysis, which 
simultaneously considers more than one phenotype pathologically or clinically related 
with the disease, may help identify additional disease-related genetic associations.  
 Several gene-based association methods33,34 and multivariate association 
methods35,36 have been developed and successfully applied to GWA studies of complex 
diseases. Recently, van der Sluis et al. developed a multivariate gene-based test 
(MGAS)39 which combines the TATES method37 for multivariate SNP association testing 
and the GATES method38 for gene-based univariate association testing.  
 In this study, we evaluated the statistical performance of combinations of 
multivariate association methods and gene-based association methods in various 
simulation models. The gene-based methods tested in this study include VEGAS106 and 
GATES38 which have been frequently used for analyzing common SNPs. The tested 
multivariate association methods were O’Brien104,105, TATES37, and MultiPhen133. These 
methods have been implemented in freely available standalone software or in an R library 
that accepts as input files produced by commonly used GWAS tools. The goal of this 
study is to provide guidance on how to optimally select multivariate gene-based 
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association method for analyzing common variants given the correlation of phenotypes 
and genetic background (e.g. linkage disequilibrium [LD]). 
 
3.2 Methods 
3.2.1 Approaches for multiphenotype association testing 
 The O’Brien method combines univariate test statistics (i.e. Z scores or β) of all 
SNPs from GWAS of multiple phenotypes to compute a test statistic for pleiotropic 
effects104,134 and is implemented in an R library, CUMP.105 This method calculates a 
statistic assumed to follow a multivariate normal distribution with mean (combined Z 
scores of all SNPs) and covariance matrix of the multiple phenotypes. The covariance 
matrix among phenotypes can be approximated by the sample covariance matrix of the Z 
scores of all SNPs.104,105  
 The TATES was developed to detect effects across correlated traits measured in 
the same individuals using summary association statistics in the form of P-value for each 
trait.37 For each variant, the approach takes the minimum P-value across a set of 
univariate tests carried out on each phenotype and then applies a weight to the P-value to 
account for the number of phenotypes tested and their correlation. TATES requires 
univariate test statistics (i.e. P-values) and a correlation matrix of the multiple 
phenotypes.  
 MultiPhen performs ordinal regression using an inverted model whereby the 
genotype or imputed SNP allele dosage is the outcome variable and the phenotypes are 
the predictors.135 This program uses individual-level data (genotypes and phenotypes) for 
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computing regression models, whereas the O’Brien method and TATES use summary 
statistics (β and SE or P-values), and tests association between a SNP and a set of 
phenotypes by conducting likelihood ratio test for model fit, testing whether all 
regression coefficients in the model are jointly significantly different from zero. 
MultiPhen is an R package available from CRAN. 
 
3.2.2 Approaches for gene-based testing 
 The Gene-based Association Test using the Extended Simes procedure (GATES) 
computes a gene-based P-value using SNP-based P-values and correlations between 
SNPs (or pairwise LD information) in a gene38 The individual SNP p-values are 
combined in a manner which appropriately controls for the independent number of SNPs 
in a gene. The independent number of SNPs is estimated from the eigenvalues of the 
pairwise LD matrix38.  
 The Versatile gene-based test for Genome-wide Association Studies (VEGAS) 
allows the SNP-based chi-square test statistics in a gene to be combined in a gene-based 
test statistic.106 An empirical null distribution for this gene-based test statistic is obtained 
through a simulation of multivariate standard normal random vectors (Z statistics) with 
mean 0 and the correlations (or LD) between SNPs in a gene. The simulated gene-based 
test statistic is the sum of the squared Z statistics (with a chi-square distribution). The 
observed gene-based test statistic is the sum of chi-squares (converted from P-values). 
The empirical gene-based P-value is the proportion of simulated gene-based test statistics 
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that surpass the observed gene-based test statistics. To compute the empirical gene-based 
P-value, we performed 106 simulations. 
 
3.2.3 Genotype simulation settings 
 Simulation studies under a range of scenarios were performed to assess and 
compare the performance (type I error and power) of six different pairs of the three 
multivariate association methods (O’Brien, TATES, and MultiPhen) with two gene-based 
association methods (GATES and TATES). For all scenarios, we simulated sequence 
genotypes from 22 autosomes obtained from the European-ancestry populations in the 
1000 human genome reference panel (GRCh37; Mar 2012). HAPGEN2 software136 was 
applied for simulating sequence genotypes for 2,000 samples. Only common SNPs with 
minor allele frequency greater or equal to 1% were evaluated in the simulation tests for 
this study. For each simulation replicate, a 10 kb region containing at least 20 SNPs was 
randomly selected in the simulated sequence genotypes for 2,000 samples. 
EIGENSTRAT137 was used to generate principal components of the simulated genotypes 
to adjust for population structures in the simulation tests. 
 
3.2.4 Correlated multiphenotype simulation settings 
 Van der Sluis S. et al. suggested various genotype-phenotype models for genetic 
architecture of complex disease37. Among the models suggested by these investigators. 
We used the primary model, “single common factor model”, which implies that 
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individual phenotypes related with a complex disease result from one shared latent factor 
influenced by genetic factors37. Three correlated phenotypes were simulated for each 
subject. The covariance matrix of three correlated phenotypes with the common factor 
were simulated according to this model:  
Σ =  Λ ∗ ΛΤ  +   Θ, 
where Σ is the 3×3 covariance matrix among three phenotypes, Λ is the 3×3 matrix of 
factor loadings, T is matrix transpose, and Θ is the 3×3 diagonal matrix of residual 
variances37. Factor loading is variance of a complex disease explained by a factor, and 
residual variance is the variance of phenotypes that is not explained by the factor. In 
general, when a factor loading value increases, the correlations among phenotypes 
simulated by the model above increase. 
 
3.2.5 Type I error simulation 
 We simulated three phenotypes that were multivariate normally distributed with 
mean 0 and covariance Σ for 2,000 samples. Five million simulation tests were performed 
to evaluate whether the combined methods for multiphenotype gene-based test 
maintained the correct type I error rate. Type I error rate was evaluated through four 
scenarios by different factor loadings (Λ = 0.15, 0.35, 0.55 or 0.75 in Appendix Table 
C.1).  
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3.2.6 Power simulation 
 To simulate multiphenotype data for the power test, we randomly chose 5% or 15 
% of causal SNPs among the total number of SNPs in the selected 10kb region. We 
simulated three continuous phenotypes for 2,000 samples using the formula 
𝑌 =  𝛽1𝐺1 + 𝛽2𝐺2 +  ⋯ + 𝛽𝑛𝐺𝑛  +   𝜀 , 
where βi is the effect size of the causal SNP i; Gi is the genotype of the causal SNP i; ε is 
error term which follows a multivariate normal distribution with means 0 and covariance 
matrix Σ138. The effect size, β, was generated by 
𝛽𝑖 =  √
ℎ2𝑞
2 ×  𝑀𝐴𝐹𝑖  × (1 − 𝑀𝐴𝐹𝑖)
 , 
where h2q, the proportion of variance explained by each causal SNP, was fixed at 1% for 
all scenarios; and MAFi is the minor allele frequency of the causal SNP i. We considered 
various scenarios in terms of different factor loadings (Λ = 0.15, 0.35, 0.55, and 0.75) i.e. 
different correlation between phenotypes and either 5% or 15% of causal SNPs as shown 
in Appendix Table C.1. 
 
3.2.7 Simulation test procedure 
 For each simulation test, multiphenotype tests of SNPs were first conducted using 
the O’Brien, TATES, and MultiPhen approaches, and the P-values of SNPs from the 
three multivariate tests were combined into single gene-based P-values using GATES and 
VEGAS. The O’Brien method requires genome-wide association statistics to compute a 
null distribution. To reduce the computation time, we generated a pruned set of 
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uncorrelated SNPs on all chromosomes. The pruned SNP set was used for computing 
genome-wide association statistics, which were applied to compute the covariance matrix 
for the O’Brien approach. The full set of unpruned SNPs were used for the rest of 
simulation tests. We used linear regression to compute univariate associations (βs and 
SEs or P-values) between SNPs and each phenotype after adjusting the first three PCs, 
and the univariate SNP associations results were then used as input for analyses using the 
O’Brien and TATES multivariate association methods,. MultiPhen computes multivariate 
associations with individual-level simulated data (SNPs and three phenotypes) after 
adjusting the three PCs. Because we simulated genotypes in the European-ancestry 
population from the 1000 Genomes reference panel139, the European LD structure from 
this panel (GRCh37; Mar 2012) was used for GATES and VEGAS to correct for the 
correlation between SNPs. 
 
3.2.8 Scenarios by factor loadings and proportions of independent SNPs 
 We investigated statistical performance of each pair of multivariate gene-based 
association methods in various scenarios by four different factor loadings (Λ = 0.15, 0.35, 
0.55, and 0.75) and proportions of independent SNPs in a gene. The effective number of 
independent SNPs in a gene was estimated in the manner applied in GATES38, and 
proportions of independent SNPs out of total SNPs in a gene were classified into three 
groups (low: < 40%, moderate: 40% - 60%, and high: > 60%). 
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3.2.9 Application to Neuropathological Traits related with Alzheimer’s Disease 
 Genetic and phenotypic data for 3,135 AD cases and 463 clinically and 
pathologically confirmed controls of European ancestry from 12 datasets (subject 
characteristics shown in Appendix Table B.1) who have genotypes and AD-related 
neuropathological phenotypes including NP, NFT, and CAA were obtained from the 
ADGC. GWAS of each of these three phenotypes has been conducted previously64, and 
GWAS summary statistics of the three traits are available at the NIAGADS website 
(https://www.niagads.org) 140. Summary statistics of the three neuropathological 
phenotypes were used to evaluate the O’Brien and TATES multivariate association 
methods. The MultiPhen program, which requires individual level genotype and 
phenotype data, was applied to each dataset and the SNP association results were 
combined across datasets using METAL76 with the weighted Z-score method based on 
sample sizes76. For the gene-based tests (VEGAS and GATES), we used SNPs within 30 
kb of both ends of transcripts after removing SNPs with MAF ≤ 1% and high imputation 
quality (R2 < 0.4). The genome-wide significance level for gene-based tests was set as 
2.7x10-6 which was calculated as the nominal significant level divided by the total 
number of genes tested (n = 18,500). We defined a gene having a pleiotropic effect on the 
three phenotypes when the multivariate gene-based P-value was at least one order of 
magnitude lower than the univariate gene-based P-value of each phenotype. 
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3.3 Results 
 On average, 60 SNPs were observed in each gene region (10kbp length). On 
average, correlation estimates (Pearson correlation, r) between phenotypes which were 
simulated by factor loadings (Λ) in scenarios were 0.01, 0.21, 0.57, and 0.86 for Λ = 
0.15, 0.35, 0.55, and 0.75, respectively. Of note, simulated phenotypes were not 
significantly correlated (P > 0.05) when the factor loading was equal to 0.15.  
 
3.3.1 Type I Error Simulations 
Because the set of phenotypes and genotypes are resampled for each of simulation test, 
the type I error estimator is unbiased. The empirical type I errors of multivariate 
association methods with the gene-based tests are shown in Table 3.1 (VEGAS) and 
Table 3.2 (GATES) at different α levels based on the proportion of independent SNPs in 
a gene (low, moderate, and high) and factor loading (Λ = 0.15, 0.35, 0.55, and 0.75). 
Applying VEGAS to the multivariate output by O’Brien (VEGAS-O’Brien) maintained 
the correct type I errors at all α levels in the three scenarios by factor loadings (Λ = 0.15, 
0.35, and 0.55) regardless of proportion of independent SNPs, but not in the scenario of 
higher factor loading (Λ = 0.75). Applying VEGAS to rest of the multivariate association 
methods has inflated type I errors at α = 0.0001 for TATES and at all α levels for 
MultiPhen for all scenarios irrespective of factor loadings or independent SNP 
proportions. When GATES was applied, all three multivariate association methods retain 
the correct type I errors at all α levels in all scenarios.  
 
65 
 
  
3.3.2 Power Simulations 
 Power simulation results of multivariate association methods with gene-based 
association methods are shown in Figure 3.1. As the proportion of independent SNPs in a 
gene increased, the power of all multivariate association methods decreased regardless of 
gene-based association method. Most of the multivariate association methods, except for 
MultiPhen, using VEGAS or GATES showed low power (< 10%) in scenarios when the 
proportion of causal SNPs in a gene is equal to 5%. In the scenarios for the proportion of 
causal SNPs fixed at 15%, the power of O’Brien and TATES, regardless of the gene-
based association methods, remained almost constant in the scenarios when factor 
loading (Λ) increases from 0.15 to 0.35, 0.55, and 0.75. In contrast, the power of 
MultiPhen combined with VEGAS or GATES was highest in the scenario including the 
lowest factor loading (Λ = 0.15), and it was reduced by about 20% when the factor 
loading increased from 0.15 to 0.75. All pairs of multivariate and gene-based association 
methods had similar power in the scenarios of the highest factor loading (Λ = 0.75). 
Applying VEGAS to the three multivariate association methods showed slightly greater 
power than GATES in all scenarios. However, this might be related to the inflated type I 
errors observed in most of the multivariate association methods using VEGAS. Among 
the pairs of multivariate gene-based association methods that correctly controlled type I 
error, MultiPhen and GATES outperformed other combinations in most scenarios, 
suggesting that the pairing GATES with MultiPhen is an omnibus method for 
multivariate gene-based association testing.  
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3.3.3 Application to AD-related Neuropathological Traits 
 The correlation estimates (r) between the three neuropathological phenotypes 
were 0.68 between NP and NFT, 0.56 between NP and CAA, and 0.40 between NFT and 
CAA. For the investigation of pleiotropic effects on the three neuropathological 
phenotypes, we applied multivariate gene-based association methods that properly 
controlled the type I error in the simulation tests. Therefore, the pairing of GATES with 
all three multivariate association methods (O’Brien, TATES, and MultiPhen) was used 
for analysis of the neuropathological phenotypes. In addition, the three phenotypes were 
analyzed using the combination of VEGAS and O’Brien because the simulations based 
on these approaches yielded correlations similar to those among the three phenotypes and 
correct type I errors (factor loading Λ = 0.15, 0.35, and 0.55).  
 Associations (P-values) from multivariate gene-based methods are shown in 
Table 3.3 for previously reported AD genes49,50,59 and Table 3.4 for new genes identified 
in this study with suggestively significant (P < 1.0x10-4) association from any 
multivariate gene-based tests. Only 8 of 27 previously known AD genes attained at least 
a nominally significant level of association with at least one of the phenotypes. Five of 
the previously reported AD genes – BIN1, PICALM, TSPOAP1, CASS4, and APOE – 
were at least nominally associated in the multivariate gene-based analyses at a 
significance level of at least one order of magnitude smaller than the results from the 
univariate analyses of three neuropathological phenotypes. APOE was detected as a gene 
with pleiotropy effect on the three phenotypes in the pairs of methods: GATES with 
O’Brien (P = 1.6x10-68) and TATES (P = 2.1x10-44). O’Brien with VEGAS also found the 
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significant association for APOE (P < 1.0x10-6) in the multivariate gene-based analysis. 
However, O’Brien with VEGAS could not differentiate whether or not the multivariate 
association in APOE is more significant than its associations from each of univariate 
analyses because VEGAS generated a gene-based P-value from a permutation approach 
that was not precise enough to detect a change of one order of magnitude. Nominally 
significant multivariate gene-based associations (P < 10-3) in BIN1, PICALM, and CASS4 
were observed from O’Brien with VEGAS, and nominal association in TSPOAP1 was 
detected from MultiPhen with GATES (Table 3.3).  
 Three neighboring genes including TRAPPC12, TRAPPC12-AS1, and ADI1 on 
chromosome 2p25.3 were identified at a gene-wide significant level (P < 2.7x10-6) in the 
multivariate gene-based test for the three phenotypes (NP, NFT and CAA) by O’Brien 
with VEGAS (Table 4). It should be noted that suggestively significant association with 
SNPs (best SNP: rs35067331; P = 5.5x10-7 in TRAPCC12) in the multivariate model (NP, 
NFT, and CAA) by the O’Brien method was observed in this region (Appendix Figure 
C.1).  
 
3.4 Discussion 
 In this study, we proposed a multivariate gene-based association test as post 
GWAS analysis by combining a multivariate association method (O’Brien, TATES, or 
MultiPhen) with a gene-based association method (GATES or TATES) to identify genes 
with pleiotropic effects on multiple phenotypes related to a complex disease. We limited 
the multivariate gene-based association tests of common SNPs (MAF ≥ 1%) because 
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those methods were originally designed for common variants. We performed numerous 
simulations to depict the genetic (proportion of causal SNPs and independent SNPs) and 
phenotypic (various correlations between phenotypes) architecture of a complex disease 
to assess the performance of multivariate gene-based methods.  
Compared with other combinations of multivariate gene-based methods, selecting 
GATES for gene-based test and MultiPhen for multivariate test is robust for type I error 
and advantageous for power when the correlation between phenotypes is relatively row (r 
≤ 0.57). However, MultiPhen requires individual-level data (genotypes and phenotypes) 
which is not always available in most cases. This also means that MultiPhen omits 
samples with any missing values in any of the phenotypes, which will reduce the study 
power. For these cases in which MultiPhen has limited power, our simulation study 
suggests O’Brien with VEGAS or TATES with GATES as the second optimal 
multivariate gene-based method. When analyzing phenotypes with high correlations (r ≥ 
0.86), we did not see noticeable difference in statistical power among the three 
multivariate association methods with GATES. O’Brien with VEGAS maintain the 
correct type I error in most scenarios for all factor loadings (or correlation between 
phenotypes) except for the highest factor loading (Λ = 0.75, r = 0.86). This suggests that 
applying VEGAS to the multivariate associations of SNPs from O’Brien method is 
appropriate when the phenotypic correlation is relatively low (at least r ≤ 0.57).  
In the multivariate gene-based analyses of the three neuropathological phenotypes (NP, 
NFT, and CAA), five known-AD genes – BIN1, PICALM, TSPOAP1, CASS4, and APOE 
– reached significant association with a p-value at least one order of magnitude smaller 
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than each of univariate association p-values. The improved association in APOE was 
found in most of multivariate gene-based methods except for the method by MultiPhen 
with GATES. We noticed that the sample analyzed through MultiPhen was much smaller 
than the sample analyzed by O’Brien and TATES. This is because MultiPhen requires 
individual-level data (genotypes and phenotypes), while other multivariate association 
methods use summary statistics for each phenotype. Multiphen tests including a smaller 
number of subjects, for whom genotype data and information for all three phenotypes 
were available, yielded relatively weak associations in APOE. The improved association 
in TSPOAP1 compared to univariate associations for the individual traits was observed 
only in the multivariate gene-based method by combining MultiPhen with GATES, and 
associations with BIN1, PICALM, and CASS4 were detected only by O’Brien with 
VEGAS.  
We identified gene-level significant (P < 2.7x10-6) associations with contiguous genes 
TRAPPC12, TRAPPC12-AS1, and ADI1 using the multivariate gene-based approach 
based on O’Brien paired with VEGAS. The association findings for these three genes 
using other methods (O’Brien with GATES and TATES with GATES) are also 
moderately significant (P < 7.0x10-5), except for MultiPhen with GATES (P < 0.01). We 
identified associations with these same genes in a bivariate analysis of NFT and CAA 
using the O’Brien method with VEGAS in Chapter 2.2. Association of rs35067331 from 
the bivariate model (NFT+CAA; P = 5.8x10-8) was more significant than the association 
of rs35067331 from the trivariate model (NP+NFT+CAA; P = 5.5x10-7). However, we 
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obtained gene-wide significant evidence that these three genes have pleiotropy effects on 
the three neuropathological phenotypes.  
In general, genes which yielded at least a moderately significant (P < 1.0x10-4) 
association using any of the multivariate gene-based methods (Table 3.4) contained an 
effective number of independent SNPs that accounted for less than 40% of the total 
number of SNPs in that region, a finding which is consistent with our observation from 
the simulation tests of statistical power.  
It should be noted that our simulation test scenarios do not represent all possible 
genotype-phenotype models for complex diseases. Therefore, the statistical performance 
(type I errors and powers) for the tested methods in this study cannot be assumed 
necessarily in all genome-wide multivariate gene-based studies. However, our simulation 
results based on diverse scenarios may indicate which multivariate association tests are 
most appropriate based on the phenotypic correlations. 
Taken together, our comparison of multivariate gene-based association methods showed 
noticeable differences in type I error and power among the tested methods. MultiPhen 
with GATES showed much greater power for less correlated phenotypes, but there was 
no substantial difference in power when the correlation between phenotypes is high. 
Overall, MultiPhen with GATES performed best for most tested scenarios, but we also 
suggest O’Brien with VEGAS or TATES with GATES as alternative approaches when 
the proportion of missing data is high or the individual-level data are not available.  
 
 
 
Table 3.1. Type I errors of multivariate association methods with a gene-based association method, VEGAS. 
Factor 
Loading 
(Λ) 
Proportion 
of  
Independent  
SNPs (%) 
VEGAS 
α = 0.01  α = 0.001  α = 0.0001 
O'Brien TATES MultiPhen   O'Brien TATES MultiPhen   O'Brien TATES MultiPhen 
  0 - 40 0.0005 0.0009 0.02  0 0.0005 0.001  0 0.0005 0.0002 
0.15 40 - 60 0.0007 0.0006 0.02  4.1x10-5 0.0004 0.003  1.4 x10-5 0.0003 0.0005 
  60 - 100 0.0009 0.0004 0.02  4.8x10-5 0.0002 0.003  0 0.0002 0.0007 
 0 - 40 0.004 0.0011 0.02  0.0002 0.0006 0.002  0 0.0006 0.0002 
0.35 40 - 60 0.007 0.0006 0.02  0.0002 0.0004 0.003  3.3 x10-5 0.0004 0.0004 
  60 - 100 0.009 0.0004 0.02  0.0003 0.0003 0.003  5.7 x10-5 0.0003 0.0006 
 0 - 40 0.009 0.0015 0.02  0.002 0.0010 0.003  0.0001 0.0008 0.0002 
0.55 40 - 60 0.011 0.0007 0.02  0.002 0.0005 0.003  0.0002 0.0004 0.0003 
  60 - 100 0.015 0.0006 0.02  0.001 0.0004 0.003  0.0002 0.0004 0.0006 
 0 - 40 0.06 0.0015 0.02  0.01 0.0008 0.002  0.0015 0.0005 0.0006 
0.75 40 - 60 0.12 0.0011 0.02  0.02 0.0007 0.003  0.0032 0.0006 0.0003 
  60 - 100 0.19 0.0004 0.02  0.03 0.0003 0.005  0.0071 0.0003 0.0009 
  
  
 
 
 
Table 3.2. Type I errors of multivariate association methods with a gene-based association method, GATES. 
Factor 
Loading 
(Λ) 
Proportion 
of  
Independent  
SNPs (%) 
GATES 
α = 0.01  α = 0.001  α = 0.0001 
O'Brien TATES MultiPhen   O'Brien TATES MultiPhen   O'Brien TATES MultiPhen 
  0 - 40 0.0000 0.0055 0.01  0.000 0.0004 0.000  0.0000 0.0001 0.0001 
0.15 40 - 60 0.0000 0.0033 0.00  0.000 0.0004 0.000  0.0000 0.0000 0.0000 
  60 - 100 0.0000 0.0016 0.00  0.000 0.0002 0.000  0.0000 0.0000 0.0000 
 0 - 40 0.000 0.0064 0.01  0.000 0.0008 0.000  0.0000 0.0001 0.0001 
0.35 40 - 60 0.000 0.0034 0.00  0.000 0.0003 0.001  0.0000 0.0000 0.0001 
  60 - 100 0.000 0.0015 0.00  0.000 0.0001 0.000  0.0000 0.0000 0.0000 
 0 - 40 0.002 0.0063 0.01  0.000 0.0009 0.000  0.0000 0.0001 0.0001 
0.55 40 - 60 0.001 0.0041 0.01  0.000 0.0004 0.000  0.0000 0.0000 0.0000 
  60 - 100 0.001 0.0015 0.00  0.000 0.0002 0.000  0.0000 0.0000 0.0000 
 0 - 40 0.01 0.0075 0.01  0.000 0.0005 0.001  0.0000 0.0000 0.0000 
0.75 40 - 60 0.01 0.0047 0.00  0.000 0.0005 0.000  0.0000 0.0001 0.0000 
  60 - 100 0.00 0.0016 0.00  0.000 0.0001 0.000  0.0000 0.0000 0.0000 
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Table 3.3. Associations (P-values) of known-AD genes from the analysis of neuropathological phenotypes using 
multivariate gene-based association methods. 
  VEGAS  GATES 
  Univariate  Multivariate  Univariate  Multivariate 
Gene 
Eff. / Total  
(%) 
NP 
 
NFT 
 
CAA 
 
 
NP+NFT+CAA 
O'Brien 
 
NP 
 
NFT 
 
CAA 
 
 
NP   +   NFT   +   CAA 
O'Brien TATES MultiPhen 
CR1 90.6/422 (21.5%) 0.66 0.27 0.17  0.37  0.91 0.63 0.27  0.81 0.69 0.97 
BIN1 80.3/390 (20.6%) 3.2x10-3 1.1x10-3 0.66  7.5 x10-4  7.9Ex10-4 3.0x10-4 0.79  1.8x10-3 5.3x10-4 0.11 
INPP5D 91.6/279 (32.8%) 0.47 0.07 0.12  0.54  0.99 0.60 0.43  0.55 0.83 0.38 
CIDEC 47.8/146 (32.7%) 0.45 0.57 0.58  0.34  0.76 0.06 0.59  0.57 0.14 0.70 
MEF2C 88.8/338 (26.3%) 0.09 0.06 0.44  0.34  0.06 0.18 0.83  0.65 0.14 0.91 
HBEGF 38.8/91 (42.6%) 0.76 0.96 0.05  0.30  0.62 0.96 0.15  0.43 0.31 0.26 
HLA-DRB5 874.5/1847 (47.3%) 0.12 0.08 0.63  0.14  2.8x10-3 0.02 1.00  0.32 7.4x10-3 0.06 
CD2AP 77.6/472 (16.4%) 0.24 0.46 0.31  0.27  0.48 0.67 0.64  0.66 0.71 0.63 
ZCWPW1 24.5/90 (27.2%) 0.68 0.37 0.73  0.77  0.66 0.11 0.78  0.90 0.26 0.50 
PLXNA4 377.7/1435 (26.3%) 0.81 0.80 0.85  0.84  0.65 0.76 0.92  0.94 0.96 0.31 
EPHA1 59.1/158 (37.4%) 0.24 0.13 0.09  0.27  0.39 0.21 0.21  0.37 0.27 0.21 
PTK2B 120.8/500 (24.2%) 0.10 0.63 2.9x10-3  0.07  0.31 0.80 0.01  0.13 0.03 0.05 
CLU 60.8/178 (34.2%) 0.36 0.47 0.42  0.19  0.49 0.35 0.63  0.29 0.47 0.53 
PPP2CB 30.3/145 (20.9%) 0.82 0.70 0.99  0.87  0.89 0.80 0.96  0.82 0.96 0.09 
USP6NL 104.5/456 (22.9%) 0.40 0.12 0.85  0.86  0.55 0.54 0.97  0.53 0.79 0.13 
CELF1 47.5/159 (29.9%) 0.97 0.39 0.54  0.69  0.99 0.02 0.70  0.28 0.04 0.51 
MS4A6A 31.4/129 (24.4%) 0.24 0.14 0.97  0.25  0.11 0.46 0.93  0.46 0.28 0.83 
PICALM 80.0/396 (20.2%) 0.02 2.4x10-3 0.03  8.6x10-4  0.10 5.2x10-3 0.04  2.5x10-3 0.01 0.08 
SORL1 105.2/359 (29.3%) 0.20 0.08 0.92  0.51  0.22 0.13 0.96  0.08 0.34 0.18 
FERMT2 72.2/260 (27.8%) 0.10 0.16 0.69  0.37  0.13 0.26 0.78  0.09 0.31 0.30 
SLC24A4 210.7/766 (27.5%) 0.73 0.06 0.56  0.54  0.86 0.30 0.49  0.69 0.45 0.42 
MAPT 94.2/919 (10.3%) 0.33 0.39 0.35  0.15  0.28 0.90 0.15  0.22 0.30 0.06 
TSPOAP1 65.4/193 (33.9%) 0.50 0.68 0.29  0.40  0.76 0.52 0.18  0.14 0.36 0.05 
ABCA7 116.1/339 (34.3%)  3.4x10-3 1.00  0.06  0.05 3.9x10-3 1.00  0.06 0.01 8.7x10-3 
NFIC 159.0/432 (36.8%) 0.58 0.84 0.54  0.38  0.85 0.94 0.82  0.58 0.95 0.46 
APOE 57.0/145 (39.3%) < 1.0x10-6 < 1.0x10-6 < 1.0x10-6  < 1.0x10-6  8.2x10-45 2.9x10-42 1.7x10-19  1.6x10-68 2.1x10-44 2.5x10-17 
CASS4 64.9/215 (30.2%) 0.07 0.02 0.10  4.4x10-3  0.25 0.08 0.33  0.04 0.19 0.01 
Eff. indicates the number of effective (or independent) SNPs in a gene range. The total SNPs were selected within 30 
kb of both ends of the defined gene range. 
 
 
 
 
Table 3.4. Novel associations (P-values) from the analysis of neuropathological phenotypes using multivariate gene-based association methods.  
     VEGAS  GATES 
     Univariate  Multivariate  Univariate  Multivariate 
Gene CH Start Stop 
Eff. / Total  
(%) 
NP 
 
 
NFT 
 
 
CAA 
 
 
 
NP+NFT+CAA 
 
O'Brien 
 
NP 
 
 
NFT 
 
 
CAA 
 
 
 
NP   +   NFT   +   CAA 
O'Brien TATES MultiPhen 
TRAPPC12 2 3,383,446 3,483,342 
131.2 / 509 
(25.8%) 
0.09 4.0x10-5 0.5  < 1.0x10-6  0.06 2.5x10-5 0.04  6.4x10-5 6.4x10-5 0.03 
TRAPPC12-AS1 2 3,481,242 3,482,409 
68.7 / 232 
(29.6%) 
2.0x10-3 3.9x10-5 5.0x10-3  < 1.0x10-6  0.05 1.3x10-5 0.02  3.4x10-5 3.4x10-5 0.01 
ADI1 2 3,501,690 3,523,350 
52.8 / 215 
(24.6%) 
2.6x10-3 1.6x10-5 7.4x10-4  < 1.0x10-6  0.03 1.0x10-5 0.01  2.6x10-5 2.5x10-5 6.1x10-3 
HDAC9 7 18,126,572 19,036,993 
611.5 / 1973 
(31.0%) 
0.40 0.14 0.61  0.24  0.56 0.01 5.2x10-3  6.1x10-5 0.01 3.5x10-3 
KRT2 12 53,038,342 53,045,959 
69.3 / 247 
(28.0%) 
3.7x10-4 0.11 0.01  3.3x10-5  9.5x10-3 0.21 0.17  1.5x10-3 0.02 0.03 
FLVCR2 14 76,044,940 76,114,512 
81.9 / 255 
(32.1%) 
0.02 0.01 1.3x10-3  5.8x10-5  0.15 0.11 0.02  4.2x10-3 0.04 9.4x10-3 
EXD1 15 41,474,926 41,522,895 
55.1 / 322 
(17.1%) 
9.0x10-4 6.6x10-3 0.02  7.9x10-5  0.01 0.03 0.15  4.9x10-4 0.03 0.11 
Eff. indicates the effective number of independent SNPs in a gene range. The SNPs were selected within 30 kb of both ends of the defined gene range. 
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Figure 3.1. Power comparisons of multivariate association methods (O’Brien, TATES, and MultiPhen) with 
gene-based association methods (VEGAS and GATES). 
  
Several scenarios were tested by varying the proportions of independent or causal SNPs in a gene. Empirical power 
calculated at α level of 0.0001.  
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CHAPTER 4 A Versatile Multi-Phenotype Gene-Based Association Test for Rare 
Variants 
 Large proportion of heritability of complex diseases, which is unexplained by 
common variants, may be uncovered by jointly analyzing rare variants with multiple 
disease-related phenotypes, called multivariate gene-based test. We propose a new 
method called VEMPHAS to identify novel associations between sets of rare variants and 
multiple phenotypes. VEMPHAS combines gene-based associations for multiple 
phenotypes into one multivariate gene-based association by using Monte Carlo 
simulations accounting for the correlations among phenotypes. We examined the 
performance of VEMPHAS through extensive simulation studies. VEMPHAS correctly 
controls the type I error in all scenarios and its statistical power increases as correlation 
between phenotypes decreases or when more phenotypes are used. We further illustrate 
its usefulness with rare variant analysis of Alzheimer’s disease-related phenotypes in the 
ADNI study. Strongly significant association (VEMPHAS P-value = 6.0x10-6), but not 
gene-wide significant (P < 4.15x10-6), was observed in the gene TRIM22 which may be 
worthy of further investigations. Our simulation study and real data analysis show that 
VEMPHAS allows to conduct multivariate gene-based analyses for rare variants 
efficiently for identifying association between sets of rare variants and phenotypes.   
 
4.1. Introduction 
 GWAS has been successfully used to identify genetic variants (or genes) 
associated with complex diseases including neurodegenerative diseases49,141,142, 
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psychiatric disorders143, and cardiovascular diseases144,145. Earlier GWAS focused on the 
analysis of common variants. Although GWAS have made substantial progress in 
identifications of common variants with complex diseases, a large portion of heritability 
of complex diseases have remained unexplained by common variants10,24,27. Further 
studies introduced that rare variants with MAF less than 5% or 1 % can fill a portion of 
the remained heritability17-19.  
 
Recent advances in next-generation sequencing technologies provided a unique 
opportunity to analyze rare variants in complex diseases146. Analysis of individual rare 
variants suffers from lack of power due to their low frequencies. To overcome this issue, 
many methods for testing association between a set of rare variants in a gene region and a 
single phenotype have been developed, including variance component score test21 and 
burden test22,23. 
 In addition to the analysis of rare variants, joint analysis of multiple disease-
related phenotypes (i.e. multivariate analysis) rather than analysis of a single phenotype 
(i.e. univariate analysis) can uncover part of the unexplained heritability29. Complex 
diseases are often diagnosed by multiple traits28,128. For example, diabetes is derived from 
measures of different traits: fasting glucose, non-fasting plasma glucose, and HbA1c. 
Complex diseases have a combination of distinctive factors which can be measured by 
different phenotypes. For example, changes in brains of AD patients are investigated by 
brain imaging by MRI and PET scans, CSF biomarker measures, and cognitive function 
tests. These multiple phenotypes explain different aspects of a complex disease. 
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Moreover, some genetic variants (or regions) can have effects on multiple phenotypes 
relevant with a complex disease, which is called pleiotropy effect29. Therefore, the 
multivariate analysis can increase the statistical power to detect genetic variants by 
aggregating weak association with each phenotype. In addition, the multivariate analysis 
may lead to better understand of the genetic architecture underlying common diseases. 
 In this study, we propose a multivariate gene-based method, called VErsatile 
Multi-PHenotype gene-based ASsociation test (or VEMPHAS) which is designed for 
combining rare variant associations from multiple phenotypes. In VEMPHAS, we 
requires two things: 1) summary statistics (e.g. P-values) of gene-based associations with 
multiple phenotypes (one per gene); and 2) raw phenotypes data or correlation matrix 
among phenotypes. Gene-based associations of rare variants with phenotypes can be 
computed from many well-known methods such as cohort allelic sums test147, combined 
multivariate and collapsing148, weighted sum test22, or sequence kernel association test 
(SKAT or SKAT-O)21,149. VEMPHAS combines the gene-based associations with 
multiple phenotypes into one multivariate gene-based association by using Monte Carlo 
(MC) simulations accounting for the correlations among phenotypes. Using extensive and 
various simulation studies, we assess the performance of VEMPHAS. Finally, we 
investigated the VEMPHAS to the ADNI study to test the association of rare variant sets 
with three different types of AD-related phenotypes including CSF biomarker ratio, MRI 
hippocampal volume, and logical memory immediate recall test scores67,71,73.  
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4.2 Methods 
4.2.1 An Overview of VEMPHAS 
 We implemented VEMPHAS as an R library to compute multiphenotype (or 
multivariate) gene-based P-value. VEMPHAS requires two text input files. The first input 
file is for gene-based P-values of one gene from multiple phenotypes, which consists of 
(1 + K) columns: gene name and gene-based P-values from K number of phenotypes. The 
other input file is the raw data for K phenotypes to compute the covariance matrix Σ 
among the K phenotypes. The gene-based P-values can be computed by popular gene-
based association tests (e.g. SKAT or SKAT-O). The covariance matrix Σ which reflects 
the correlation structure among phenotypes can be estimated in VEMPHAS, given raw 
phenotype data by the user.  
 The gene-based P-values from K multiple phenotypes are converted to upper-tail 
chi-squared statistics (with one degree of freedom). The multivariate gene-based test 
statistics is the sum of all chi-scores from the phenotypes, which is called as observed 
multivariate gene-based statistics. The correlation matrix can be computed directly from 
the raw phenotypes, or can be obtained from literatures. Once the correlation matrix is 
estimated, VEMPHAS applies the function mvrnorm in the R library MASS to generate 
multivariate normal random vectors, Z = (z1, z2, z3 …, zk), with mean 0 and the 
correlation matrix ρ, Z ~ Nk(0, ρ). Then, the random vectors Z will be squared (equal to 
chi-squares) and summed to form a simulated multivariate gene-based test statistics. 
VEMPHAS will generate a sufficient number of simulated multivariate gene-based test 
statistics, which will approximate the distribution of our observed multivariate gene-
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based statistics under the assumption of no association. The empirical multivariate gene-
based P-value is the proportion of simulated test statistics that exceed the observed 
multivariate gene-based statistics.  
In general, the Bonferroni-corrected threshold of genome-wide gene-based P-value is set 
at 2.6 x 10-6 (= 0.05 / 19,000). In order to correctly estimate the desired precision of 
significance threshold, we require the number of permutations would be at least 20 times 
what can evaluate the P-value at the level 2.6x10-6. Therefore, VEMPHAS generates 
2x107 simulations for testing one gene. For computational reason, if no empirical gene-
based exceeds the observed test statistic, then it can be interpreted as the empirical P-
value < 10-6. The minimum empirical P-value in VEMPHAS (< 10-6) can go beyond the 
Bonferroni-corrected P-value, so VEMPHAS can be applied in genome-wide scale test.  
 
4.2.2 Multivariate Genotype-Phenotype simulation settings 
 We conducted a variety of simulation studies to assess the performance (type I 
error and power) of VEMPHAS. We generated sequence genotypes and ten correlated 
phenotypes for 2,000 samples as previously described in Chapter 3.2. Twenty-two 
autosomal chromosomes for the simulation studies were generated by the software 
HAPGEN2136 which mimicked real genotypes from the European-ancestry population 
using the 1000 human genome reference (GRCh37; Mar 2012). EIGENSTRAT137 was 
used to generate principal components of the simulated genotypes to adjust for population 
structures in the simulation tests. Only rare SNPs, defined by MAF less than 1%, were 
analyzed for the simulation tests. A 10 kb region was randomly chosen in the mimicked 
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chromosomes for each simulation test. For generating correlated phenotypes, the “single 
common factor model” designed by van der Sluis S. et al. was applied37. This model 
infers that correlated phenotypes reflect one common disease-factor which is caused by 
genetic factors. The covariance matrix of the ten correlated phenotypes of 2,000 samples 
for each simulation test were computed under the one common factor model:  
Σ =  Λ ∗ ΛΤ  +   Θ, 
where Σ is the K × K covariance matrix of ten phenotypes, Λ is the K × K matrix of factor 
loadings, T is matrix transpose, and Θ is the K × K diagonal matrix of residual variances 
(see details in chapter 3). Factor loading is variance of a complex disease explained by 
one factor, and residual variances is the variance of phenotypes that is not explained by 
the factor. Higher factor loading will generate more correlated phenotypes.  
 
4.2.3 Type I error simulation 
 For each simulation test, ten phenotypes for 2,000 samples were generated, which 
were multivariate normally distributed with mean 0 and covariance Σ. To make different 
scenarios by the number of phenotypes (K = 3, 5, or 10), we used the total ten phenotypes 
or randomly selected 3 and 5 phenotypes among the ten phenotypes. Approximately 
5×106 simulation tests were conducted to evaluate type I error of VEMPHAS in various 
scenarios.  
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4.2.4 Power simulation 
 We made ten correlated phenotypes of 2,000 samples as previously described 
(chapter 3), using this model: 
𝑌 =  𝛽1𝐺1 + 𝛽2𝐺2 +  ⋯ + 𝛽𝑛𝐺𝑛  +   𝜀 , 
where Gi is defined as the genotype of a causal rare SNPi; βi is the effect size of the 
causal SNPi; ε is error vector which follows a multivariate normal distribution with 
means 0 and covariance matrix Σ. The effect size, βi, was generated by 
𝛽𝑖 =  √
𝑅2
2 ×  𝑀𝐴𝐹𝑖  × (1 − 𝑀𝐴𝐹𝑖)
 , 
where R2, the total proportion of variance explained by each causal SNP, was fixed at 1% 
for all scenarios; MAFi is the MAF of the causal SNP i. We also made more realistic 
scenarios by selecting different percentage of causal rare SNPs (% = 1 and 3). We 
randomly selected causal variants for each phenotype so that the causal variants selected 
for a phenotype differ from the selected ones for the other phenotypes.  
 
4.2.5 Simulation test procedure 
 For each simulation test, gene-based tests of rare variants with phenotypes were 
first conducted using SKAT-O149, and then the SKAT-O P-values for phenotypes were 
combined into one multivariate gene-based P-value using VEMPHAS.  
 Statistical performance (type I error and power) of VEMPHAS was evaluated in a 
variety of scenarios by four different factor loadings (Λ = 0.15, 0.35, 0.55, and 0.75) and 
different number of phenotypes (K = 3, 5, and 10). As explained earlier, additional 
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scenarios were tested for measuring statistical power of VEMPHAS, which is randomly 
selecting two different proportions (% = 1 and 3) of causal variants among the total 
number of rare variants in a gene region for each phenotype.  
 
4.2.6 Application to Endophenotypes Related with Alzheimer Disease 
 To evaluate the performance of VEMPHAS on real data, we applied VEMPHAS 
to the ADNI study data. ADNI was designed to measure the progression of MCI and 
early AD and provides genetic, structural and functional neuroimaging, and clinical data 
for ADNI participants in a public-access database (http:www.loni.usc.edu). ADNI 
genetic data is comprised of two GWAS datasets: ADNI 1 (n = 757) and ADNI GO/2 (n 
= 432). Previously, we have analyzed these ADNI GWAS data with AD-related 
phenotypes including cerebrospinal fluid (CSF) levels of beta amyloid peptide (Aβ42) and 
tau proteins, structural brain changes quantified by MRI, and neuropsychological test 
measures of cognitive functioning (in chapter 2.1). Details of quality control and 
population substructure analyses are explained in Chapter 2.1. The Haplotype Reference 
Consortium (HRC) has accumulated more than 32,000 whole-genome sequencing 
individuals and provided accurate imputation of rare variants (e.g. at allele frequencies as 
low as 0.05%)9. Since we focused on gene-based test of rare variants, we imputed the 
cleaned ADNI genotypes of 1,076 subjects from the two ADNI waves using the HRC in 
the University of Michigan Imputation Server9. The imputed variants with MAF < 1% 
and imputation quality > 0.4, which are located within 30 kb of transcription start and end 
sites, were extracted for the further analyses. Then, functional annotation (i.e. putative 
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impact on gene expression or protein function) was predicted using SnpEff150 for the 
remaining variants. The variants, which were considered as high, moderate, low, or 
moderate impacts by SnpEff, were included in the gene-based tests. We selected three 
different phenotypes: the ratio of CSF biomarkers (p-Tau over Aβ42; p-Tau/Aβ42), brain 
MRI measure for HPV, and LMiT score. The gene-based analyses of these phenotypes 
using the two ADNI datasets were performed in R with the seqMeta package151.  
 Genes with more than one variant were considered as the input for VEMPHAS. 
Gene-wide significant level for VEMPHAS was set as 4.15x10-6 which was calculated as 
the nominal significant level divided by the total number of genes tested (n = 12,040). 
We defined a gene having a pleiotropic effect on the three phenotypes when the 
multivariate gene-based P-value from VEMPHAS is at least one order of magnitude 
lower than the univariate gene-based P-value of each phenotype from seqMeta152. 
 
4.3 Results 
 Pearson correlation, r2 among phenotypes which were simulated by factor 
loadings (Λ) in scenarios were 0.0, 0.04, 0.33, and 0.75 for Λ = 0.15, 0.35, 0.55, and 
0.75, respectively. When the factor loading was equal to 0.15, simulated phenotypes were 
not correlated (correlation P-value > 0.05). 
 
4.3.1 Simulation Results for Type I Error and Power 
 The empirical type I error (α = 0.01, 0.001, and 0.0001) of VEMPHAS in various 
scenarios is summarized in Table 4.1. VEMPHAS had a well-controlled type I error, at 
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all α levels, regardless of the number of phenotypes (K = 3, 5, or 10) or the factor 
loadings (Λ = 0.15, 0.35, 0.55, or 0.75; i.e. correlations among phenotypes).  
 Figure 4.1 and Table 4.2 summarize the empirical power of VEMPHAS under 
significant level α = 0.0001 for various scenarios. As we learned from previous studies 
about gene-based association tests (e.g. SKAT and SKAT-O)21,149, the power of 
VEMPHAS increases as the proportion of the number of causal variants in a gene 
increases from 1% to 3% across all scenarios by factor loadings (Λ = 0.15, 0.35, 0.55, or 
0.75) or the number of phenotypes (K = 3, 5, or 10). We found that VEMPHAS has 
higher power when the factor loading decreases from 0.15 to 0.35, 0.55, and 0.75. In 
other words, VEMPHAS gained bigger power as the correlations of phenotypes decrease. 
Hence, when phenotypes are not strongly correlated, there is a potential benefit of 
VEMPHAS even if a few variants in a gene are associated with the phenotypes. Also, as 
the number of phenotypes increased, the power of VEMPHAS improved, regardless of 
the factor loadings (Λ = 0.15, 0.35, 0.55, or 0.75) or the proportions of the number of 
causal variants (1 or 3 %). However, VEMPHAS gained a little power (3.0%) by 
increasing the number of phenotypes (K = 3, 5, and 10) in the scenarios with highly 
correlated phenotypes (Λ = 0.75) and the proportion of the number of causal variants in a 
gene is equal to 1%. In contrast, VEMPHAS gained noticeable power (10.1%) as the 
number of phenotypes (K) increases from 3, to 5, and 10 when factor loading (Λ) and the 
proportion of the number of causal variants were fixed to 0.75 and 3%, respectively.  
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4.3.2 Application to AD-related Phenotypes in ADNI Study 
 We next analyzed sets of rare variants (MAF < 1%) with potential impacts (high, 
moderate, low, or moderate) in the imputed genetic dosage data from the ADNI study 
with three different types of AD-related phenotypes including the CSF ratio (p-
Tau/Aβ42), the HPV, and the LMiT.  
 We investigated the multivariate gene-based association between these three 
phenotypes and rare variants in 25 genes previously identified in large scale 
GWAS49,50,59. Eighteen out of 25 genes have at least two rare variants with a potential 
functional impact. The VEMPHAS result did not identify these 18 known AD genes as 
significantly associated with the phenotypes tested, either because of the limited sample 
size or due to performing region-based analysis containing many non-associated variants. 
However, we observed VEMPHAS has a smaller P-value at one gene, CLU (P = 0.003), 
compared to its seqMeta P-value (HPV = 0.07, LMiT = 0.02, and CSF p-Tau/Aβ42 = 
0.16; Table 4.3). 
 We detected no gene-wide significant (P < 4.0x10-6) association from the 
multivariate gene-based test of VEMPHAS (Figure 4.2). Genes ZNF34 and TRIM22 
reached suggestive significance level with P-values equal to 6.0x10-6 (Table 4.4). 
However, the VEMPHAS P-value for ZNF34 is not at least one of magnitude less than 
the best seqMeta P-value of ZNF34 (CSF p-Tau/Aβ42 = 8.9x10-6). In contrast, the 
VEMPHAS P-value (6.0x10-6) for TRIM22 is at least one of magnitude smaller than the 
seqMeta P-values of ZNF34 (HPV = 4.4x10-5, LMiT = 1.8x10-3, and CSF p-Tau/Aβ42 = 
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9.1x10-3), which indicates that ZNF34 is associated with this trivariate model of these 
three phenotype.  
 VEMPHAS P-values from this ADNI study are compared with seqMeta P-values 
from three phenotypes in Figure 4.3, clearly showing that VEMPHAS P-values tend to be 
smaller than the seqMeta P-values when genes have moderate associations (P-values < 
1.0x10-3) with the three phenotypes. Hence, VEMPHAS has the potential to improve 
statistical power over single phenotype tests (e.g. seqMeta or SKAT) in the tail of the QQ 
distribution.  
 
4.4 Discussion 
 Several methods have been introduced for univariate gene-based association test 
of rare variants. We developed a new method for multivariate gene-based association test, 
called VEMPHAS, which combines univariate gene-based associations with multiple 
disease-related phenotypes. VEMPHAS accounts for the correlations among multiple 
phenotypes by conducting MC simulations from the multivariate normal distribution 
given the correlation structure of phenotypes.  
VEMPHAS can be applied to whole genome or exome sequencing studies where traits of 
a complex disease are quantified by multiple phenotypes. We found from our simulation 
study that VEMPHAS successfully conserved type I error rates over a wide range of 
disease models (i.e. scenarios). VEMPHAS has the potential to increase statistical power 
when less correlated phenotypes or more number of phenotypes are used.  
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 We applied VEMPHAS test to the ADNI GWAS data. The rare variants for 
ADNI GWAS data was imputed using the HRC panel. We choose three different types of 
AD-related phenotypes in the ADNI data: the CSF biomarker ratio of the phosphorylated 
tau over Aβ42, the MRI scan of hippocampal volume, and the logical memory scores from 
immediate recall tests. VEMPHAS did not identify gene-wide significant association 
between rare variants in any gene regions and the three phenotypes. However, 
VEMPHAS observed strong association with these phenotypes in the gene, TRIM22 
(VEMPHAS P = 6.0x10-6). Scherzer et al. found that TRIM22 (or called STAF50) was 
up-regulated in lymphocytes of AD patients compared to controls from the gene 
expression study using microarray153,154. Also, significant association of a missense SNP 
(rs12364019; MAF = 0.018; P = 8.78x10-19) in TRIM22 was identified in the AD age of 
onset study using whole exome sequencing data of 71 PSEN1 E280A mutation 
carriers155. Further research is required for understanding the possible role of rare variants 
in TRIM22 for AD or its relevant phenotypes.  
 During the review of this study, we found that several statistical methods 
MAAUSS156, MSKAT31, and MURAT157 were introduced as multivariate gene-based 
association methods for rare variants. Interestingly, these methods are built based on the 
SKAT algorithm. To account for correlation among phenotypes, these methods estimate a 
covariance matrix among the phenotypes and build a linear mixed effect model assuming 
that variants effects follow the distribution with mean 0 and the estimated covariance 
matrix. However, these methods requires raw genetic and phenotypic data, which may 
not be often acquired easily. Also, these methods limit subjects who have all the 
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phenotypes to test. In real datasets, some subjects may not have one of the phenotypes, 
and then these SKAT-based methods cannot incorporate the entire sample due to a few 
missing data. In contrast, VEMPHAS needs gene-level summary statistics (e.g. P-values) 
for each phenotype and use simulation-based approach to compute one multivariate gene-
based P-value for each gene. These facts can make VEMPHAS computationally more 
efficient and much faster than those SKAT-based methods. The current version of 
VEMPHAS requires raw phenotype data to compute the correlation matrix among 
phenotypes unless it is given by the users. Zhu X et al. showed a multivariate association 
test by estimating correlation structure from summary statistics of multiple correlated 
phenotypes158. Future work may involve the extension of our approach to estimate the 
correlation structure based on the summary GWAS statistics of multiple phenotypes so 
that VEMPHAS do not require raw phenotypic data. 
Another issue for these SKAT-based methods is that same covariates are adjusted for all 
phenotypes to test even though some covariates are needed only for some of phenotypes, 
not all. For our VEMPHAS analysis of the ADNI data, age and sex were adjusted for all 
the three phenotypes (p-Tau/Aβ42, HPV, and LMiT), and intracranial volumes and 
education spans were further adjusted only for the phenotypes HPV and LMiT, 
respectively, but not for p-Tau/Aβ42. If those three SKAT-based methods were applied 
for these three phenotypes (p-Tau/Aβ42, HPV, and LMiT) in the ADNI data, then we 
cannot avoid the overfitting issue by including unnecessary covariates for some 
phenotypes. 
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 In summary, we introduced VEMPHAS as a statistical method for multivariate 
gene-based analysis, and demonstrated VEMPHAS to enhance the detection of rare 
variant sets through a large number of simulations under a variety of scenarios. 
Therefore, we propose the use of VEMPHAS for rare variant analysis of multiple 
disease-related phenotypes, which are often collected in most genetic studies.   
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Table 4.1. The estimated type I error of VEMPHAS under various scenarios by factor loadings (Λ) and 
phenotype numbers (N).  
Factor Loading 
(Λ) 
Phenotypes 
(N) 
α = 0.01 α = 0.001 α = 0.0001 
  3 0.008 0.0008 0.00007 
0.15 5 0.008 0.0009 0.00007 
  10 0.009 0.0008 0.00009 
 3 0.008 0.0008 0.00007 
0.35 5 0.008 0.0007 0.00007 
  10 0.007 0.0006 0.00005 
 3 0.008 0.0008 0.00007 
0.55 5 0.008 0.0008 0.00007 
  10 0.009 0.0009 0.00008 
 3 0.009 0.0009 0.00008 
0.75 5 0.009 0.0010 0.00009 
  10 0.010 0.0010 0.00010 
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Table 4.2. The estimated power of VEMPHAS under various scenarios by factor loadings (Λ), phenotype numbers (N), and causal variant proportions (%). 
Factor Loading 
(Λ) 
Phenotypes 
(N) 
α = 0.01  α = 0.001  α = 0.0001 
1% 3%  1% 3%  1% 3% 
  3 49.04% 97.94%   33.77% 94.22%   23.28% 88.65% 
0.15 5 61.11% 99.42%  47.71% 98.10%  36.17% 95.74% 
  10 76.15% 99.89%   64.68% 99.58%  54.95% 98.90% 
 3 48.71% 97.68%  32.34% 93.26%  21.56% 86.61% 
0.35 5 60.05% 99.22%  43.75% 97.37%  31.68% 93.93% 
  10 72.17% 99.80%   57.64% 99.16%   45.07% 97.72% 
 3 44.72% 96.86%  27.11% 90.71%  16.57% 81.74% 
0.55 5 52.47% 98.62%  33.90% 95.04%  21.61% 88.84% 
  10 60.76% 99.44%   41.18% 97.49%   27.38% 93.54% 
 3 37.37% 95.07%  20.22% 85.79%  11.06% 73.47% 
0.75 5 41.53% 97.00%  22.83% 89.85%  12.59% 79.15% 
  10 45.44% 98.12%   25.30% 92.71%   14.06% 83.56% 
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Table 4.3. Previously identified Alzheimer’s disease genes from VEMPHAS association testing of three 
phenotypes including the cerebrospinal fluid (CSF) biomarker ratio p-Tau/Aβ42, the MRI hippocampal volume 
(HPV) measures, and logical memory immediate recall test (LMiT) scores. 
Gene CH Start Stop No. of SNPs 
P-values 
seqMeta 
(Univariate) 
 
VEMPHAS 
(Multivariate) 
HPV LMiT CSF  HPV + LMiT + CSF 
CR1 1 207,669,613 207,818,681 11 0.52 0.29 0.34  0.45 
BIN1 2 127,806,098 127,864,526 4 0.27 0.16 0.22  0.19 
INPP5D 2 233,925,181 234,115,396 9 0.19 0.05 0.67  0.12 
CD2AP 6 47,445,972 47,591,966 8 0.79 0.93 0.45  0.87 
EPHA1 7 143,084,852 143,104,780 14 0.25 0.97 0.53  0.60 
PTK2B 8 27,168,332 27,321,478 14 0.23 0.19 0.91  0.34 
CLU 8 27,455,749 27,472,284 9 0.07 0.02 0.16  0.003 
USP6NL 10 11,504,431 11,639,623 7 0.63 0.21 0.28  0.37 
CELF1 11 47,493,806 47,591,446 5 0.76 0.88 0.03  0.19 
MS4A6A 11 59,939,655 59,949,181 2 0.28 0.63 0.78  0.66 
PICALM 11 85,685,793 85,779,831 4 0.91 0.27 0.13  0.29 
SORL1 11 121,323,072 121,500,253 20 0.03 0.11 0.33  0.05 
FERMT2 14 53,325,090 53,417,269 3 0.12 0.69 0.42  0.34 
MAPT 17 44,039,713 44,110,565 8 0.64 0.52 0.80  0.86 
ABCA7 19 1,036,121 1,068,740 15 0.97 0.77 0.93  0.99 
NFIC 19 3,359,679 3,462,773 7 0.13 0.52 0.06  0.10 
APOE 19 45,404,020 45,412,509 4 0.003 0.15 0.07  0.04 
CASS4 20 54,987,512 55,033,782 5 0.76 0.17 0.01  0.04 
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Table 4.4. Top-ranked genes from VEMPHAS association testing of three phenotypes including the cerebrospinal fluid (CSF) biomarker ratio p-Tau/Aβ42, the 
MRI hippocampal volume (HPV) measures, and logical memory immediate recall test (LMiT) scores. 
Gene CH Start Stop No. of SNPs 
P-values 
seqMeta  VEMPHAS 
HPV LMiT CSF  HPV + LMiT + CSF 
ZNF34 8 145,998,649 146,017,491 5 5.5x10-3 0.045 8.9x10-6  6.0x10-6 
TRIM22 11 5,717,462 5,758,715 11 4.4x10-5 1.8x10-3 9.1x10-3  6.0x10-6 
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Figure 4.1. The estimated power of VEMPHAS under various scenarios by factor loadings (Λ), phenotype numbers (N), and causal variant proportions (%). 
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Figure 4.2. Manhattan plot of VEMPHAS association results of three phenotypes including the cerebrospinal fluid (CSF) biomarker ratio p-Tau/Aβ42, the MRI 
hippocampal volume (HPV) measures, and logical memory immediate recall test (LMiT) scores. 
   
97 
 
 
  
Figure 4.3. Comparison of –log 10 (P-values) between VEMPHAS (X-axis) and seqMeta tests (Y-axis) on each of 
the 12,040 genes in the ADNI data analysis.  
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CHAPTER 5 Post RNA-Seq Analysis GUI 
 Post RNA-Seq GUI is an integrated workflow that incorporates genetics, 
genomics, and structural biology (protein) for analyzing isoform-specific expression data. 
The user is able to 1) view comparison of isoform expression levels between cases and 
controls, 2) do eQTL-mapping with genotype data, 3) locate an amino acid encoded by a 
genetic variant (or SNP) of interest in protein structure, and 4) retrieve genetic locations 
(chromosome and base pair positions) that correspond to targeted amino acids. The 
retrieved genetic locations can be used for annotating variants included in gene-based 
association tests. 
 Post RNA-Seq GUI is a stand- alone software. Its source codes, video tutorials, 
demo datasets are available 
 
5.1 Introduction 
 Many DNA sequence variants that located in regulatory regions including 
promotors, transcription biding sites or alternative splicing regulatory sites, alter 
transcript expression159,160. Also, the coding mutations on exons alter protein structures, 
which may change their biological functions. There are many RNA-Seq data analysis 
tools with a GUI for quantitating the expression levels of transcripts and comparing them 
in samples of individuals with and without a particular disease or discrete trait161. 
Additionally, RNA-Seq data are used for eQTL mapping. However, current software 
tools limit the comparison of RNA-Seq data with other genetic and protein structure data. 
We have developed an interactive software program, Post RNA-Seq GUI that facilitates 
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exploration of the association of genetic variants with expression of individual transcripts 
and corresponding protein structures. Post RNA-Seq GUI software is designed to 
integrate isoform-specific expression levels from the RNA-Seq analysis tools, 
MISOPY162 or RSEM163, with genotype DNA sequence and protein structure data. 
Specifically, this software facilitates (1) testing comparison of isoform-specific 
expression levels with SNP genotypes, (2) evaluation of genetic variants in strong linkage 
disequilibrium (LD) with a SNP of interest, (3) interactive viewing of the amino acid in 
protein structure encoded by a particular SNP, and (4) mapping a coding SNP to the 
corresponding location in a three-dimensional protein structure.  
 
5.2 Features of RNA-Seq GUI Browser 
 Post RNA-Seq GUI is an interactive program that facilitates rapid searching of 
isoform-specific expression in RNA-Seq data by MISOPY or RSEM. The main interface 
is divided into three sections (Figure 5.1A): the menu bar on top, graphic displays in the 
middle, and query boxes at the bottom. Graphic displays include an isoform-specific plot, 
a regional association plot, and a genotype-specific expression plot. The program accepts 
input that is numeric, strings, or both, and produces one or more plots or a table. 
Alternatively, the program can be executed by simply clicking with a cursor. The sections 
of the Post RNA-Seq GUI main interface are briefly described below. 
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5.2.1. Import Expression by Isoform and Genetic variants Data on Menu 
Upon opening the GUI, the isoform-specific expression and genetic variant data can be 
imported by clicking the “File” option in the main menu. All input files required here 
must be tab-delimited and indexed by the software Tabix163.  
 
5.2.2. Input Gene Symbol and SNP on Query Box 
 Isoform-specific expression plots can be produced and will be displayed on the 
left side by entering a gene symbol or Ensembl ID in the query boxes located at the 
bottom of the application window. A regional association plot can be produced and will 
be displayed on the top-right side of the window by entering the chromosome number 
along with a range of base positions. Lastly, a boxplot of genotype-specific expression 
results can be produced and will be displayed at the bottom-right of the window by 
entering the base position or SNP ID for a specific variant in the query box.  
 
5.2.3 Browse graphic displays of genotype-specific and isoform-specific expression, and 
regional association. 
 The isoform-specific expression plot consists of a bar plot in the upper half of the 
graph that shows the expression level (by percentage) of each isoform of a given gene 
and each isoform structure below the bar plot. The design of the regional association plot 
was inspired by the program LocusZoom164. This plot shows the strength of association 
levels, genetic position, and recombination rate. The strength of association levels is 
101 
 
 
  
computed using analysis of variance (ANOVA) by comparing the mean isoform-
expression levels among three genotype groups: AA, AB, and BB. The box plot shows 
the selected isoform’s expression level for each genotype of the genetic variant entered in 
the query box.  
 
5.2.4 Search for amino acids encoded by specific SNPs in a 3D protein structure 
 Post RNA-Seq GUI can search for and download protein structures in the protein 
data bank (PDB; http://www.rcsb.org) that correspond to the gene selected by the user, 
and then permits these structures to be viewed using a molecular visualization programs, 
PyMol or Maestro (Figure. 5.1D; Schrödinger, LLC, New York, NY, 2016). One can 
display a specific amino acid encoded by a SNP of interest (Figure 5.1B), the neighboring 
amino acids that are physically proximate to (e.g., five Angströms away) the amino acid 
of interest, and the genetic location of DNA encoding for the neighboring amino acids 
(Figure. 5.1C). 
 
5.3 Usage 
 Post RNA-Seq GUI is very versatile. For example, one can easily compare 
isoform expression levels between cases and controls and among SNP genotypes 
(AA/AB/BB) using bar/box plots with summary statistics (e.g., ANOVA). It is possible 
to determine whether a particular SNP is located near exons that are encoded only in 
specific isoforms, and thus may be involved in alternative splicing, through the graphic 
display of isoform structures. In addition, the software allows localization of a SNP 
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within the transcript and consequently to a particular amino acid in the three dimensional 
protein structure. It is thus possible to ascertain if the amino acid encoded by a specified 
SNP is located in a biologically important protein domain that, for examples, enables or 
prevents binding with other key molecules. Moreover, the program can help identify 
SNPs in amino acids that are physically adjacent in the three dimensional protein but 
possibly dispersed within the genomic sequence. This capability can thus facilitate 
selection of an annotated group of SNPs based on their corresponding location in the 
protein for gene-based association tests.  
 
5.4 CONCLUSION 
 Analysis of RNA-Seq data and comparison of subsequent findings with other 
genetics and proteomic data has been very cumbersome and time-consuming. The Post 
RNA-Seq GUI software allows interpretation of results from RNA-Seq analysis in a 
manner that integrates genetic, genomic, and structural biology data. Other currently 
available programs do not easily translate genetic findings at the genomic or protein 
structure level, or vice-versa. Post RNA-Seq GUI is a stand-alone software written in 
python and R programming languages. This software is available as an open-source 
application with a convenient graphical interface and provides aid to new users via video 
tutorials and demo datasets. 
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Figure 5.1. Visualization of the Post RNA-Seq GUI software interface.  
 
This example demonstrates how to display the results from the RNA-Seq analysis tool, MISOPY, (A) Appearance of Post RNA-Seq GUI software. (B) Sub-window to 
display DNA coordinate and their encoding amino acids number in a protein structure. (C) Sub-window to display DNA coordinates that corresponds to amino acids of 
interest. (D) Viewing a protein structure with amino acids (represented as spheres) encoded by certain DNA coordinate. 
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CHAPTER 6 Summary and Future work 
 Conventional GWAS, which focuses on identifying single base pair variants 
associated with disease risk,   has been successfully applied to a variety of complex 
diseases. However, majority of the disease heritability is still unexplained by 
conventional GWAS approach. The unexplained heritability may be due to genetic or 
phenotypic heterogeneities or rare variants. The motivation behind this thesis is to 
uncover a portion of the unexplained heritability of complex diseases by aggregating 
genetic and phenotypic information, which is not the primary approach of conventional 
GWAS. This thesis explored analyses of various disease-related endophenotypes rather 
than disease risk and evaluated multivariate gene-based association methods for common 
variants. Also, we developed a new multivariate rare variant association method (called 
VEMPHAS) and a GUI software for combining genetic variants, their eQTL associations 
with target genes and protein structures encoded by the target genes. 
 Chapter 2-1 is one GWAS example of AD-related phenotypes including CSF 
biomarkers, MRI hippocampal volume, and logical memory test scores in preclinical 
stages of AD. We found four novel loci, which have not been detected in (conventional) 
GWAS of AD risk, including SRRM4, C14orf79, MTUS1, and ZNF804B. These 
findings show AD-related brain changes prior to clinical AD which can provide insight 
about early AD-related biological processes. Chapter 2-2 is about bivariate analyses of 
AD-related neuropathological traits including NP, NFT, CAA from brain autopsy sample. 
We identified ECRG4 and HDAC9 from the bivariate models of NP+NFT and 
NFT+CAA, respectively. We also found another genes including TRAPPC12, 
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TRAPPC12-AS1, and ADI1 by gene-based test of the bivariate associations with NFT 
and CAA. This indicates that the multivariate gene-based association test can identify 
novel genetic loci which are not detected by the conventional GWAS approach and 
thereby uncover some of the unexplained heritability.  
 In chapter 3, we conducted extensive simulation study to compare methods for 
multivariate gene-based association test using common variants. We found noticeable 
differences among the methods, dependent on the various scenarios. Overall, the method 
combining MultiPhen with GATES performed best for most tested scenarios especially 
when correlations among phenotypes are relatively low. We also suggest the combination 
of O’Brien with VEGAS or TATES with GATES as alternative method because 
MultiPhen requires raw data (genotypes and phenotypes) but O’Brien uses GWAS 
summary statistics.  
 In chapter 4, we propose a new method called VEMPHAS to identify novel 
associations between sets of rare variants and multiple disease-related phenotypes. 
Various scenarios in the extensive simulation study were performed to evaluate the 
performance of VEMPHAS and showed that VEMPHAS correctly controlled type I 
error. VEMPHAS was applied for rare variant analysis of AD-related phenotypes in the 
ADNI study. Suggestively significant association was observed in the gene TRIM22 (P < 
4.15x10-6) which may be worthy of further investigations. The current algorithm of 
VEMPHAS requires raw phenotypic data for computing correlations among phenotypes, 
which are not often easy for real data analysis. Zhu X et al. showed a multivariate 
association test by estimating correlation structure from summary statistics of multiple 
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phenotypes165. Future work may involve the extension of our approach to estimate the 
correlation structure based on the summary GWAS statistics of multiple phenotypes so 
that VEMPHAS do not require raw phenotypic data. 
 In chapter 5, we introduce a stand-alone software with GUI called Post RNA-Seq 
GUI which is designed for exploring genetic variants, their associations with gene 
expressions, and protein structures with amino acids encoded by the variants highlighted. 
We can extend this approach to predict functional genetic variants based on protein 
structural information, which can increase statistical power of gene-based association 
test.   
.
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Appendix A Genotyping, Quality Control (QC), and Imputation, and Population 
Substructure 
The ADNI-1 and ADNI-GO/2 samples were genotyped using the Illumina 
Human610-Quad, and HumanOmniExpress microarray chips (Illumina, Inc., San Diego, 
CA), respectively. QC procedures for the genotype data were performed using PLINK166. 
Samples with genotyping call rates <95% were excluded. Subjects with non-European 
ancestry were removed based on the self-reported ethnicity. We excluded SNPs with a 
minor allele frequency (MAF) <5% or significant deviation from Hardy-Weinberg 
equilibrium (P < 1.0x10-6). A total of 548,010 SNPs for ADNI-1 and 641,106 SNPs for 
ADNI-GO/2 were retained after cleaning. Genome-wide imputation of SNP allele dosages 
was performed using the 1000 Genomes reference panel (v37, March, 2012) and IMPUTE2 
software after estimating haplotypes using SHAPEIT167. Imputed SNPs with an imputation 
quality estimate (R2) ≥ 0.40 were used for association analyses. After QC, the ADNI-1 
sample with GWA data consisted of 187 CN, 329 MCI, and 163 AD subjects, and the 
ADNI-GO/2 contained 118 CN, 252 MCI, and 27 AD subjects with GWA data. 
Population substructure was evaluated in each dataset with reference populations 
from the 1000 Genome Project by principal components analysis using EIGENSTRAT137. 
Only individuals clustering with European samples were retained for further analysis. 
Population substructure in the remaining European ancestry sample was assessed using 
genotyped SNPs that passed QC. These SNPs were pruned to remove pairs with high LD 
based on pairwise LD (r2) > 0.2 using PLINK, and using a window size of 1,500 SNPs. 
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Principal components (PCs) of ancestry were derived using the smartpca script in 
EIGENSTRAT. The first three PCs were included as covariates in association test models 
to minimize spurious associations and maximize power to detect true associations. 
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Appendix B Eisai Bio Bank Description 
 The Eisai Bio Bank has human brain samples from University of Miami and McLean Hospital. Total RNA purified from 
hippocampal brain regions were extracted with Qiagen RNeasy Mini Kits (Qiagen, Hilden, Germany). Poly-A-enriched mRNA was 
reverse transcribed and amplified using the Nugen Ovation Kit (NuGEN, San Carlos, CA, USA). Paired-end cDNA was sequenced 
with an Illumina MiSeq at 106 base pair length (Illumina, San Diego, CA, USA). RNA-sequencing reads were checked with FASTX-
Toolkit (http://hannonlab.cshl.edu/fastx_toolkit), trimmed with Trimmomatic, and aligned to the GRCh38 assembly transcriptome 
with Bowtie168. Transcript expression levels were estimated in transcripts per million (TPM) using RSEM163. Samples of RIN larger 
than 5 were kept for downstream analysis.  
 
Source 
Total Braak Stages   AD cases   Controls 
N 
NA 0 1 2 3 4 5 6   
N Age RIN   N Age RIN 
  (Female) (Mean/SD) (Mean/SD)   (Female) (Mean/SD) (Mean/SD) 
McLean 26 0 1 6 3 4 3 3 6   16 (7) 76.1 (5.5) 6.7 (0.95)   10 (5) 66.8 (8.9) 6.6 (1.1) 
U of Miami 25 6 0 4 1 5 3 5 1   19 (11) 85.8 (9.0) 6.6 (0.89)   6 (3) 85.7 (6.6) 6.8 (1.0) 
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Appendix C Co-expression network analysis 
 We constructed a gene co-expression network in the human hippocampus 
transcriptomic data in the Eisai Bio Bank using an R package WGCNA81. This software 
defines module of genes highly co-expressed based on Pearson correlation analysis of 
gene expression values. The correlation coefficients were applied to the following 
function for calculating adjacency matrix α. 
𝛼𝑖𝑗 = |0.5 + 0.5 × 𝑐𝑜𝑟(𝒙𝑖 , 𝒙𝑗)|
𝛽
 
where 𝑥𝑖 is a vector including expression levels of gene i in 38 samples. This power 
function was used for reducing effects of weak correlation and increasing effect of strong 
correlation. The parameter β was 12 in this study to meet scale-free topology of the co-
expression networks. The adjacency α was used to calculate topological overlap matrix 
(TOM), an indicator assigned for every pair of genes and representing whether the pair is 
closely located in the co-expression network. Hierarchical clustering of the genes was 
performed based on TOM with the average linkage method81,169. Co-expression modules 
were defined from the hierarchical tree by “dynamic tree cut algorithm”170. The modules 
including less than 100 genes were considered as noisy modules and ignored for the 
further analyses. Expression patterns of the modules were summarized with their first 
principal components (module eigengenes). Pearson correlations between gene 
expressions and the module eigengenes were calculated as module membership values81.  
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Appendix D Definition of brain cell type-specific genes 
 We used single-cell RNA sequencing data of human brain cells published by 
Darmanis et al.171. Mapping results were downloaded from Gene Expression Omnibus 
(Accession number: GSE67835) and the mapped read counts were normalized into CPM 
(count per million) as previously described171. Cell type-specific genes were defined 
when median and mean expression levels (CPM) of genes greater than 4.0. 
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Appendix Table A.1. Sample size and characteristics of three endophenotypes at the baseline in ADNI 1 and ADNI GO/2. 
    
ADNI 1 
 
 
ADNI GO/2 
Trait Subgroup  
N Age Trait 
 
N Age Trait 
(Female %) (Mean/SD) (Mean/SD) (Female %) (Mean/SD) (Mean/SD) 
CSF 
Aβ42 
ALL  365 (40) 74.9 (6.9) 167.6 (55.8)  365 (44.1) 72.9 (7.3) 215.6 (73.1) 
CN  96 (47.9) 75.6 (4.9) 201.2 (55.6)  110 (49.1) 74.8 (5.6) 231.2 (68.7) 
MCI  177 (34.5) 74.6 (7.2) 161.4 (54.1)  230 (42.6) 71.7 (7.4) 215.5 (73.9) 
AD  92 (42.4) 74.6 (7.8) 144.3 (41.6)  25 (36) 75.7 (10.8) 147.3 (39.8) 
CSF 
t-Tau 
 
ALL   365 (40) 74.9 (6.9) 98.2 (53.7)   359 (44.6) 73 (7.3) 88.2 (52.7) 
CN  96 (47.9) 75.6 (4.9) 71.9 (30.6)  107 (49.5) 74.8 (5.6) 72.9 (33) 
MCI  177 (34.5) 74.6 (7.2) 101.1 (55.7)  228 (43) 71.7 (7.4) 90.2 (56.4) 
AD   92 (42.4) 74.6 (7.8) 120.1 (57.8)   24 (37.5) 76.3 (10.7) 137.1 (56.4) 
CSF 
p-Tau  
ALL   362 (40.1) 74.9 (6.9) 34.4 (18.6)   364 (44) 72.9 (7.4) 25.2 (12.4) 
CN  94 (47.9) 75.6 (5) 25.5 (14.8)  109 (48.6) 74.8 (5.6) 22.6 (8.9) 
MCI  176 (34.7) 74.6 (7.3) 35.4 (17.7)  230 (42.6) 71.7 (7.4) 25.4 (13.3) 
AD   92 (42.4) 74.6 (7.8) 41.3 (20.3)   25 (36) 75.7 (10.8) 34 (12.7) 
HPV 
ALL   546 (40.3) 74.9 (6.7) 6500.2 (1191.3)   337 (44.5) 72.3 (7.1) 7155.2 (1101.4) 
CN  166 (43.4) 75.6 (4.8) 7297.8 (922)  102 (50) 74.1 (5.4) 7397.6 (848.2) 
MCI  261 (36.4) 74.6 (7.1) 6378.9 (1082.6)  213 (42.3) 71.1 (7.1) 7177.1 (1125.8) 
AD   119 (44.5) 74.6 (7.8) 5653.9 (1065)   22 (40.9) 74.9 (10.4) 5818.8 (996.2) 
LMiT 
  
ALL   679 (39.9) 75.4 (6.7) 8.4 (4.9)   397 (43.8) 72.8 (7.3) 10.8 (4.2) 
CN  187 (43.9) 75.9 (4.9) 14.1 (3.4)  118 (49.2) 74.7 (5.6) 14.4 (2.9) 
MCI  329 (35) 75.3 (7.1) 7.2 (3.2)  252 (42.1) 71.6 (7.4) 9.9 (3.3) 
AD   163 (45.4) 75.3 (7.7) 4.2 (2.9)   27 (37) 75.1 (10.5) 4.1 (2.6) 
LMdT 
ALL  679 (39.9) 75.4 (6.7) 5.8 (5.5)  397 (43.8) 72.8 (7.3) 9.1 (4.4) 
CN  187 (43.9) 75.9 (4.9) 13.3 (3.6)  118 (49.2) 74.7 (5.6) 13.6 (3.1) 
MCI  329 (35) 75.3 (7.1) 3.8 (2.7)  252 (42.1) 71.6 (7.4) 7.7 (2.8) 
AD   163 (45.4) 75.3 (7.7) 1.2 (1.9)   27 (37) 75.1 (10.5) 1.7 (2) 
Aβ42, t-Tau, and p-Tau: CSF biomarkers of Aβ42 and total and phosphorylated tau proteins. HPV: the MRI scan of hippocampal volume. LMiT and LMdT: the scores 
from logical memory tests (immediate and delayed recalls). CN: clinically normal subjects. MCI: subjects with mild cognitive impairment. ALL: a composed group of 
CN, MCI and AD subjects. 
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Appendix Table A.2. Association of APOE ε4 carrier status with CSF levels of Aβ42, total tau (t-Tau), and 
phosphorylated tau (p-Tau), with hippocampal volume (HPV), and with logical memory tests of immediate 
(LMiT) and delayed (LMdT) recall. 
 
Trait Subgroup ε4 FREQ BETA SE P 
 ALL 0.22 -0.95 0.07 5.43x10-41 
CSF CN 0.12 -0.87 0.14 5.46x10
-9 
Aβ42 MCI 0.24 -0.89 0.09 1.48x10
-20 
 AD 0.34 -0.73 0.15 6.18x10-6 
 ALL 0.22 0.69 0.07 5.31x10-21 
CSF CN 0.12 0.26 0.14 0.06 
t-Tau MCI 0.24 0.76 0.09 1.37x10-14 
 AD 0.34 0.23 0.19 0.24 
 ALL 0.22 0.63 0.07 2.19x10-17 
CSF CN 0.12 0.30 0.15 0.04 
p-Tau MCI 0.24 0.68 0.10 1.04x10-11 
 AD 0.34 0.23 0.18 0.22 
 ALL 0.23 -0.55 0.07 1.20x10-16 
HPV CN 0.13 -0.05 0.11 0.66 
 MCI 0.26 -0.29 0.09 8.04x10-4 
 AD 0.35 -0.59 0.14 5.26x10-5 
 ALL 0.23 -0.49 0.06 4.05x10-15 
LMiT CN 0.13 -0.08 0.09 0.36 
 MCI 0.25 -0.19 0.06 2.87x10-3 
 AD 0.33 0.07 0.12 0.59 
 ALL 0.23 -0.55 0.06 3.77x10-19 
LMdT CN 0.13 -0.08 0.08 0.28 
 MCI 0.25 -0.21 0.06 2.84x10-4 
 AD 0.33 -0.05 0.10 0.61 
ε4 FREQ is the ε4 allele frequency  
114 
 
 
  
Appendix Table A.3. Association P-values of Alzheimer disease loci previously established by GWAS with CSF 
Aβ42 according to clinical subgroup.  
   ALL   CN   MCI   AD   
CHR SNP Gene Beta SE P Beta SE P Beta SE P Beta SE P 
1 rs6656401 CR1 -0.12 0.07 0.11 -0.06 0.15 0.67 -0.09 0.10 0.35 -0.01 0.13 0.97 
2 rs6733839 BIN1 -0.06 0.06 0.26 -0.11 0.10 0.26 -0.03 0.08 0.71 -0.06 0.12 0.60 
2 rs35349669 INPP5D -0.10 0.05 0.07 -0.15 0.10 0.13 -0.05 0.07 0.48 0.23 0.12 0.05 
5 rs190982 MEF2C -0.05 0.06 0.41 0.00 0.10 0.99 -0.11 0.08 0.18 -0.21 0.13 0.12 
5 rs11168036 HBEGF 0.01 0.06 0.84 0.00 0.10 0.98 0.08 0.08 0.33 -0.15 0.11 0.20 
6 rs9271192 HLA region 0.02 0.06 0.75 0.26 0.11 0.02 -0.04 0.09 0.64 0.13 0.12 0.30 
6 rs10948363 CD2AP 0.06 0.06 0.33 -0.10 0.12 0.41 0.00 0.08 0.98 0.34 0.12 4.15E-03 
7 rs2718058 NME8 -0.02 0.06 0.71 -0.06 0.11 0.57 0.01 0.07 0.90 0.11 0.12 0.36 
7 rs1476679 ZCWPW1 -0.09 0.06 0.16 -0.09 0.11 0.43 -0.07 0.08 0.37 0.02 0.13 0.90 
7 rs11771145 EPHA1 0.05 0.06 0.41 0.09 0.10 0.39 0.09 0.08 0.28 -0.10 0.12 0.41 
8 rs28834970 PTK2B 0.06 0.06 0.26 0.14 0.10 0.17 0.04 0.08 0.64 -0.04 0.12 0.73 
8 rs9331896 CLU -0.07 0.06 0.27 -0.05 0.10 0.59 -0.05 0.08 0.57 0.01 0.12 0.96 
10 rs7920721 USP6NL -0.07 0.06 0.21 -0.25 0.10 0.01 -0.03 0.07 0.69 0.05 0.11 0.63 
11 rs10838725 CELF1 0.08 0.06 0.17 0.15 0.11 0.15 0.08 0.08 0.29 0.12 0.14 0.37 
11 rs983392 MS4A region 0.00 0.05 0.94 0.12 0.09 0.20 -0.03 0.08 0.68 0.01 0.12 0.93 
11 rs10792832 PICALM 0.06 0.06 0.26 0.08 0.10 0.43 0.06 0.08 0.40 -0.12 0.12 0.34 
11 rs11218343 SORL1 -0.23 0.15 0.11 -0.40 0.27 0.14 -0.12 0.18 0.51 -0.27 0.49 0.59 
14 rs17125944 FERMT2 0.20 0.09 0.04 0.14 0.18 0.44 0.20 0.13 0.13 0.09 0.18 0.62 
14 rs10498633 SLC24A4 -0.14 0.07 0.03 -0.32 0.12 5.93E-03 -0.05 0.09 0.54 -0.04 0.14 0.77 
17 rs2732703 KANSL1 -0.15 0.10 0.12 -0.02 0.20 0.93 -0.28 0.13 0.03 0.15 0.21 0.48 
17 rs2632516 BZRAP1 -0.05 0.05 0.38 -0.08 0.10 0.42 -0.10 0.07 0.17 -0.01 0.12 0.91 
19 rs9749589 NFIC -0.05 0.08 0.56 -0.26 0.15 0.08 0.03 0.11 0.81 0.07 0.18 0.72 
19 rs4147929 ABCA7 -0.08 0.07 0.22 0.20 0.15 0.18 -0.15 0.09 0.08 0.07 0.14 0.63 
19 rs3865444 CD33 -0.01 0.06 0.87 -0.18 0.11 0.09 0.03 0.08 0.72 -0.07 0.12 0.55 
20 rs7274581 CASS4 0.02 0.09 0.80 0.36 0.16 0.03 -0.13 0.12 0.28 0.40 0.21 0.06 
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Appendix Table A.4.  Association P-values of Alzheimer disease loci previously established by GWAS with CSF 
total tau according to clinical subgroup.  
   ALL   CN   MCI   AD   
CHR SNP Gene Beta SE P Beta SE P Beta SE P Beta SE P 
1 rs6656401 CR1 0.08 0.08 0.30 0.10 0.13 0.44 0.04 0.10 0.69 -0.04 0.15 0.77 
2 rs6733839 BIN1 0.02 0.06 0.74 -0.02 0.09 0.87 0.00 0.08 1.00 -0.04 0.14 0.77 
2 rs35349669 INPP5D 0.07 0.06 0.22 -0.01 0.09 0.93 0.09 0.07 0.19 -0.19 0.13 0.16 
5 rs190982 MEF2C 0.22 0.06 1.94E-04 0.06 0.09 0.55 0.31 0.08 1.03E-04 -0.10 0.15 0.52 
5 rs11168036 HBEGF -0.01 0.06 0.89 0.08 0.09 0.37 -0.07 0.08 0.38 0.10 0.13 0.46 
6 rs9271192 HLA region -0.02 0.07 0.81 -0.02 0.10 0.84 -0.06 0.09 0.50 -0.09 0.14 0.52 
6 rs10948363 CD2AP -0.05 0.06 0.44 -0.04 0.11 0.71 -0.03 0.08 0.73 -0.10 0.14 0.45 
7 rs2718058 NME8 0.07 0.06 0.21 0.01 0.10 0.95 0.06 0.07 0.44 0.10 0.14 0.45 
7 rs1476679 ZCWPW1 0.10 0.06 0.10 0.08 0.10 0.43 0.05 0.08 0.58 -0.32 0.15 0.03 
7 rs11771145 EPHA1 0.11 0.06 0.06 0.04 0.09 0.68 0.04 0.08 0.62 -0.28 0.13 0.04 
8 rs28834970 PTK2B -0.06 0.06 0.29 -0.04 0.09 0.64 -0.06 0.08 0.44 -0.01 0.14 0.96 
8 rs9331896 CLU 0.03 0.06 0.57 -0.01 0.09 0.96 0.07 0.08 0.37 0.17 0.14 0.23 
10 rs7920721 USP6NL -0.01 0.06 0.87 0.04 0.09 0.64 -0.01 0.07 0.95 -0.07 0.13 0.57 
11 rs10838725 CELF1 0.00 0.06 0.98 -0.14 0.09 0.13 0.01 0.08 0.90 0.06 0.16 0.70 
11 rs983392 MS4A region 0.10 0.06 0.07 0.10 0.08 0.25 0.03 0.08 0.65 0.17 0.13 0.22 
11 rs10792832 PICALM -0.11 0.06 0.06 0.10 0.09 0.29 -0.20 0.08 0.01 -0.02 0.14 0.89 
11 rs11218343 SORL1 0.10 0.15 0.52 0.17 0.24 0.47 0.05 0.19 0.79 -0.32 0.57 0.57 
14 rs17125944 FERMT2 0.03 0.10 0.78 -0.02 0.17 0.92 0.09 0.13 0.46 0.12 0.21 0.58 
14 rs10498633 SLC24A4 0.07 0.07 0.31 0.12 0.11 0.26 0.04 0.09 0.67 0.04 0.16 0.79 
17 rs2732703 KANSL1 0.02 0.10 0.85 -0.13 0.18 0.46 0.12 0.13 0.38 -0.40 0.24 0.09 
17 rs2632516 BZRAP1 -0.10 0.05 0.07 -0.15 0.09 0.08 -0.04 0.07 0.60 0.07 0.14 0.64 
19 rs9749589 NFIC -0.04 0.08 0.62 0.20 0.13 0.13 -0.07 0.11 0.53 0.11 0.21 0.59 
19 rs4147929 ABCA7 0.12 0.07 0.09 0.01 0.14 0.93 0.08 0.09 0.39 0.11 0.16 0.50 
19 rs3865444 CD33 0.01 0.06 0.89 -0.09 0.10 0.35 0.03 0.08 0.68 -0.11 0.14 0.43 
20 rs7274581 CASS4 0.24 0.09 0.01 -0.04 0.15 0.80 0.33 0.12 6.40E-03 -0.13 0.24 0.59 
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Appendix Table A.5.  Association P-values of Alzheimer disease loci previously established by GWAS with CSF 
phosphorylated tau endophenotypes according to clinical subgroup.  
   ALL   CN   MCI   AD   
CHR SNP Gene Beta SE P Beta SE P Beta SE P Beta SE P 
1 rs6656401 CR1 0.07 0.07 0.33 0.01 0.14 0.93 0.05 0.10 0.63 -0.01 0.14 0.96 
2 rs6733839 BIN1 0.04 0.06 0.53 -0.01 0.09 0.89 0.01 0.08 0.89 -0.09 0.13 0.49 
2 rs35349669 INPP5D 0.09 0.05 0.10 -0.02 0.10 0.82 0.13 0.07 0.08 -0.21 0.13 0.10 
5 rs190982 MEF2C 0.13 0.06 0.03 0.07 0.10 0.49 0.18 0.08 0.02 0.03 0.15 0.84 
5 rs11168036 HBEGF 0.01 0.06 0.90 0.23 0.09 0.02 -0.12 0.08 0.12 0.13 0.13 0.30 
6 rs9271192 HLA region 0.02 0.06 0.82 -0.07 0.11 0.51 0.01 0.09 0.87 -0.11 0.14 0.41 
6 rs10948363 CD2AP -0.07 0.06 0.27 0.05 0.12 0.65 -0.04 0.08 0.59 -0.23 0.13 0.08 
7 rs2718058 NME8 0.03 0.06 0.64 -0.02 0.10 0.82 0.02 0.07 0.81 -0.05 0.13 0.68 
7 rs1476679 ZCWPW1 0.15 0.06 0.02 0.19 0.10 0.06 0.09 0.08 0.28 -0.26 0.15 0.07 
7 rs11771145 EPHA1 0.07 0.06 0.20 -0.01 0.10 0.94 -0.01 0.08 0.94 -0.30 0.13 0.02 
8 rs28834970 PTK2B -0.01 0.06 0.90 -0.03 0.10 0.75 0.03 0.08 0.73 0.01 0.13 0.95 
8 rs9331896 CLU 0.05 0.06 0.42 0.07 0.10 0.46 0.07 0.08 0.41 0.16 0.13 0.25 
10 rs7920721 USP6NL -0.01 0.06 0.89 0.07 0.10 0.48 0.00 0.07 0.97 -0.15 0.12 0.23 
11 rs10838725 CELF1 -0.07 0.06 0.23 -0.19 0.10 0.05 -0.11 0.08 0.17 0.19 0.15 0.22 
11 rs983392 MS4A region 0.08 0.06 0.16 0.06 0.09 0.47 0.04 0.08 0.59 0.09 0.13 0.50 
11 rs10792832 PICALM -0.11 0.06 0.06 0.08 0.10 0.43 -0.22 0.08 5.55E-03 0.08 0.13 0.53 
11 rs11218343 SORL1 0.11 0.15 0.47 0.32 0.25 0.21 0.00 0.18 0.99 -0.08 0.55 0.88 
14 rs17125944 FERMT2 -0.04 0.10 0.65 0.01 0.17 0.93 -0.04 0.13 0.78 0.07 0.20 0.73 
14 rs10498633 SLC24A4 0.12 0.07 0.08 0.20 0.11 0.07 0.05 0.09 0.59 -0.06 0.15 0.71 
17 rs2732703 KANSL1 -0.06 0.10 0.57 0.10 0.18 0.57 -0.01 0.13 0.97 -0.61 0.22 0.01 
17 rs2632516 BZRAP1 -0.07 0.05 0.19 -0.10 0.09 0.26 -0.03 0.07 0.66 -0.01 0.13 0.94 
19 rs9749589 NFIC 0.00 0.08 0.97 0.14 0.14 0.32 -0.03 0.11 0.77 -0.09 0.20 0.67 
19 rs4147929 ABCA7 0.11 0.07 0.10 0.11 0.14 0.45 0.08 0.09 0.35 0.05 0.15 0.76 
19 rs3865444 CD33 -0.04 0.06 0.51 -0.13 0.10 0.20 -0.04 0.08 0.59 -0.10 0.14 0.48 
20 rs7274581 CASS4 0.15 0.09 0.10 -0.32 0.16 0.04 0.30 0.12 0.01 -0.02 0.23 0.94 
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Appendix Table A.6.  Association P-values of Alzheimer disease loci previously established by GWAS with MRI 
hippocampus volumes according to clinical subgroup.  
   ALL   CN   MCI   AD   
CHR SNP Gene Beta SE P Beta SE P Beta SE P Beta SE P 
1 rs6656401 CR1 -0.02 0.06 0.74 0.12 0.10 0.25 0.08 0.08 0.31 0.02 0.12 0.88 
2 rs6733839 BIN1 -0.02 0.05 0.64 0.03 0.07 0.70 -0.06 0.07 0.38 -0.11 0.10 0.26 
2 rs35349669 INPP5D -0.08 0.05 0.12 -0.05 0.07 0.52 -0.05 0.06 0.42 0.07 0.11 0.55 
5 rs190982 MEF2C -0.02 0.05 0.75 0.07 0.07 0.31 -0.01 0.07 0.84 -0.07 0.12 0.59 
5 rs11168036 HBEGF -0.02 0.05 0.68 -0.02 0.07 0.80 -0.02 0.06 0.79 0.19 0.10 0.06 
6 rs9271192 HLA region 0.05 0.06 0.39 0.03 0.08 0.72 0.06 0.07 0.39 -0.09 0.11 0.43 
6 rs10948363 CD2AP 0.01 0.05 0.82 0.10 0.08 0.22 -0.11 0.07 0.11 -0.10 0.11 0.34 
7 rs2718058 NME8 -0.07 0.05 0.13 0.00 0.07 0.96 -0.11 0.06 0.06 0.13 0.10 0.23 
7 rs1476679 ZCWPW1 -0.04 0.05 0.43 -0.01 0.07 0.88 0.04 0.07 0.56 . . . 
7 rs11771145 EPHA1 -0.09 0.05 0.08 -0.03 0.07 0.68 -0.09 0.06 0.14 0.04 0.11 0.70 
8 rs28834970 PTK2B 0.03 0.05 0.61 -0.01 0.07 0.91 0.01 0.06 0.81 . . . 
8 rs9331896 CLU -0.05 0.05 0.36 -0.06 0.07 0.42 -0.05 0.07 0.48 . . . 
10 rs7920721 USP6NL 0.06 0.05 0.25 0.03 0.07 0.69 0.09 0.06 0.14 -0.10 0.09 0.29 
11 rs10838725 CELF1 -0.01 0.05 0.81 0.06 0.07 0.39 0.02 0.06 0.75 -0.24 0.12 0.05 
11 rs983392 MS4A region -0.10 0.05 0.05 0.01 0.07 0.83 -0.06 0.06 0.33 -0.13 0.11 0.24 
11 rs10792832 PICALM 0.13 0.05 0.01 0.11 0.07 0.13 0.13 0.06 0.05 0.06 0.11 0.55 
11 rs11218343 SORL1 -0.26 0.12 0.03 -0.25 0.16 0.13 -0.16 0.16 0.31 -0.38 0.27 0.17 
14 rs17125944 FERMT2 0.10 0.09 0.27 -0.15 0.13 0.24 0.07 0.11 0.52 0.22 0.17 0.19 
14 rs10498633 SLC24A4 0.04 0.06 0.44 0.08 0.08 0.37 0.02 0.07 0.74 -0.15 0.11 0.20 
17 rs2732703 KANSL1 -0.05 0.09 0.60 0.10 0.12 0.41 -0.09 0.11 0.42 0.11 0.19 0.56 
17 rs2632516 BZRAP1 0.01 0.05 0.76 0.01 0.07 0.85 0.02 0.06 0.69 0.10 0.11 0.34 
19 rs9749589 NFIC 0.06 0.07 0.41 -0.12 0.10 0.24 0.05 0.09 0.61 0.02 0.16 0.91 
19 rs4147929 ABCA7 -0.03 0.06 0.57 0.02 0.10 0.84 -0.10 0.07 0.20 0.24 0.13 0.06 
19 rs3865444 CD33 0.04 0.05 0.41 0.07 0.07 0.30 0.01 0.07 0.86 0.07 0.11 0.56 
20 rs7274581 CASS4 -0.05 0.08 0.55 0.02 0.11 0.88 -0.07 0.11 0.50 0.19 0.18 0.29 
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Appendix Table A.7.  Association P-values of Alzheimer disease loci previously established by GWAS with 
logical memory immediate recall test scores according to clinical subgroup.  
   ALL   CN   MCI   AD   
CHR SNP Gene Beta SE P Beta SE P Beta SE P Beta SE P 
1 rs6656401 CR1 -0.14 0.06 0.02 -0.20 0.08 0.01 0.01 0.06 0.93 0.06 0.10 0.58 
2 rs6733839 BIN1 -0.03 0.05 0.46 -0.01 0.06 0.93 -0.04 0.05 0.44 -0.03 0.08 0.68 
2 rs35349669 INPP5D -0.08 0.04 0.06 0.04 0.06 0.51 -0.10 0.04 0.02 -0.06 0.09 0.49 
5 rs190982 MEF2C -0.03 0.05 0.58 0.03 0.06 0.64 -0.07 0.05 0.13 -0.25 0.09 9.30E-03 
5 rs11168036 HBEGF 0.03 0.05 0.54 -0.04 0.06 0.49 0.09 0.05 0.04 0.04 0.08 0.59 
6 rs9271192 HLA region 0.05 0.05 0.31 0.08 0.06 0.23 0.07 0.05 0.19 0.12 0.09 0.18 
6 rs10948363 CD2AP 0.04 0.05 0.40 -0.02 0.07 0.76 0.00 0.05 0.98 -0.02 0.09 0.82 
7 rs2718058 NME8 -0.04 0.04 0.39 0.03 0.06 0.65 -0.02 0.04 0.59 0.00 0.09 0.97 
7 rs1476679 ZCWPW1 -0.12 0.05 0.01 -0.03 0.06 0.64 -0.10 0.05 0.05 . . . 
7 rs11771145 EPHA1 0.00 0.05 0.96 0.03 0.06 0.60 -0.02 0.05 0.62 -0.13 0.09 0.16 
8 rs28834970 PTK2B 0.03 0.05 0.56 0.11 0.06 0.06 -0.03 0.04 0.49 -0.03 0.09 0.74 
8 rs9331896 CLU 0.01 0.05 0.89 0.02 0.06 0.76 0.06 0.05 0.18 -0.02 0.09 0.85 
10 rs7920721 USP6NL 0.08 0.05 0.07 0.05 0.06 0.38 0.10 0.04 0.02 0.09 0.08 0.24 
11 rs10838725 CELF1 0.01 0.05 0.84 0.10 0.06 0.09 -0.03 0.05 0.55 0.02 0.09 0.80 
11 rs983392 MS4A region -0.08 0.05 0.09 -0.04 0.05 0.50 -0.02 0.05 0.75 0.04 0.09 0.63 
11 rs10792832 PICALM 0.07 0.05 0.11 -0.02 0.06 0.79 0.08 0.05 0.08 0.10 0.09 0.25 
11 rs11218343 SORL1 -0.14 0.12 0.22 -0.18 0.14 0.19 -0.09 0.12 0.44 0.10 0.22 0.66 
14 rs17125944 FERMT2 0.10 0.08 0.22 0.05 0.11 0.66 0.01 0.08 0.87 -0.02 0.13 0.88 
14 rs10498633 SLC24A4 0.03 0.05 0.59 -0.07 0.07 0.28 0.06 0.05 0.28 -0.11 0.10 0.25 
17 rs2732703 KANSL1 -0.05 0.08 0.55 0.05 0.10 0.60 -0.12 0.08 0.13 0.14 0.15 0.38 
17 rs2632516 BZRAP1 0.09 0.04 0.03 0.03 0.05 0.61 0.07 0.04 0.10 -0.04 0.08 0.65 
19 rs9749589 NFIC 0.08 0.07 0.21 -0.08 0.08 0.35 -0.01 0.07 0.87 -0.20 0.12 0.11 
19 rs4147929 ABCA7 -0.04 0.06 0.45 -0.07 0.08 0.35 0.00 0.05 0.99 0.12 0.10 0.24 
19 rs3865444 CD33 0.06 0.05 0.23 0.03 0.06 0.63 0.07 0.05 0.16 -0.02 0.09 0.82 
20 rs7274581 CASS4 -0.06 0.07 0.40 0.16 0.09 0.06 -0.07 0.08 0.40 0.10 0.15 0.48 
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Appendix Table A.8.  Association P-values of Alzheimer disease loci previously established by GWAS with 
logical memory delayed recall test scores according to clinical subgroup.  
   ALL   CN   MCI   AD   
CHR SNP Gene Beta SE P Beta SE P Beta SE P Beta SE P 
1 rs6656401 CR1 -0.14 0.06 0.02 -0.13 0.07 0.07 -0.01 0.06 0.90 0.05 0.08 0.53 
2 rs6733839 BIN1 -0.01 0.05 0.80 -0.01 0.05 0.90 0.00 0.05 0.93 -0.05 0.06 0.43 
2 rs35349669 INPP5D -0.05 0.04 0.22 0.01 0.05 0.79 -0.06 0.04 0.12 -0.15 0.07 0.04 
5 rs190982 MEF2C -0.07 0.05 0.17 0.02 0.05 0.74 -0.11 0.04 0.01 -0.12 0.08 0.10 
5 rs11168036 HBEGF 0.01 0.05 0.80 -0.01 0.05 0.77 0.06 0.04 0.19 0.00 0.06 0.96 
6 rs9271192 HLA region 0.07 0.05 0.20 0.07 0.05 0.22 0.06 0.05 0.24 0.00 0.07 0.97 
6 rs10948363 CD2AP 0.01 0.05 0.91 -0.06 0.06 0.25 -0.06 0.05 0.23 -0.03 0.07 0.69 
7 rs2718058 NME8 -0.07 0.04 0.14 -0.06 0.05 0.22 -0.04 0.04 0.38 0.00 0.07 0.97 
7 rs1476679 ZCWPW1 -0.10 0.05 0.03 -0.02 0.05 0.62 -0.09 0.05 0.05 . . . 
7 rs11771145 EPHA1 -0.01 0.05 0.83 0.00 0.05 0.96 0.02 0.04 0.65 -0.04 0.07 0.55 
8 rs28834970 PTK2B 0.00 0.05 0.95 0.09 0.05 0.05 -0.07 0.04 0.08 -0.05 0.07 0.51 
8 rs9331896 CLU -0.04 0.05 0.41 -0.06 0.05 0.23 0.02 0.05 0.69 -0.05 0.07 0.44 
10 rs7920721 USP6NL 0.01 0.05 0.85 -0.01 0.05 0.85 0.07 0.04 0.08 -0.11 0.06 0.08 
11 rs10838725 CELF1 0.02 0.05 0.68 0.10 0.05 0.06 -0.01 0.04 0.87 -0.05 0.08 0.47 
11 rs983392 MS4A region -0.11 0.05 0.02 -0.01 0.05 0.81 -0.04 0.04 0.34 0.00 0.07 1.00 
11 rs10792832 PICALM 0.02 0.05 0.61 -0.08 0.05 0.11 0.04 0.04 0.35 0.02 0.07 0.80 
11 rs11218343 SORL1 -0.25 0.12 0.03 -0.21 0.12 0.07 -0.20 0.11 0.07 -0.16 0.18 0.37 
14 rs17125944 FERMT2 0.13 0.08 0.09 0.10 0.09 0.27 0.03 0.08 0.66 0.09 0.11 0.42 
14 rs10498633 SLC24A4 0.02 0.05 0.73 -0.04 0.06 0.46 0.11 0.05 0.02 0.10 0.08 0.20 
17 rs2732703 KANSL1 0.00 0.08 0.96 0.03 0.08 0.71 0.03 0.07 0.71 0.13 0.12 0.30 
17 rs2632516 BZRAP1 0.06 0.04 0.18 0.02 0.05 0.61 0.02 0.04 0.55 0.01 0.07 0.89 
19 rs9749589 NFIC 0.08 0.07 0.20 -0.04 0.07 0.52 -0.01 0.06 0.87 -0.10 0.10 0.31 
19 rs4147929 ABCA7 -0.07 0.06 0.20 -0.05 0.06 0.45 -0.04 0.05 0.49 0.11 0.08 0.21 
19 rs3865444 CD33 0.02 0.05 0.75 -0.03 0.05 0.50 0.07 0.05 0.12 0.11 0.07 0.13 
20 rs7274581 CASS4 -0.12 0.07 0.12 0.16 0.07 0.02 -0.07 0.07 0.35 -0.07 0.12 0.54 
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Appendix Table A.9. Top-ranked genes based on the genetic association tests in the CN and MCI subgroups 
with P<10-6.  
Symbol Entrez Gene Name 
ADAMTS18 ADAM metallopeptidase with thrombospondin type 1 motif 18 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif 3 
AKR7A3 aldo-keto reductase family 7 member A3 
ANAPC4 anaphase promoting complex subunit 4 
ANO2 anoctamin 2 
APOE apolipoprotein E 
ARHGAP24 Rho GTPase activating protein 24 
ART3 ADP-ribosyltransferase 3 
BCL2L14 BCL2 like 14 
BEST3 bestrophin 3 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
C20orf96 chromosome 20 open reading frame 96 
C6orf58 chromosome 6 open reading frame 58 
CAMK2B calcium/calmodulin dependent protein kinase II beta 
CCDC3 coiled-coil domain containing 3 
CDCP1 CUB domain containing protein 1 
CLIC5 chloride intracellular channel 5 
CMAHP cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene 
CYTH3 cytohesin 3 
DAB1 DAB1, reelin adaptor protein 
DENND4A DENN domain containing 4A 
DMGDH dimethylglycine dehydrogenase 
ERBIN erbb2 interacting protein 
FILIP1 filamin A interacting protein 1 
FLJ37035 uncharacterized LOC399821 
FRA10AC1 fragile site, folic acid type, rare, fra(10)(q23.3) or fra(10)(q24.2) candidate 1 
FSHR follicle stimulating hormone receptor 
FSIP1 fibrous sheath interacting protein 1 
GOLM1 golgi membrane protein 1 
GRIN2B glutamate ionotropic receptor NMDA type subunit 2B 
IFITM10 interferon induced transmembrane protein 10 
JPH3 junctophilin 3 
KCNE4 potassium voltage-gated channel subfamily E regulatory subunit 4 
KCNK10 potassium two pore domain channel subfamily K member 10 
KIAA2026 KIAA2026 
LRRTM4 leucine rich repeat transmembrane neuronal 4 
MCM5 minichromosome maintenance complex component 5 
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Appendix Table A.9. Continued 
Symbol Entrez Gene Name 
MMP28 matrix metallopeptidase 28 
MTUS1 microtubule associated tumor suppressor 1 
NRG1 neuregulin 1 
PATJ PATJ, crumbs cell polarity complex component 
PDGFRL platelet derived growth factor receptor like 
PDS5B PDS5 cohesin associated factor B 
PLD4 phospholipase D family member 4 
PRKG1 protein kinase, cGMP-dependent, type I 
RCAN1 regulator of calcineurin 1 
RGS19 regulator of G-protein signaling 19 
RNF165 ring finger protein 165 
SDAD1 SDA1 domain containing 1 
SNTB2 syntrophin beta 2 
SORCS1 sortilin related VPS10 domain containing receptor 1 
SRRM4 serine/arginine repetitive matrix 4 
SYT9 synaptotagmin 9 
TEKT5 tektin 5 
TNIK TRAF2 and NCK interacting kinase 
TRPV2 transient receptor potential cation channel subfamily V member 2 
WBSCR17 Williams-Beuren syndrome chromosome region 17 
WDR5 WD repeat domain 5 
ZCCHC4 zinc finger CCHC-type containing 4 
ZNF7 zinc finger protein 7 
ZNF804B zinc finger protein 804B  
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Appendix Table A.10. Co-expression network profiles for the modules that contain known AD genes as well as 
the genes with significant association (P<1.0x10-6) with at least one trait for CN, MCI, or all subjects.  
Module 
(Size)  
Gene (MM) 
Known AD genes 
(MM) 
in a same module 
Enriched Gene Ontology 
(FDR) 
Enriched Diseases 
(FDR) 
M1 
(1618) 
C14orf79 (0.49) MAPT-AS1 (0.37)   AD (6.2x10-3) 
M2 
(314) 
PRKG1(0.88) 
GLIS3 (0.89) 
FERMT2 (0.80) 
Protein binding (6.8x10-39) 
Focal adhesion (1.9x10-10) 
Signal transduction (8.8x10-
10) 
AD (2.2x10-9) 
CP (3.1x10-9) 
PD (8.4x10-7) 
M3 
(528) 
ARHGAP24 (0.07) BZRAP1-AS1 (0.59)     
M4 
(229) 
MTUS1(0.87) BACE1-AS (0.72) 
Protein binding (3.5x10-8)   
ERBIN (0.86) ZCWPW1 (0.67) 
M5 
(879) 
AKAP9 (0.66) CELF1 (0.82) 
DNA binding (2.0x10-43) 
Protein binding (7.6x10-40) 
Transcription (3.3x10-39) 
Schizophrenia (3.0x10-
4) 
AD (0.01) 
PD (0.01) 
M6 
(843) APOE (0.65) 
 APOE (0.65) 
Type I interferon signaling  
(0.03) 
  
M7 
(3885) 
GRIN2B (0.95) 
CAMK2B (0.88) 
SRRM4 (0.84) 
NRG1 (0.83) 
JPH3 (0.78) 
DAB1 (0.73) 
ZNF804B (0.55) 
BRIP1 (0.51) 
PTK2B (0.89) 
APP (0.86) 
PLXNA4 (0.84) 
MAPT (0.75) 
BZRAP1 (0.67) 
PSEN2 (0.64) 
Chemical synaptic 
transmission  
(1.8x10-84) 
Neuron projection (1.7x10-
30) 
Nervous system 
development 
Axon guidance (1.6x10-24) 
Postsynaptic density 
(8.6x10-22) 
AD (1.8x10-46) 
PD (1.3x10-25) 
CP (2.4x10-23) 
M8 
(476) 
RCAN1 (0.74) 
BIN1 (0.87) 
PSEN1 (0.79) 
Protein binding (2.8x10-16) 
Microtubule binding 
(4.1x10-5) 
Regulation cell shape 
(2.3x10-4) 
AD (3.8x10-5) 
Schizophrenia (0.01) 
CP (0.01) 
Module membership (MM) means a hub-gene score in a module of co-expression network. The FDR indicates false 
discovery rate estimated using the Benjamin-Hochberg procedure. Enriched diseases were the first three enriched 
diseases for the module.  Bold SNPs denote the study-wide significant association (P<8.33x10-9) with a trait. AD, PD, 
or CP indicates Alzheimer disease, Parkinson disease, and cognitive performance, respectively. 
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Appendix Table B.1. Sample demography of the brain autopsy data. 
 AD Cases Controls 
N 3,135 463 
Female (%) 1,742 (55.6%) 219 (47.3%) 
Age (SD) 73.9 (7.9) 78 (8.8) 
APOE ε4 carriers 1,984 83 
Neuritic plaque   
     None 0 354 
     Sparse 0 109 
     Moderate 507 0 
     Frequent 2,628 0 
Neurofibrillary tangles   
     0 0 70 
     I-II 0 393 
     III-IV 671 0 
     V-VI 2,464 0 
Cerebral amyloid angiopathy   
     any 703 130 
     absence 1,531 39 
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Appendix Table B.2. Association P-values of Alzheimer’s disease loci previously established by GWAS in univariate and bivariate tests of neuropathologic 
features. 
   Univariate analysis  Bivariate analysis 
   NP  NFT  CAA  NP+NFT  NP+CAA  NFT+CAA 
CH SNP Gene β SE P  β SE P  β SE P  Dir P  Dir P  Dir P 
1 rs6656401 CR1 0.02 0.06 0.76  0.09 0.06 0.10  0.03 0.08 0.67  + 0.25  + 0.61  + 0.17 
2 rs6733839 BIN1 0.24 0.06 9.2x10-6  0.22 0.05 7.8x10-6  0.02 0.06 0.71  + 1.6x10-7  + 9.8x10-4  + 1.5x10-3 
2 rs35349669 INPP5D -0.02 0.05 0.70  0.00 0.05 0.95  -0.03 0.06 0.67  - 0.80  - 0.58  - 0.75 
5 rs190982 MEF2C 0.10 0.05 0.06  0.10 0.05 0.03  0.02 0.06 0.80  + 0.02  + 0.15  + 0.11 
5 rs11168036 HBEGF 0.01 0.05 0.85  0.03 0.05 0.56  0.13 0.07 0.04  + 0.65  + 0.12  + 0.08 
6 rs113788164 HLA region 0.61 0.16 1.5x10-4  0.53 0.13 8.5x10-5  -0.01 0.19 0.95  + 5.5x10-6  + 0.01  + 0.01 
6 rs10948363 CD2AP -0.08 0.06 0.14  -0.06 0.05 0.22  0.02 0.07 0.81  - 0.11  - 0.39  - 0.52 
7 rs2718058 NME8 0.06 0.05 0.26  -0.06 0.05 0.19  -0.04 0.06 0.53  - 0.91  + 0.74  - 0.20 
7 rs1476679 ZCWPW1 0.09 0.05 0.09  0.10 0.05 0.04  -0.07 0.07 0.31  + 0.03  + 0.65  + 0.49 
7 rs11771145 EPHA1 -0.06 0.05 0.22  -0.11 0.05 0.03  0.07 0.06 0.27  - 0.04  - 0.96  - 0.47 
8 rs28834970 PTK2B -0.08 0.05 0.12  -0.02 0.05 0.60  0.10 0.06 0.11  - 0.22  + 0.96  + 0.48 
8 rs9331896 CLU 0.08 0.05 0.15  0.06 0.05 0.17  0.06 0.07 0.38  + 0.10  + 0.11  + 0.14 
10 rs7920721 USP6NL 0.04 0.05 0.48  -0.04 0.05 0.43  -0.05 0.06 0.39  - 0.95  - 0.90  - 0.27 
11 rs10838725 CELF1 -0.01 0.05 0.92  -0.03 0.05 0.57  0.06 0.06 0.35  - 0.69  + 0.56  + 0.81 
11 rs983392 MS4A region 0.09 0.05 0.07  0.09 0.05 0.06  0.03 0.06 0.65  + 0.03  + 0.12  + 0.13 
11 rs10792832 PICALM -0.19 0.05 2.1x10-4  -0.15 0.05 1.2x10-3  -0.05 0.06 0.47  - 4.4x10-5  - 0.00  - 0.01 
11 rs11218343 SORL1 0.19 0.12 0.13  0.25 0.10 0.02  . . .  + 0.02  + 0.26  + 0.09 
14 rs17125944 FERMT2 -0.19 0.09 0.03  -0.08 0.08 0.27  0.10 0.10 0.36  - 0.05  - 0.39  - 0.91 
14 rs10498633 SLC24A4 0.02 0.06 0.75  -0.06 0.05 0.22  0.00 0.07 0.96  - 0.59  + 0.85  - 0.40 
17 rs2732703 KANSL1 -0.18 0.11 0.10  -0.07 0.09 0.43  -0.12 0.12 0.33  - 0.15  - 0.07  - 0.24 
17 rs116089788 BZRAP1 -0.15 0.19 0.44  -0.29 0.14 0.04  -0.68 0.26 8.8x10-3  - 0.09  - 0.02  - 2.0x10-3 
19 rs4147929 ABCA7 0.14 0.07 0.04  0.13 0.06 0.03  0.06 0.08 0.47  + 0.01  + 0.05  + 0.06 
19 rs429358 APOE -0.98 0.08 1.3x10-35  -0.81 0.07 1.9x10-33  -0.61 0.09 1.9x10-11  - 3.4x10-47  - 4.83x10-40  - 5.8x10-35 
19 rs7412 APOE -0.43 0.15 3.4x10-3  -0.32 0.14 0.02  0.04 0.18 0.83  - 1.8x10-3  - 0.06  - 0.16 
19 rs3865444 CD33 -0.14 0.05 1.1x10-2  -0.06 0.05 0.18  -0.07 0.07 0.31  - 0.02  - 0.01  - 0.12 
20 rs7274581 CASS4 0.15 0.09 0.10  0.26 0.08 1.8x10-3  -0.07 0.11 0.57  + 4.9x10-3  + 0.47  + 0.10 
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Appendix Table B.3. Association summary of cis-eQTL for HDAC9 in the Mayo Clinic brain expression genome-wide association study (eGWAS). 
        Genetic Association Test Summary  cis-eQTL  Test Summary 
        NFT CAA NFT+CAA  AD Non-AD 
ALL 
(AD + Non-AD) 
SNP CH EA RA EAF  r2 D`  β Se P β Se P Dir P  β P β P β P 
rs17348528 7 C T 0.10  0.24 0.90  0.24 0.08 0.002 0.31 0.10 0.003 + 5.4x10-5  -0.14 0.03 -0.13 0.11 -0.13 0.008 
rs4721719 7 A G 0.11  0.24 0.90  0.20 0.07 0.005 0.27 0.10 0.006 + 2.5x10-4  -0.11 0.08 -0.14 0.06 -0.13 0.007 
rs4721720 7 A G 0.11  0.23 0.90  0.19 0.07 0.006 0.24 0.10 0.014 + 6.0x10-4  -0.11 0.08 -0.14 0.06 -0.13 0.007 
rs4721721 7 C T 0.12  0.23 0.95  0.16 0.07 0.021 0.24 0.09 0.009 + 1.1x10-3  -0.09 0.17 -0.19 0.01 -0.14 0.003 
rs6960494 7 G A 0.11  0.26 0.95  0.21 0.07 0.004 0.24 0.10 0.016 + 5.2x10-4  -0.09 0.16 -0.11 0.17 -0.11 0.035 
Brain region: Cerebellum 
Probe ID: ILMN_1803563 
EA: effect allele. RA: reference allele. EAF: effect allele frequency.  
Rs79524815 was not available in the Mayo Clinic brain eGWAS, so Proxy SNPs that are LD (D` > 0.90) with rs79524815 were used to for eQTL test with HDAC9 
expressions (r2 and D` with rs79524815).  
Linear regression was used for eQTL association tests between expression levels (outcome) and imputed SNPs (predictor) after adjusting for covariates (age at death, 
gender, plate, RIN, (RIN-RINmean)2, and APOE ε4 dosage). For the ALL sample, AD status as covariate was also included in the model.  
Interpretation of negative beta (β) for eQTL is that carriers with effect allele have lower expression level of HDAC9 compared to non-carriers.  
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Appendix Table B.4. Association summary of eQTL for TRAPPC12-AS1 and ADI1 in the GTEx Portal database 
     Genetic Association Test Summary  eQTL Association Summary 
     NFT   CAA   NFT+CAA  
Gene β (SE) P Tissue 
SNP EA RA EAF  β (SE) P   β (SE) P   Dir P  
rs35067331 T C 0.27 
  
-0.25 
(0.05) 
2.5x10-7 
  
-0.21 
(0.07) 
2.0x10-3 
  
- 5.8x10-8 
  
ADI1 
-0.18 (0.08) 0.03 Caudate 
    -0.17 (0.08) 0.05 Hippocampus 
     
TRAPPC12-AS1 
-0.59 (0.10) 2.1x10-7 Cortex 
    -0.40 (0.10) 2.7x10-4 Nucleus accumbens 
    -0.42 (0.12) 6.8x10-4 Frontal Cortex 
    -0.39 (0.14) 0.01 Putamen 
    -0.35 (0.14) 0.02 Anterior cingulate cortex 
    -0.29 (0.13) 0.03 Hippocampus 
        -0.27 (0.12) 0.03 Caudate 
EA: effect allele. RA: reference allele. EAF: effect allele frequency. 
Interpretation of negative beta (β) for eQTL is that carriers with effect allele have lower expression level of a gene compared to non-carriers.  
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Appendix Table C.1. Simulation design parameters. 
Parameter 
Names 
Designed levels 
Type I  error rate Power 
Factor loading (Λ) 0.15, 0.35, 0.55, and 0.75 0.15, 0.35, 0.55, and 0.75 
Causal Variants (%) . 5 and 15 
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Appendix Figure A.1. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values for CSF Aβ42 in 
the total sample (ALL), clinically normal (CN), Mild Cognitively Impaired (MCI), and AD subjects.  
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Appendix Figure A.2. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values for CSF t-Tau in 
the total sample (ALL), clinically normal (CN), Mild Cognitively Impaired (MCI), and AD subjects.  
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Appendix Figure A.3. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values for CSF p-Tau 
from the sample in ALL, Clinically normal (CN), Mild Cognitive Impairment (MCI), and AD.  
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Appendix Figure A.4. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values for 
Hippocampal volume (HPV) from the sample in ALL, Clinically normal (CN), Mild Cognitive Impairment 
(MCI), and AD.  
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Appendix Figure A.5. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values for logical 
memory test (LMT)-immediate recalls from the sample in ALL, Clinically normal (CN), Mild Cognitive 
Impairment (MCI), and AD.  
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Appendix Figure A.6. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values for logical 
memory test (LMT)-delayed recalls from the sample in ALL, Clinically normal (CN), Mild Cognitive 
Impairment (MCI), and AD.  
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Appendix Figure A.7. Manhattan plot showing the meta-analyzed results of CSF Aβ42 from all the subjects and 
three subgroups  
 
CN: clinically normal, MCI: mild cognitive impairment, and AD: Alzheimer’s disease. Blue dot line represents the 
genome-wide significance threshold of P<5.0x10-8, and the red dot line indicates study-wide significant threshold of 
P<8.33x10-9. Loci achieving study-wide significance are highlighted in red, and loci at genome-wide significance are in 
blue.  
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Appendix Figure A.8. Manhattan plot showing the meta-analyzed results of CSF total Tau from all the subjects 
and three subgroups  
 
CN: clinically normal, MCI: mild cognitive impairment, and AD: Alzheimer’s disease. Blue dot line represents the 
genome-wide significance threshold of P<5.0x10-8, and the red dot line indicates study-wide significant threshold of 
P<8.33x10-9. Loci achieving study-wide significance are highlighted in red, and loci at genome-wide significance are in 
blue.  
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Appendix Figure A.9. Manhattan plot showing the meta-analyzed results of CSF phosphorylated tau from all 
the subjects and three subgroups 
 
CN: clinically normal, MCI: mild cognitive impairment, and AD: Alzheimer’s disease. Blue dot line represents the 
genome-wide significance threshold of P<5.0x10-8, and the red dot line indicates study-wide significant threshold of 
P<8.33x10-9. Loci achieving study-wide significance are highlighted in red, and loci at genome-wide significance are in 
blue.  
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Appendix Figure A.10. Manhattan plot showing the meta-analyzed results of hippocampal volume (HPV) in 
brains from all the subjects and three subgroups  
 
CN: clinically normal, MCI: mild cognitive impairment, and AD: Alzheimer’s disease. Blue dot line represents the 
genome-wide significance threshold of P<5.0x10-8, and the red dot line indicates study-wide significant threshold of 
P<8.33x10-9. Loci achieving study-wide significance are highlighted in red, and loci at genome-wide significance are in 
blue.  
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Appendix Figure A.11. Manhattan plot showing the meta-analyzed results of logical memory test (LMT)-
immediate recall from all the subjects and three subgroups 
 
CN: clinically normal, MCI: mild cognitive impairment, and AD: Alzheimer’s disease. Blue dot line represents the 
genome-wide significance threshold of P<5.0x10-8, and the red dot line indicates study-wide significant threshold of 
P<8.33x10-9. Loci achieving study-wide significance are highlighted in red, and loci at genome-wide significance are in 
blue.  
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Appendix Figure A.12. Manhattan plot showing the meta-analyzed results of logical memory test (LMT)-
delayed recall from all the subjects and three subgroups 
 
CN: clinically normal, MCI: mild cognitive impairment, and AD: Alzheimer’s disease. Blue dot line represents the 
genome-wide significance threshold of P<5.0x10-8, and the red dot line indicates study-wide significant threshold of 
P<8.33x10-9. Loci achieving study-wide significance are highlighted in red, and loci at genome-wide significance are in 
blue.  
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Appendix Figure A.13. Regional association plots of PDE7B, GRIN2B, NRG1, AKAP9, and BDNF. 
A. 
  
PDE7B from association test with hippocampal volume in AD subjects, 
 
B. 
 
GRIN2B from association test with CSF Aβ42 in CN subjects  
  
141 
 
 
  
C. 
 
NRG1 from logical memory test immediate recall in MCI subjects 
 
D. 
 
AKAP9 from CSF phosphorylated Tau in the MCI subjects  
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E. 
 
BDNF from CSF phosphorylated Tau using CN subjects  
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Appendix Figure A.14. Association between gene expression levels in brains from the GTEx Portal database and 
SNPs. A. C14orf79 in hippocampus and rs2819438. B. MTUS1 in caudate and rs55653268. 
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Appendix Figure B.1. Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P-values of all SNPs (black dots) and after excluding SNPs in APOE 
region (blue dots) for the bivariate analysis of (A) NP and NFT, (B) NP and CAA, and (C) NFT and CAA using the O’Brien method. 
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Appendix Figure B.2. Manhattan plots showing genome-wide bivariate analyses of (A) NP and NFT, (B) NP and CAA, and (C) NFT and CAA using the 
O’Brien method.  
 
Red dot line represents the genome-wide significance threshold of P < 5.0x10-8. Loci achieving genome-wide significance are highlighted in red, and known Alzheimer 
disease genes are highlighted in gold.  
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Appendix Figure B.3. Regional association plots of genes including TRAPPC12, TRAPPC12-AS1, and ADI1 on chromosome 2 from the bivariate model of NFT 
and CAA. 
147 
  
Appendix Figure C.1. Regional association plot of genes including TRAPPC12, TRAPPC12-AS1, and ADI1 from 
the multivariate model of NP, NFT and CAA using O’Brien method  
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